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Trust, Oxford, UK
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Background: Multidisciplinary rehabilitation is recommended for Parkinson’s disease, but evidence
suggests that benefit is not sustained.
Objectives: (1) Implement a specialist domiciliary rehabilitation service for people with Parkinson’s and
carers. (2) Provide continuing support from trained care assistants to half receiving the rehabilitation.
(3) Evaluate the clinical effectiveness of the service, and the value added by the care assistants, compared
with usual care. (4) Assess the costs of the interventions. (5) Investigate the acceptability of the service.
(6) Deliver guidance for commissioners.
Design: Pragmatic three-parallel group randomised controlled trial.
Setting: Community, county of Surrey, England, 2010–11.
Participants: People with Parkinson’s, at all stages of the disease, and live-in carers.
Interventions: Groups A and B received specialist rehabilitation from a multidisciplinary team
(MDT) – comprising Parkinson’s nurse specialists, physiotherapists, occupational therapists, and speech
and language therapists – delivered at home, tailored to individual needs, over 6 weeks (about 9 hours’
individual therapy per patient). In addition to the MDT, participants in group B received ongoing support
for a further 4 months from a care assistant trained in Parkinson’s (PCA), embedded in the MDT
(1 hour per week per patient). Participants in control group (C) received care as usual (no co-ordinated
MDT or ongoing support).
Main outcome measures: Follow-up assessments were conducted in participants’ homes at 6, 24 and
36 weeks after baseline. Primary outcomes: Self-Assessment Parkinson’s Disease Disability Scale (patients);
the Modified Caregiver Strain Index (carers). Secondary outcomes included: for patients, disease-specific
and generic health-related quality of life, psychological well-being, self-efficacy, mobility, falls and speech;
for carers, strain, stress, health-related quality of life, psychological well-being and functioning.
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Results: A total of 306 people with Parkinson’s (and 182 live-in carers) were randomised [group A,
n= 102 (n= 61); group B, n= 101 (n= 60); group C, n= 103 (n= 61)], of whom 269 (155) were analysed
at baseline, pilot cohort excluded. Attrition occurred at all stages. A per-protocol analysis [people with
Parkinson’s, n= 227 (live-in carers, n= 125)] [group A, n= 75 (n= 45); group B, n= 69 (n= 37); group C,
n= 83 (n= 43)] showed that, at the end of the MDT intervention, people with Parkinson’s in groups A and
B, compared with group C, had reduced anxiety (p= 0.02); their carers had improved psychological
well-being (p= 0.02). People with Parkinson’s in groups A and B also had marginally reduced disability
(primary outcome, p= 0.09), and improved non-motor symptoms (p= 0.06) and health-related quality of
life (p= 0.07), compared with C. There were significant differences in change scores between week 6
(end of MDT) and week 24 (end of PCA for group B) in favour of group B, owing to worsening in group A
(no PCA support) in posture (p= 0.001); non-motor symptoms (p= 0.05); health-related quality of life
(p= 0.07); and self-efficacy (p= 0.09). Carers in group B (vs. group A) reported a tendency for reduced
strain (p= 0.06). At 36 weeks post recruitment, 3 months after the end of PCA support for group B,
there were few differences between the groups. Participants reported learning about Parkinson’s,
and valued individual attention. The MDT cost £833; PCA support was £600 extra, per patient
(2011 Great British pounds).
Conclusions: Further research is needed into ways of sustaining benefits from rehabilitation including the
use of care assistants.
Study registration: Current Controlled Trials: ISRCTN44577970.
Funding: This project was funded by the National Institute for Health Research Health Services and
Delivery Research programme and the South East Coast Dementias and Neurodegenerative Disease
Research Network (DeNDRoN), and the NHS South East Coast. The report will be published in full in
Health Services and Delivery Research; Vol. 2, No. 51. See the NIHR Journals Library website for further
project information.
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DOI: 10.3310/hsdr02510 HEALTH SERVICES AND DELIVERY RESEARCH 2014 VOL. 2 NO. 51
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Gage et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
xxi

Plain English summary
Parkinson’s disease (or ‘Parkinson’s’) is caused by the deterioration of brain cells. Most people withParkinson’s are older. The condition makes it difficult for them to move, and many experience
uncontrollable trembling. As the disease progresses, they require help with everyday activities such as
eating, dressing and washing. There is currently no cure, and management of symptoms relies on
medicines and rehabilitative therapies (physiotherapy, occupational therapy and speech and language
therapy). A collaborative multidisciplinary team (MDT) approach to rehabilitation is recommended, but its
effectiveness has not been widely researched. The Specialist Parkinson’s Integrated Rehabilitation Team
Trial (SPIRiTT) sought to address this gap in evidence.
People with Parkinson’s received a 6-week MDT intervention in their own homes, and the impact on their
functioning and well-being was measured. Family carers were included in the trial (if they wished) to see if
the intervention reduced their strain and stress. Some participants additionally received telephone calls and
visits from a care assistant trained in Parkinson’s for 4 months after the MDT intervention ended to see if
ongoing support maintained improvements.
A total of 227 people with Parkinson’s (plus 125 live-in carers) completed the 6-month study. The MDT
intervention resulted in the improved psychological well-being of people with Parkinson’s and carers, and a
small reduction in Parkinson’s disability. Ongoing care assistant support helped to maintain some benefits
from the MDT, and to slightly reduce carer strain. Participants reported that they valued the information and
advice from the MDT professionals. More research is needed to identify effective management strategies.
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Scientific summary
Background
Parkinson’s disease (sometimes referred to as Parkinson’s) is a degenerative neurological condition that
affects mainly older people, but there are also significant numbers with young onset. Although frequently
designated as a movement disorder, it additionally inflicts a range of distressing non-motor symptoms,
(problems with pain, sleep, speech, swallowing, constipation, incontinence, sexual dysfunction,
communication and social isolation). There is currently no known cure for Parkinson’s disease, and
treatment revolves around maintaining quality of life through symptom relief. The mainstay of management
is a pharmacological regimen, which gradually becomes less effective and more complicated as the disease
progresses. This is supported by rehabilitative therapies, assistive technologies and, occasionally, surgery.
Given the range of symptoms and the complexity of managing Parkinson’s disease, a collaborative
multidisciplinary team (MDT) approach to rehabilitation is recommended. However, the effectiveness of the
MDT approach has not been widely researched.
The Specialist Parkinson’s Integrated Rehabilitation Team Trial (SPIRiTT) builds on the findings of a
previous multidisciplinary rehabilitation programme, co-ordinated by a Parkinson’s nurse specialist (PNS)
in a day-hospital setting. This intervention resulted in significant immediate gains for patients in mobility,
independence, well-being and health-related quality of life, but, in the absence of continuing input, these
benefits had largely dissipated 4 months after the intervention ended. SPIRiTT delivers rehabilitation to
people in their own homes, and evaluates whether or not the fading of benefit when specialist input
is withdrawn can be avoided by providing continuing support from trained care assistants. Participants in
SPIRiTT received an equivalent package of specialist rehabilitation to that used in the day-hospital study
so that comparisons can be drawn between the models of domiciliary and day-hospital provision.
The SPIRiTT model of service delivery is based on recent NHS policy which promotes the provision of
services closer to patients’ homes, co-ordination of care by specialist nurses, supported self-management,
personalised care planning, rehabilitation and carer support. The use of trained assistants is consistent with
workforce policy which advocates the integration of non-registered health and social care workers
with enhanced roles in MDTs, to implement and deliver therapy and monitor and support patients.
Objectives
1. Implement a specialist neurological rehabilitation service for people with Parkinson’s and their family
carers, delivered in their own homes, comprising MDT assessment, care planning and treatment
(following the protocol previously evaluated in a day hospital).
2. Provide ongoing support from trained care assistants to those receiving the rehabilitation.
3. Evaluate the clinical effectiveness of the specialist rehabilitation service, and the value added by
ongoing support from trained care assistants embedded in the MDT, compared with usual care,
(largely non-specialist and non-team based).
4. Assess the costs of the specialist rehabilitation intervention, and of the ongoing care assistant support,
and calculate relative cost-effectiveness, including consideration of savings from service use offsets.
5. Investigate the acceptability of the new service delivery models from the perspectives of all stakeholders
(commissioners, MDT members, care assistants, managers, patients and family carers).
6. Deliver guidance for commissioners, providers and policy-makers.
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Methods
Design
Pragmatic three-parallel group randomised controlled trial.
Setting
Contiguous communities around three district general hospitals in the county of Surrey, England,
containing urban, suburban and rural localities and a broad mix of socioeconomic and ethnic groups.
Participants
People with Parkinson’s, at all stages of the disease, and their live-in carers (where applicable).
Recruitment
People with Parkinson’s were identified through hospital clinic lists; general practitioners; Parkinson’s UK
contacts; PNSs; community-based therapists; and word of mouth. Research nurses from the Primary Care
Research Network and the Dementias and Neurodegenerative Diseases Research Network (DeNDRoN)
assisted with recruitment. The interventions were delivered over 18 months, commencing
September 2010.
Inclusion criteria
People with Parkinson’s were included if they were 18 years of age or over; had a clinical diagnosis of
Parkinson’s disease; lived in the community (own home or minimally sheltered accommodation); lived in
the catchment areas of three district hospitals in the county of Surrey; were able to read and write English
in order to complete the self-report questionnaires; had not received a multidisciplinary package of care
over the last 6 months; and had not taken part in rehabilitation research in the last 6 months. Live-in
carers were included if they were 18 years of age or over and were able to read and write English in order
to complete the self-report questionnaires. If a live-in carer did not want to take part in the research,
the person with Parkinson’s could still join the trial. However, carers were not accepted if the person with
Parkinson’s did not want to participate. Carers who did not take part in the research were included in
the intervention.
Baseline data collection
Volunteers were entered into the trial in blocks (cohorts) of 30 (10 per group). They were visited at home
by a research nurse. Consent was received and baseline data collection was completed (background
demographic and health information and baseline outcome measures). Baseline data were checked to
confirm participant eligibility.
Exclusion criteria
People with Parkinson’s were excluded if they scored at the most favourable end of all outcome scales
(as the trial would not be able to demonstrate improvement, and, in 6 months, had little likelihood of
demonstrating reduction in any expected decline); and scored < 24 out of 30 on the Mini Mental State
Examination (to ensure that those recruited could follow instructions associated with the rehabilitation
intervention). Live-in carers were excluded if they scored at the most favourable end of all outcome scales
(i.e. had no limitations).
Randomisation
Eligible volunteers were randomised to either group A (received MDT assessment and management for
6 weeks), group B (same MDT package and additionally received ongoing support for 4 months from a
trained care assistant) or group C [received usual care: no co-ordinated MDT assessment and care, no
ongoing support from a care assistant trained in Parkinson’s (Parkinson’s care assistant: PCA)]. A separate
randomisation sequence was prepared for people with Parkinson’s with and without live-in carers. In each
instance, blocked randomisation was used to keep the group sizes even at 10 people with Parkinson’s per
group, that is to say a cohort of 30 people.
SCIENTIFIC SUMMARY
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Specialist rehabilitation intervention (groups A and B)
A MDT comprising a PNS, a physiotherapist (PT), an occupational therapist (OT), and a speech and
language therapist (SLT) visited the homes of participants to deliver a specialist rehabilitation package,
tailored to individual needs, over 6 weeks (about 9 hours of individual therapy per patient). Educational
materials were provided on aspects of Parkinson’s disease. A client record form was left in the participant’s
home for the duration of the intervention, and was completed by each professional at each visit.
There were two team meetings per cohort to discuss patient care plans and progress. Referrals to other
professionals were made when indicated, including to a neurologist, a community mental health team
and a Parkinson’s UK support worker.
Ongoing support (group B)
In addition to the programme of specialist MDT rehabilitation, participants in group B received ongoing
support for 4 months from a PCA, starting at the end of the 6-week MDT intervention. The PCAs received
training in Parkinson’s disease, were embedded in the MDT and worked under the supervision of the PNS.
Contact was via home visits and telephone (about 1 hour per week per patient of support), through which
the PCA monitored progress in implementation of the agreed care plan and reported back to the MDT.
Usual care/control (group C)
Participants in the control group continued to receive care as usual (no co-ordinated MDT care or ongoing
support). They were sent generic information (available from Parkinson’s UK) about Parkinson’s disease
(which was also given to people in groups A and B by the MDT). At the end of the trial, people in the
control group were offered an assessment by a member of the MDT (of their choice), and advice and
referrals were provided, as indicated.
Outcome assessments
Research nurses visited participants in their homes to conduct follow-up assessments at three points
(6 weeks, 24 weeks and 36 weeks) over 6 months.
Outcome measures
Measures of relevance to daily functioning were chosen as the primary outcomes: the Self Assessment
Parkinson’s Disease Disability Scale (patients report ease or difficulty of doing 25 general activities on a
five-point scale) and the Modified Caregiver Strain Index. Secondary outcomes included: for patients,
disease-specific and generic health-related quality of life, psychological well-being, self-efficacy, mobility,
falls, speech and voice; and for carers, strain, stress, health-related quality of life, psychological well-being,
and functioning.
Sample size calculations
Two hundred and seventy people with Parkinson’s (90 per group) were required in order to detect a
difference between groups in the change in the disability score of 1.25, after allowance for loss to
follow-up. We expected to recruit 71 carers per group (because 79% of people with Parkinson’s in the
day-hospital study had carers).
Statistical analysis
Groups were compared at baseline. All outcomes were analysed at each follow-up assessment point.
The null hypotheses tested were that there were no differences between the groups with respect to
changes in each primary and secondary outcome measure from baseline (week 0) to each follow-up
point (weeks 6, 24 and 36), and between each sequential follow-up point (weeks 6–24 and weeks 24–36).
Within-group changes were also analysed.
Acceptability of the intervention
Feedback from participants was obtained using semistructured questionnaires. All members of the MDT
and the PCAs were asked to provide reflective feedback (open comments) at three points during the
trial, and through ‘exit’ interviews. Data were analysed descriptively and using thematic analysis.
DOI: 10.3310/hsdr02510 HEALTH SERVICES AND DELIVERY RESEARCH 2014 VOL. 2 NO. 51
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Gage et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
xxvii
Economic evaluation
A NHS perspective was adopted. The costs of the intervention were calculated in 2011 Great British
pounds. The use of health and social care services were collected by self-report at baseline, 24- and
36-week assessments by recall for the previous 3 months, to explore cost offsets arising from the
interventions. Outcomes were evaluated with reference to costs.
Results
A total of 306 people with Parkinson’s (182 live-in carers) were randomised [group A, n= 102 (n= 61);
group B, n= 101 (n= 60); group C, n= 103 (n= 61)]. Of these, 269 (155) were analysed at baseline.
The first (pilot) cohort was not included in the analysis as the MDT processes were under development.
There were some differences between groups at baseline. People with Parkinson’s in group B scored worse
on the Frenchay Activities Index (p= 0.01) and tended to display higher disability (Barthel Activities of Daily
Living, p= 0.08) than those in groups A and C. Higher proportions in C screened positive for depression
(Yale Depression Screen, p= 0.01); groups A and B scored worse than C on some speech items (p= 0.03
to p= 0.08).
Attrition occurred at all stages, and a per-protocol analysis is reported for 227 people with Parkinson’s
(125 live-in carers) [group A, n= 75 (n= 45); group B, n= 69 (n= 37); group C, n= 83 (n= 43)].
An intention-to-treat analysis was also conducted. The results and conclusions from each analysis
are similar.
Effects of the multidisciplinary team
Compared with group C (control), people with Parkinson’s receiving the 6-week MDT intervention
(groups A and B) experienced an immediate reduction in anxiety (p= 0.02); their carers recorded improved
psychological well-being [Short Form questionnaire-36 items (SF-36) mental component summary (MCS),
p= 0.02]. People with Parkinson’s also had marginally improved disability (primary outcome, p= 0.09),
non-motor symptoms (p= 0.06) and health-related quality of life [European Quality of Life-5 Dimensions
(EQ-5D) Index, p= 0.07].
Effects of ongoing support from Parkinson’s care assistants
There were significant differences in change scores between week 6 (end of MDT) and week 24
(end of PCA for group B) in favour of group B due to worsening in group A (no PCA support) in posture
(p= 0.001), non-motor symptoms (p= 0.05), health-related quality of life (EQ-5D Index, p= 0.07), and
self-efficacy (p= 0.09). Carers in group B (vs. group A) reported a tendency for reduced strain (primary
outcome, p= 0.06).
Long-term follow-up
At 36 weeks post recruitment (3 months after PCA support for group B ended), there were few differences
between the groups. There were significant differences between changes in people with Parkinson’s in
group B and in groups A and C in psychological well-being (SF-36 MCS, both p= 0.05) and Speech Self
Report (p= 0.02, 0.03) due to significant deteriorations in A and C. Gait of people with Parkinson’s
improved in group B versus group A (p= 0.09); mobility (Timed Up and Go) improved in group A
versus group C (p= 0.06). The psychological well-being of carers in group A declined versus group B
(SF-36 MCS, p= 0.04).
Acceptability
People with Parkinson’s who received the MDT intervention reported that they had learnt a lot about the
condition, and how to manage it; they valued the tailored advice and the opportunity to discuss their
problems with knowledgeable professionals.
SCIENTIFIC SUMMARY
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Costs of the intervention
The total cost per patient was £833 for the 6-week MDT, and an additional £600 for the 4 months of
ongoing PCA support. There were no differences between groups in the cost of other service use. As no
statistically significant differences in change scores between groups for either the patient or the carer
primary outcome measures, or EQ-5D Index scores (for quality-adjusted life-years), at the final end point
(6 months) were found, a full cost-effectiveness analysis was not undertaken.
Conclusions
Information on alternative specialist community rehabilitation models, such as that provided by the SPIRiTT
trial, is important to enable evidence-based decisions to be made by service planners and commissioners.
The SPIRiTT intervention incorporates key elements of interprofessional working (shared goal setting and
care planning, effective communication channels and appropriate referrals to other specialities), and a
client-centred approach that invites participants to prioritise their concerns. It also provides support for
carers, which is a high policy priority, because it protects their health and improves their ability to cope.
The results showed that people with Parkinson’s experienced reduced anxiety and a tendency for reduced
disability and improved symptom control and health-related quality of life after the MDT intervention.
There is also evidence that continuing PCA input provided some benefits [in symptom control, posture
and (marginally) health-related quality of life] to people with Parkinson’s while it lasted. Similarly, carers
recorded improved psychological well-being at the end of the MDT intervention, and tendency to report
reduced strain after the PCA support. Feedback from participants suggested that the MDT intervention
was effective at increasing their understanding of the condition and signposting to other services.
Further research on the relative benefits and costs of alternative models of specialist multidisciplinary
rehabilitation for people with Parkinson’s in the community is required, including the means by which
improvements gained from specialist MDT rehabilitation can be sustained. The potential of PCA support for
people with Parkinson’s and carers deserves further attention. A relatively small amount of PCA input in
SPIRiTT helped to maintain patient functioning on some indicators, and to reduce carer strain, while it was
provided, but more research is required on how the nature and ‘dose’ might affect longer-term outcomes.
Study registration
This trial is registered as ISRCTN44577970.
Funding
Funding for this study was provided by the Health Services and Delivery Research programme of the
National Institute for Health Research, the South East Coast Dementias and Neurodegenerative Disease
Research Network (DeNDRoN), and the NHS South East Coast.
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Chapter 1 Introduction
Parkinson’s disease
Parkinson’s disease (sometimes referred to as Parkinson’s) is a degenerative neurological condition that
affects mainly older people, but there are also significant numbers with young onset.1 Globally, it is the
second most common neurological condition.2 Within the UK, it is estimated that 1% of people over the age
of 65 years have Parkinson’s, with the prevalence rising to 2% among those over 85 years.1 Parkinson’s
disease is caused by the destruction of cells in the substantia nigra of the brain, resulting in a lack of the
neurotransmitter dopamine, and hence difficulties with movement. The main motor symptoms are
bradykinesia (slowness of movement) and muscle rigidity. Tremor is also experienced in about 70% of people
with Parkinson’s. Although frequently designated a movement disorder, Parkinson’s disease additionally
inflicts a range of distressing non-motor symptoms, including pain, sleep disturbance, postural instability
(leading to falls), and problems with speech, swallowing, constipation, incontinence and sexual
dysfunction.3–5 Difficulties with communication and impaired cognitive function can result in social isolation,
and many people with Parkinson’s suffer depression. About 25% will develop dementia.6
There is currently no known cure for Parkinson’s disease. Symptoms usually appear gradually on one side of
the body first and worsen over time. As the disease progresses, people with Parkinson’s become increasingly
dependent, and a considerable burden is carried by family carers. Treatment revolves around maintaining
quality of life through symptom relief, and may involve a large number of different professionals and services
(specialist neurology, primary care, nursing, physiotherapy, occupational therapy, speech and language
therapy, pharmacy, dietetics, continence, psychiatry, mental health and social care).7
Four stages in the development of Parkinson’s disease have been identified, each requiring different
types and levels of care. Around the time of diagnosis, when the symptoms are mild, patients and carers
need information and support to help them understand the nature of the condition and services available.
As symptoms gradually worsen, patients enter a maintenance stage, when minor disability is managed
effectively by a drug regimen and input from a range of therapists. In the complex stage, when
medications are less effective, symptoms become difficult to manage and a variety of complications
arise, new medicines have to be added and carefully adjusted to control for side effects, and additional
non-pharmacological treatment input is required. At the palliative stage, when drugs may no longer be
effective, relieving distress, pain and other symptoms and providing support for the patient and family are
the sole remaining options.8
The mainstay of management of Parkinson’s disease is a pharmacological regimen, which gradually
becomes less effective and more complicated as the disease progresses. This is supported by rehabilitative
therapies, assistive technologies and, occasionally, surgery. The range of pharmacological options has
increased over time, and centres around levodopa (which acts through replacing depleted dopamine
stores in the brain), dopamine agonists, (typically used early in the disease to stimulate the production of
dopamine) and monoamine oxidase type B (MAO-B) inhibitors and catechol-O-methyltransferase (COMT)
inhibitors (to prolong the effect of levodopa).9
Parkinson’s is a complex condition and affects people differently, so individual assessment, and treatments
tailored to specific needs, are required.9 In particular, Parkinson’s medications need to be titrated to
balance symptom relief with significant side effects, including nausea, daytime sleepiness, vivid dreams
and hallucinations, increased libido and compulsive behaviours (gambling, shopping and other repetitive
activities).2 When drugs are working, the patient is said to be ‘on’, but as the effect of a dose wears off,
symptoms return (the patient is ‘off’), and the prevention of large and rapid swings in functioning requires
careful adjustment of the timing and size of doses. Over time, the efficacy of medications diminishes, and
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increases in the dosage need to be managed carefully to reduce the risk of dyskinesia (large uncontrollable
limb movements). Rehabilitative therapies have a role in primary and secondary prevention, and to
optimise health, functioning and quality of life, at all stages of the disease.10
Rationale for Specialist Parkinson’s Integrated Rehabilitation
Team Trial
Given the range of symptoms and the complexity of managing Parkinson’s disease, a collaborative
multidisciplinary team (MDT) approach to rehabilitation is recommended in order to provide a co-ordinated
and seamless package of care to people with Parkinson’s, and is accepted best practice.3,10–13 However,
the effectiveness of the MDT approach has not been widely researched.3,13–18 Active management within
a co-ordinated multidisciplinary Parkinson’s disease centre had a positive impact on functioning over
12 months,19 and two community-based studies have identified short-term benefits of treatment.20,21
One self-management programme has been found to have positive effects on health-related quality of life
at 6 months,22 but another study found that short-term effects were not sustained.23 A need has been
expressed for studies that identify cost-effective service delivery models that reduce disability and dependency
and prevent admission to long-term care.12–16,24,25 The Specialist Parkinson’s Integrated Rehabilitation Team
Trial (SPIRiTT) investigates the effectiveness and cost-effectiveness of two alternative models of specialist
rehabilitation for people with Parkinson’s in a community setting.
SPIRiTT builds on the findings of a previous multidisciplinary rehabilitation programme, co-ordinated by a
Parkinson’s nurse specialist (PNS) in a day-hospital setting.26 This intervention resulted in significant
immediate gains for patients in mobility, independence, well-being and health-related quality of life,21
but, in the absence of continuing input, these benefits had largely dissipated 4 months after the intervention
ended.26 Some patients were excluded because they could not get to the day hospital. Moreover, the
accompanying economic evaluation showed that day-hospital treatment incurred facility overhead costs and
involved the use of expensive hospital transport for patients with more advanced disease.27
SPIRiTT specifically addresses the issue of patient transport raised by the day-hospital model by delivering
rehabilitation to people in their own homes. Moreover, it evaluated whether or not the fading of benefit
when specialist input is withdrawn (a common feature of time-limited rehabilitation interventions)27
can be avoided in a cost-effective way by providing continuing support from specially trained care
assistants. Participants in SPIRiTT received an equivalent package of specialist rehabilitation to that used
in the day-hospital study so that valid comparisons could be drawn between the models of domiciliary and
day-hospital provision.
Policy context
The SPIRiTT model of service delivery is grounded in the recommendations of several recent policy
documents of the English NHS. These promote the integration of health and social care services,28
provision of services closer to patients’ homes,28 co-ordination of care for particular patient groups by
specialist disease-specific nurses,29 supported self-management29 and personalised care planning,
rehabilitation and carer support in order to reduce costly unplanned hospital admissions.30 Moreover,
guidelines from the National Institute for Health and Care Excellence (NICE) for the management of
Parkinson’s disease12 recommend regular patient review, comprehensive care plans, a central role for PNSs
and regular access to physiotherapy, occupational therapy, and speech and language therapy. PNSs are
deployed in many parts of the NHS, supporting specialist neurology teams in acute settings, or as part of
community services. Evaluations of PNS roles suggest that they do not improve outcomes, compared with
doctors, but that their input is highly valued by patients and carers because they are accessible, and for the
information and support that they provide.31,32 PNSs are key to the organisation of a MDT, being pivotal to
the co-ordination of care around the patient.
INTRODUCTION
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Many people with Parkinson’s do not routinely see PNSs or individual therapists, and even fewer receive
co-ordinated MDT input.33,34 Inequalities in care, shortages of specialist nurses and therapists, poorly
integrated services, and inadequate information provision and signposting are key features of the gap
between established standards of care and the care received, that have recently been identified.33,35–38
SPIRiTT investigates the impact of implementing a proactive approach to Parkinson’s management, in line
with recent recommendations. Other research has shown routine assessment and support for older people
living in the community, with a variety of conditions, can have positive effects on mortality and admission
to long-term care.39 Evaluations have been conducted in a range of countries, including the USA,40–43
Canada,44 Australia,45,46 Denmark,47,48 Italy49 and Switzerland,50 but overall evidence on outcomes (such as
physical functioning and health-related quality of life), service use and costs is inconsistent.46,51,52 Through a
focus on outcomes for people with Parkinson’s, SPIRiTT seeks to extend the current evidence base.
Workforce issues
Capacity constraints in the form of high PNS caseloads and shortages of therapists were identified by NICE
as barriers to the delivery of their guidance for management of Parkinson’s disease,12 and these have been
confirmed by a recent survey of PNSs.53 While NICE recommends a caseload of 300 patients, over half of
PNSs have lists in excess of 500, with adverse effects on the amount of routine support that they can
provide to patients. In common with other advanced practice nurses in the community, PNSs report
undertaking a variety of tasks (some of which do not require advanced skills), and that time pressures
create a need to risk stratify patients. Their focus is on ‘crisis’ management rather than ongoing advice and
support.54,55 The use of care assistants, trained in the special features and management of Parkinson’s,
working with PNSs and MDTs of health-care professionals in the community on assigned tasks appropriate
to their skill level and knowledge, is one way in which resources for delivering care and support to people
with Parkinson’s can be increased.
Competency-based training enables non-registered staff to properly complement the activities of
professionals,28,56 and professionals to appropriately meet supervision, delegation and accountability
challenges.57 Trained care assistants have been shown to be effective at underpinning professional working
and to have a positive impact on nurses’ ability to provide high-quality care, their work experiences, and the
cost-effectiveness of service delivery.58 The use of trained assistants is consistent with NHS policy for
the health and social care workforce which advocates the integration of non-registered health and social
care workers with enhanced roles in MDTs, to implement and deliver therapy and monitor and support
patients,30,59 as a means of increasing the flexibility, efficiency and responsiveness of services.60,61
Aims, objectives and hypotheses
The aims of the SPIRiTT study were to evaluate two models of specialist MDT rehabilitation for people
with Parkinson’s in the community, to add to the existing evidence base, to inform future service
development and commissioning, and ultimately to improve the quality of care and outcomes for patients
and live-in carers (i.e. family, friends and paid carers living in the same household). The specialist
rehabilitation was based on a multidisciplinary service that works with the patient and family to resolve
problems, through a process of goal setting, care planning, intervention and evaluation, to achieve
outcomes that maximise functioning and social participation with minimum distress to patient or family
carer.62 The research set out to explore not just the multidisciplinary professional input, but also budgetary
and management arrangements, and barriers and facilitators to cross-sector working, that may impact on
future implementation of the model.
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The specific objectives were to:
1. implement a specialist neurological rehabilitation service for people with Parkinson’s and their live-in
carers, delivered in their own homes, comprising MDT assessment, care planning and treatment
(following the protocol previously evaluated in a day-hospital setting)
2. provide ongoing support from specially trained care assistants to half (randomly selected) of those
receiving the specialist rehabilitation
3. evaluate the clinical effectiveness of the specialist rehabilitation service, and the value added by ongoing
support from trained care assistants embedded in the MDT, compared with usual care (which is largely
non-specialist and non-team based), across a range of patient and carer outcomes
4. assess the costs of the specialist rehabilitation intervention and of the ongoing care assistant support,
and calculate relative cost-effectiveness, including the consideration of savings from service use offsets
5. investigate the acceptability of the new service delivery models (specialist domiciliary rehabilitation with
and without ongoing support from trained care assistants) from the perspectives of all stakeholders
including commissioners, MDT members, care assistants, service managers, patients and live-in
carers and
6. deliver guidance for commissioners, providers and policy-makers about the acceptability, clinical
effectiveness and cost-effectiveness of different models of specialist neurological rehabilitation.
The hypotheses were that:
1. a package of domiciliary multidisciplinary specialist rehabilitation would benefit:
i. people with Parkinson’s in terms of maintaining mobility and independence (primary outcome for
patients) and improving well-being and health-related quality of life
ii. live-in carers in terms of reduced strain (primary outcome for carers) and improved health-related
quality of life and
iii. society through reduced use of other health and social care services, including hospitalisations and
admissions to long-term care
2. the addition of 4 months of ongoing support from trained care assistants would help to maintain the
benefits of the specialist team rehabilitation, and avoid the fading of effects that typically accompanies
the withdrawal of input
3. the intervention would be acceptable to major stakeholders, and barriers and facilitators to wider
implementation would be identified.
INTRODUCTION
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Chapter 2 Methods
Design
The study consisted of a pragmatic three-parallel group randomised controlled trial (RCT). People with
Parkinson’s in group A were assessed and managed by a specialist MDT for 6 weeks according to a care
plan that was agreed among the professionals and with the patient and carer. Group B had the same MDT
assessment and management, and additionally received ongoing support for 4 months from a trained care
assistant. Group C received normal care (i.e. no co-ordinated MDT assessment and care planning, and no
ongoing support). Follow-up was conducted at three points (6, 24 and 36 weeks) over 6 months to
determine the impact and relative cost-effectiveness of the two interventions. Qualitative interviews were
undertaken with providers (MDT members, care assistants), and patients and carers in groups A and B, to
gain feedback about the acceptability of the interventions. The Consolidated Standards of Reporting Trials
(CONSORT) flow diagram63 summarises the study design (Figure 1).
Setting
Contiguous communities around three district general hospitals in the county of Surrey, England. The study
area contains urban, suburban and rural localities and a broad mix of socioeconomic and ethnic groups.
Participants
The project sought to recruit people with Parkinson’s, at all stages of the disease, and their live-in carers
(where applicable). People with Parkinson’s were identified by a variety of means, including hospital clinic
lists; general practitioners (GPs); Parkinson’s UK contacts; PNSs; community-based therapists; and word
of mouth. Research nurses from the Primary Care Research Network (PCRN) and the Dementias and
Neurodegenerative Diseases Research Network (DeNDRoN) assisted with the identification of people with
Parkinson’s through general practices and specialist Parkinson’s hospital clinics, respectively. Any interested
person with Parkinson’s was given a leaflet which included a brief description of the study and the contact
details of the research team (see Appendix 1). Posters (see Appendix 2) were sent to relevant organisations
with a request that they be displayed in areas visible to people with Parkinson’s.
People with Parkinson’s could volunteer to take part in the study by contacting the research team by
telephone, post or e-mail. An initial eligibility screen was undertaken by a researcher by telephone
(see Appendix 3). Volunteers who met the inclusion criteria (Box 1) were sent full information about the
trial, and a consent form. A separate information sheet and consent form was provided for people
with Parkinson’s and live-in carers (family, friends, and paid carers living in the same household),
where appropriate (see Appendix 4).
Recruitment
Following telephone screening, a pool of eligible volunteers was built up. The MDT intervention was started
once this pool contained 180 people with Parkinson’s, a process that took about 3 months (June to
August 2010). The establishment of this pool of patients ensured that the 6-week intervention could be
delivered continuously to six cohorts of 30 patients, without any delays. Volunteers were informed during
the telephone screening that it could be a few months before their turn for starting the trial came around.
While the early volunteers were receiving treatment, recruitment of further people with Parkinson’s
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Assessment – 36 weeks Assessment – 36 weeks Assessment – 36 weeks 
Assessment – 24 weeks Assessment – 24 weeks Assessment – 24 weeks 
Care assistant support for 
4 months
Assessment – 6 weeks Assessment – 6 weeks Assessment – 6 weeks 
Allocated to group A
(6 weeks’ specialist
rehabilitation)
• People with PD, n = 90
• Live-in carers, n = 71
Allocated to group B
(6 weeks’ specialist
rehabilitation and care
assistant support)
• People with PD, n = 90
• Live-in carers, n = 71
Allocated to group C
(Usual care controls, given
information pack)
• People with PD, n = 90
• Live-in carers, n = 71
Randomisation: people with PD (n = 270); live-in carers (n = 213)
Research nurse makes home visit to collect consent and baseline information from people with  
PD and live-in carers
Community-dwelling people with PD identified by hospital doctors, GPs, specialist 
nurses, Parkinson’s UK contacts, word of mouth, and given information about study. Separate 
information provided for live-in carers. Patients and carers opt into study
FIGURE 1 Consolidated Standards of Reporting Trials flow chart for SPIRiTT. GP, general practitioner;
PD, Parkinson’s disease.
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continued until the study target sample size of 270 (see sample size calculations below) was achieved.
In this way, the research team ensured that the next cohort of patients was assembled for the MDT in a
timely manner, and that the MDT professionals had no idle periods pending recruitment of participants.
Treatment of the first cohort started in September 2010. An ex post decision was made to consider the
first cohort as a pilot, and recruitment was increased to 306 people with Parkinson’s so that an additional
cohort could be treated and any volunteers found ineligible at baseline could be replaced. The MDT
rehabilitation programme for the final cohort ended December 2011, with PCA support for that cohort
finishing in April 2012, and final assessments completed in July 2012.
Consent and baseline data collection
Volunteers were entered into the trial in blocks (cohorts) of 30. These blocks were initially defined on the
basis of participants’ home addresses, in order to reduce the time and costs of travel to participants’
homes for the delivery of the intervention and collection of the research data. In the later cohorts,
geographical grouping was no longer possible as the last volunteers were spread around the whole
catchment area.
When a volunteer was assigned to a cohort, an appointment was made for a research nurse to make a
home visit to answer further questions, receive consent (person with Parkinson’s and carer separately), and
collect baseline information (see Appendix 4). If a live-in carer did not want to take part in the research,
the person with Parkinson’s could still join the trial. However, carers were not accepted if the person with
Parkinson’s did not want to participate. When live-in carers opted out of taking part in the research, they
were still invited to be part of the MDT treatment programme. The baseline visit was arranged as close as
possible to the start of the intervention for any cohort. However, with 30 volunteers (and live-in carers) in
each cohort to be assessed, the visits had to be spread over a period of 4 to 6 weeks.
BOX 1 Inclusion criteria
People with Parkinson’s (any stage of the disease) were included if they:
l were 18 years of age, or over
l had a clinical diagnosis of Parkinson’s disease
l lived in the community (own home or minimally sheltered accommodation) with their own living areas
l lived in the catchment areas of three district hospitals in the county of Surrey
l were able to read and write English in order to complete the self-report questionnaires
l had not received a multidisciplinary package of care over the last 6 months
l had not taken part in rehabilitation research in the last 6 months.
Live-in carers were included if they were:
l 18 years of age, or over
l able to read and write English in order to complete the self-report questionnaires.
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Baseline information
People with Parkinson’s self-reported details of their age, sex, ethnicity, education, housing tenure, living
situation (alone or with others), caring arrangements, employment status, income, benefits, smoking,
height and weight [for body mass index (BMI)], and comorbidities (see Appendix 5). The abbreviated
Lubben Social Network Scale was used to screen for social isolation.64 This asks respondents to report on
frequency of contacts with friends (three items) and relatives (three items), each scored on a scale of 0 to 5,
and summed; total scores of ≤ 12 deem the respondent to be at risk of social isolation. The research nurse
assessed time since Parkinson’s diagnosis, MDT service use, falls, disease stage [using the six-category
modified Hoehn and Yahr scale (0, no sign of disease to 5, wheelchair bound/bedridden without help, but
not using the 0.5 increments that are not clinimetrically tested)]65 and cognitive function [using the 30-item
Mini Mental State Examination (MMSE),66 which includes simple tests of arithmetic, memory and orientation
(see Appendix 5)]. Background information requested from live-in carers included age, sex, ethnicity,
education, employment status, smoking, height and weight (for BMI), comorbidities (see Appendix 5), and
relationship to, and time spent caring for, the person with Parkinson’s. The baseline assessment included
the outcome measures selected for the trial (see Table 2). If participants found the baseline data collection
process tiring, some items suitable for self-completion were left with them, and the research nurse made a
second visit a few days later to collect the remaining questionnaires.
Exclusion
Baseline data were examined at the research office to confirm eligibility for the trial, and some volunteers
were excluded at this stage (Box 2). Specifically, people with Parkinson’s with a MMSE score of< 24 were
excluded because it was judged that they would not be able to follow instructions associated with the
rehabilitation intervention. People with Parkinson’s and live-in carers were excluded if they scored at
the most favourable end of all outcome scales as the trial would not be able to demonstrate improvement,
and, in 6 months, had little likelihood of demonstrating reduction in any expected decline; provided that
they scored under the maximum on at least one measure, they were included. They were informed of the
decision by letter (see Appendix 6), and were replaced by another volunteer, whenever possible, in order
to keep the cohort sizes at 30 people with Parkinson’s.
BOX 2 Exclusion criteria
People with Parkinson’s were excluded if they:
l scored at the most favourable end of all outcome scales (i.e. had no limitations)
l scored< 24 out of 30 on the MMSE,66 to ensure that those recruited could follow instructions associated
with the rehabilitation intervention.
Live-in carers were excluded if they:
l scored at the most favourable end of all outcome scales (i.e. had no limitations).
METHODS
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Registration and randomisation
After consent and baseline data had been collected, volunteers were given a unique registration number
by the project administrator. Those that were eligible were randomised to either group A – specialist
rehabilitation; group B – specialist rehabilitation and ongoing care assistant support; or group C – usual
care, control group. A separate randomisation sequence was prepared by the study statistician prior to the
commencement of the study for patients without live-in carers and for patients with live-in carers. In each
instance, blocked randomisation was used to formulate the sequence involving the three comparison
groups. With three groups in the study, there are six possible sequences (ABC, ACB, BAC, BCA, CAB, CBC).
A die was thrown to determine the group order within any block of three. Hence, any of the six possible
group sequences in a block were equally possible, and group sizes were kept even (10 people with
Parkinson’s per group, provided that the cohort had the full complement of 30 people). Only the project
administrator and the study statistician had access to each randomisation sequence.
The project administrator informed all participants of the group to which they were randomised, and
provided a schedule of dates indicating when they might expect the treatment visits (groups A and B only)
and research visits (all groups) (see Appendix 7). Contact details of the participants randomised to either of
the treatment arms were passed to the MDT. The GPs of all participants were informed of their involvement
in the trial and the group to which they had been randomised (see Appendix 8).
Interventions
Specialist rehabilitation intervention (groups A and B)
A MDT comprising two PNSs, two physiotherapists (PTs), one occupational therapist (OT) and two speech
and language therapists (SLTs) was assembled from local professionals. They worked part-time for the trial
from a base in the University of Surrey, and were employed by other health-care providers for the rest of
the week. Friday was assigned (for the convenience of all concerned) for the delivery of the intervention,
and for team meetings. Some team members also conducted treatment visits on Thursdays as the
workload required. An administrative assistant in the research office provided support, to confirm MDT
schedules and appointments with participants (by mail and telephone), organise team meetings, keep
records and arrange travel expenses.
Team members visited the homes of participants to deliver a specialist rehabilitation package, tailored to
individual needs. In order to make the outcome from the trial comparable with that of the previous study
set in a day hospital,21,23,26 a similar programme of specialist rehabilitation was provided comprising an initial
assessment and the formation of an agreed care plan reflecting the needs, wishes and expectations of the
person with Parkinson’s and carers. A group education and relaxation component in the day-hospital trial
could not be replicated in the domiciliary setting. As a substitute, the MDT provided participants with a
folder containing 11 fact sheets produced by Parkinson’s UK and the research team, and discussed these
with participants according to individual needs. Topics included various aspects of living with Parkinson’s,
such as medications, physiotherapy exercises, foot care, diet and nutrition, speech and language, sleep and
fatigue, continence and bowel care, welfare rights and benefits, advice for carers, and relaxation techniques
(see Appendix 9).
The rehabilitation intervention was co-ordinated by the PNSs, and involved specialist input from each
professional, over a period of 6 weeks. Most patients received one visit from one of the professionals each
week. The team met face to face twice in each 6-week cycle to discuss patient plans and progress, and
communicated by e-mail and telephone at other times. Two hospital consultants (a neurologist and a
gerontologist), both with a special interest in movement disorders, were available to the MDT, and
provided patient-specific advice as required. Referrals to other professionals were made when indicated,
including to a neurologist, a community mental health team and a Parkinson’s UK support worker.
Further treatment for people with ongoing needs beyond the end of the 6-week intervention was
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arranged through referrals to local community services. The MDT input was expected to be about
9–12 hours of individualised patient-facing nursing and therapy input, which was largely equivalent to
that delivered in the previous day-hospital trial, so that findings could be compared. However, it was
recognised that some people may need more, and others less, time than this. Including patient-related
non-patient-facing time spent in travel, writing case notes, meetings, etc., 3 days of professional time was
allowed for each person with Parkinson’s in the trial.
Ongoing support (group B)
In addition to the programme of specialist MDT rehabilitation, participants randomised to group B received
ongoing support for 4 months from a care assistant trained in Parkinson’s [Parkinson’s care assistant (PCA)],
starting at the end of the 6-week MDT intervention. Three PCAs were employed over the period of the
trial (Table 1). The main one had sole responsibility for five cohorts, and shared three other cohorts with
another PCA. The other PCAs had sole responsibility each for one other cohort. The PCAs were embedded
in the MDT and worked under the supervision of the PNS. About 1 hour per week per patient was allowed
for ongoing support, and contact was via a mix of home visits and telephone contacts, through which the
PCA monitored progress in the implementation of the agreed care plan and reported back to the MDT. If
required, MDT members continued to provide input. Care assistants were recruited to the project from
local health and social care employers.
Usual care/control (group C)
Participants in the control group continued to receive care as usual (no co-ordinated MDT care planning or
ongoing support). When informed of their group allocation, people with Parkinson’s and their live-in carers
(as appropriate) were sent generic information (available from Parkinson’s UK) about Parkinson’s disease
(see Appendix 10). This was a small enhancement on the service they were likely to be receiving. In order to
measure the impact of the interventions, this information was also given to the participants in groups A and
B by the MDT (additional to the educational fact sheets that they received). At the end of the trial, people
in the control group were offered an assessment by a member of the MDT (of their choice), and the
educational fact sheets provided to groups A and B were provided for them at that time. The assessment
was the same as that provided by the MDT to the intervention groups, and advice and referrals were
provided as indicated.
Cross-contamination between groups was minimised through recruiting people with Parkinson’s individually,
and giving treatments tailored to their specific needs. Moreover, the intervention and research assessments
took place in participants’ homes, which were geographically dispersed over the catchment areas of three
large district general hospitals.
The MDT treatment started for the first cohort in September 2010 and ran continuously for 10 cohorts
(cohort 1 was a pilot) until December 2011, with the PCA input to the last cohort ending in April 2012.
On completion of the intervention, or the assessment for the control group, a detailed report was written
about each participant and sent to their GP. All participants continued to receive care as usual during their
time in the trial, attending for routine outpatient appointments or contacting their GPs, as required.
TABLE 1 Group B PCA allocation
PCA
Cohort
1 2 3 4 5 6 7 8 9 10
PCA 1
PCA 2
PCA 3
Shaded cells indicate support provided.
METHODS
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Multidisciplinary team processes and monitoring
Members of the MDT met prior to the trial to discuss and agree the details of the intervention, including
the roles and protocol to be followed by individual therapists (see Appendix 11). A client record form (CRF)
was designed comprising sections for (1) general information about the patient [age, sex, contact details,
GP’s name and telephone number, description of home (e.g. steps), services received, driving status,
date of Parkinson’s diagnosis, falling history, other health problems]; (2) PNS assessment, based on the
Movement Disorder Society (MDS) Unified Parkinson’s Disease Rating Scale (UPDRS),67 and review of
non-motor symptoms, medication and side effects; (3) PT assessments of balance, posture, gait and
mobility; (4) OT assessment of activities; and (5) SLT subjective and objective assessment of speech, voice
and swallowing. Each professional had space to record problems, actions and recommendations for the
patient (see Appendix 12). The goals of the agreed care plan were reviewed and ratified at team meetings
and summarised in the CRF, which also contained instructions for the care assistant (group B only). The
start and end time of each contact (visit and telephone call), all referrals and recommendations made were
recorded in summary form on the front cover.
The CRF was left in the participant’s home for the duration of the 6-week intervention, and was
completed by each professional at each visit. At the end of each visit, each professional sent a brief report
by e-mail to the MDT administrator, who compiled a master document for team meeting discussions which
took place in the third and sixth week of each cohort, in a meeting room at the university (team base).
The purpose of the meeting in week 3 was to review the professionals’ assessments for each patient
and agree on the subsequent treatment plan. The meeting at the end of the cohort was to confirm
individualised future recommendations, to provide guidance for the care assistants who would take over
supporting participants in group B, and to plan the schedule of visits in the first 3 weeks of the next
cohort. In addition to patient-related business, team meetings were used to further interdisciplinary
understanding and working. Early in the project, each professional provided training insights for team
members from the other disciplines. These presentations were often based around case studies of
individual patients in the trial, and served to improve knowledge and interprofessional co-ordination.
Training
A one-day MDT training event was held before the launch of the intervention. Led by the PNS, the team
focused on the UPDRS,67 using a training video from the MDS. Two people with Parkinson’s [members of
the patient and public involvement (PPI) group] attended the session and each professional was able to
test out and refine their component of the CRF. Each PCA was individually trained by the PNS using the
training pack previously developed by the research team,68 fact sheets and a training video published by
Parkinson’s UK. They then shadowed each individual therapist. The PNSs accompanied the PCAs on the
early visits made by the PCAs.
Intervention pilot
The finally agreed CRF and MDT processes reflect some minor changes that were implemented, in the light
of experience, at the end of the first cohort. In particular, the original plan for three team meetings per
cohort (weeks 3, 5 and 6) was revised, and the meeting in week 5 was dropped because it was found to
be time-consuming and unnecessary. A decision was made to leave the CRF in participants’ homes and
send summary reports of each contact to the MDT administrator, because the original plan to transfer
the CRF between professionals proved impractical. It was also agreed that only the PNS would assess the
patient using the UPDRS, whereas the original idea had been that this would be undertaken by whichever
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professional met the patient first. Owing to these changes, and because the recruitment of professionals
was still under way and the team was under-resourced during the treatment of the first cohort, it was
decided to extend the trial to include a tenth cohort (a total of 300 people with Parkinson’s, instead of
270), and to consider the first cohort to be a pilot.
Outcome measures
Instruments which reflect the needs of people with Parkinson’s (functional outcomes, disease-specific and
generic health-related quality of life, psychological well-being, self-efficacy, mobility, falls and speech)
and carers (strain, stress, health-related quality of life, psychological well-being, and functioning), and
which had been found sensitive in previous rehabilitation studies undertaken by the research team,21,23,26,27
were included in the list of outcomes selected for the study. All instruments are widely used and well
validated for use with older people and in intervention studies (Table 2). Measures of relevance to daily
functioning were chosen as the primary outcomes: the Self-Assessment Parkinson’s Disease Disability Scale
(patients report ease or difficulty of doing 25 general activities on a five-point scale)69,70 and the Modified
Caregiver Strain Index.71 Information on use of other health and social services was also collected as part
of the economic evaluation (see below) to explore whether or not expenditure on the intervention was
offset by reductions in the use of other health and social services. The instrument battery was developed
and piloted in collaboration with patient and carer representatives in the PPI group. It took about 1 hour
to complete.
TABLE 2 Trial outcome measures and instruments: baseline, 6, 24 and 36 weeks
Category Instrument Description and scoring Range
Participant: people with Parkinson’sa
Disability
(primary outcome)
Self-Assessment
Parkinson’s Disease
Disability Scale69,70
Self-reported ease of or difficulty in doing
25 activities in general (e.g. getting out of
bed, getting dressed, cutting food, writing
a letter), scored on five-point scale: 1 (able
to do it alone) to 5 (unable to do it at all).
Original scale contained 24 items and
suggested two factors – gross mobility and
fine co-ordination69 – but a later paper
concludes that the items form a
unidimensional hierarchy70
25–125
(highest disability)
Parkinson’s specific PDQ-872,73 Summary index reflecting overall impact of
Parkinson’s disease on patients for use in trials.
Eight items related to self-perceived health
(getting around in public, getting dressed,
feeling depressed, embarrassed in public,
problems with close personal relationships,
concentration, communication and muscle
cramps) over the last month are each scored on
five-point scale: 0 (never) to 4 (always). The
total score is summed and transposed to a scale
of 0 to 100 (worst). PDQ-8 is derived from the
more extensive PDQ-39 and was selected to
reduce participant burden
0–100
(worst perceived health)
Non-Motor
Symptoms
Questionnaire74,75
Self-report of 30 non-motor symptoms
(e.g. bowel, pain, concentration, falling, sleep,
dreams, sweating, dribbling) in the last month
(scored yes= 1, no= 0)
0–30
(worst symptoms)
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TABLE 2 Trial outcome measures and instruments: baseline, 6, 24 and 36 weeks (continued )
Category Instrument Description and scoring Range
Participant: people with Parkinson’sa
Activities Barthel ADL76 Widely used instrument to establish the
degree of independence in 10 activities
(e.g. mobility, bathing, dressing, toilet,
feeding), scored 0 for unable or totally
dependent. Some items are binary while
others have three or four points on the scale;
maximum score 20 (totally independent)
0 (dependent) to
20 (independent)
Frenchay Activities
Index77–79
The Frenchay Activities Index is a short
questionnaire that is widely used to measure
lifestyle after stroke. The first of two parts was
used – frequency of 10 everyday activities in
the last 3 months; each scored 0 (never) to
3 (most days) (for meal preparation and
washing-up) or at least weekly (for other items
such as washing clothes, housework and
hobbies). The third part of the index was
not used as it relied on 6-month recall and
this was not suitable for more frequent
assessments
0 (no social activity) to
30 (best)
HRQoL (generic) EQ-5D
Thermometer80,81
EQ-5D is a simple standard measure, designed
for self-completion and applicable to a wide
range of health conditions. It provides a
descriptive profile [five dimensions – mobility,
self-care, usual activities, pain/discomfort and
anxiety/depression – each measured on a
three-point scale (no, some and extreme
problems)], transformed to a single index
for use in economic evaluations. There is
also a VAS (thermometer) recording the
respondent’s self-rated health on a vertical
scale (end points – best and worst imaginable
health state, 0–100)
0 (worst) to
100 (best health state)
EQ-5D Index80,81 –0.57 (worst) to
1.0 (perfect health)
SF-36 PCS82 SF-36 is a widely used scale assessing eight
health domains (limitations in physical
activities, usual activities, roles and social
activities, bodily pain, mental well-being,
vitality and general health). The instrument
was constructed for self-report or use by
interview. Scoring is by algorithm, range 0
(worst) – 100 (best) and set to US population
norm, mean of 50, SD of 10. The eight
subscales form two distinct higher-order
clusters: the PCS and the MCS
0 (worst) to 100 (best)
SF-36 MCS82 0 (worst) to 100 (best)
Psychological
well-being
HADS – anxiety83 HADS is a self-assessment scale developed
to detect states of depression and anxiety
in a hospital outpatient setting. It contains
14 questions (seven each for depression
and anxiety), scored 0–3: total range 0
(no anxiety/depression) to 21 (high
anxiety/depression). Cut-offs: 0–7= normal;
8–10= borderline; 11–21= abnormal
0 (no anxiety) to
21 (worst)
HADS – depression83 0 (no depression) to
21 (worst)
Yale Depression
Screen84,85
This is a single-item tool with reasonable
reliability and validity that can be administered
by non-registered staff to screen for
depression in the community: In the past
4 weeks, have you often felt sad or
depressed? (Yes= 1, no= 2)
Yes= 1, no= 0
continued
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TABLE 2 Trial outcome measures and instruments: baseline, 6, 24 and 36 weeks (continued )
Category Instrument Description and scoring Range
Participant: people with Parkinson’sa
Self-efficacy Self-Efficacy Scale86 Self-efficacy for managing chronic diseases
six-item scale measures confidence in doing
certain activities such as managing pain,
fatigue and medications, each scored from 1
(not confident at all) to 10 (totally confident)
and summed, and the mean calculated
1 (no self-efficacy) to
10 (high self-efficacy)
Mobility Timed Up
and Go87,88
Quick and simple nurse-measured indicator of
ability to perform sequential locomotor tasks
that incorporate walking and turning. Subject
stands from a standard armchair, walks
(a measured) 3 metres, turns, walks back
and sits. The same chair should be used in
repeated tests. Timed with stopwatch.
Recorded mean, SD ‘off’ (‘on’): 17.2, 7.3
(13.7, 3.9)
Seconds (low number
good)
Falls (self-report) In last 3 months, have you fallen? Yes= 1,
no= 0. If yes, asked how many times;
if hurt themselves; if able to get up off the
floor/ground; if saw doctor; if falls related
to freezing
Yes= 1, no= 0
Mobility UPDRSb – posture
item from motor
examination part of
the scale89
0: normal erect
1: not quite erect, slightly stooped posture;
could be normal for older person
2: moderately stooped posture, definitely
abnormal; can be slightly leaning to one side
3: severely stooped posture with kyphosis; can
be moderately leaning to one side
4: marked flexion with extreme abnormality
of posture
0 (normal) to
4 (extreme, abnormal)
UPDRSb – gait item
from motor
examination part of
the scale89
0: normal
1: walks slowly, may shuffle with short steps,
but no festination or propulsion
2: walks with difficulty, with little/no
assistance; may have some festination,
short steps, or propulsion
3: severe disturbance of gait, requiring
assistance
4: cannot walk at all even with assistance
0 (normal) to
4 (cannot walk at all)
Pain VAS, in ‘on’ and
‘off’ states90–93
Unidimensional measure of pain intensity,
with low respondent burden, and widely used
in diverse adult populations. The VAS is
shown as a continuous 10 cm horizontal line
anchored by verbal descriptors: 0 (no pain at
all) to 10 (worst pain imaginable). Participants
were asked to mark two VAS scales, one to
show pain in the ‘on’ state and one for the
‘off’ state when pain ratings are typically
higher. Measured by ruler in millimetres
0 (no pain) to
100 (worst pain imaginable)
METHODS
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TABLE 2 Trial outcome measures and instruments: baseline, 6, 24 and 36 weeks (continued )
Category Instrument Description and scoring Range
Participant: people with Parkinson’sa
Speech Speech Self Report
Questionnaire
(reproduced in
Appendix 13;
available
from authors)
Non-validated patient-centred questionnaire
used successfully in previous trial.21,23,26,27 Used in
clinical practice by SLT to identify problems
encountered by patients, and comprises
11 statements about speech problems
(e.g. voice is weak, husky, hesitant), and
15 statements about situations avoided
(e.g. making telephone calls, ordering in a café,
participating in a meeting), each scored 0 (never)
to 5 (always) and summed, giving total score
range of 0 (no speaking problems) to
130 (extreme speaking problems)
0 (no speaking problems)
to 130 (extreme
speaking problems)
UPDRSb – speech
item in the
ADL section89
0: normal
1: mildly affected, no difficulty being
understood
2: moderately affected, sometimes asked to
repeat statements
3: severely affected, frequently asked to
repeat statements
4: unintelligible most of the time
0 (normal) to
4 (unintelligible)
Speech Abridged Emerson
and Enderby
Screening
Assessment Rating
Scale – voice94
1: no impairment, voice normal for age
and sex
2: slight impairment, slight abnormal nasality,
quality or volume
3: moderate impairment, abnormal nasality,
quality or volume
4: severe impairment, severely abnormal
nasality, quality or volume
1 (normal) to
4 (severe abnormality
of voice)
Abridged Emerson
and Enderby
Screening
Assessment Rating
Scale – articulation94
1: no impairment, normal
2: slight impairment, a few articulatory
substitutions, not usually affecting
intelligibility
3: moderate impairment; abnormal
articulation noticeable, sometimes affects
intelligibility
4: severe impairment, many sounds
articulated abnormally, intelligibility
markedly affected
1 (normal) to
4 (severe abnormality
of articulation)
continued
DOI: 10.3310/hsdr02510 HEALTH SERVICES AND DELIVERY RESEARCH 2014 VOL. 2 NO. 51
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Gage et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
15
TABLE 2 Trial outcome measures and instruments: baseline, 6, 24 and 36 weeks (continued )
Category Instrument Description and scoring Range
Participant: live-in carersa
Strain
(primary outcome)
Modified Caregiver
Strain Index71
Fifteen items that caregivers can find difficult
(e.g. disturbed sleep, financial strain, work
adjustments), each rated on a three-point
scale: 0= no; 1= yes, sometimes; 2= yes, on a
regular basis
0 (no strain) to
26 (worst)
General health General Health
Questionnaire –1295
Widely used questionnaire to assess stress in
carers, with 12 questions about their
emotional state over the last 4 weeks
(e.g. ability to concentrate, enjoyment of
day-to-day activities, feeling happy, under
strain, lost sleep), scored on four-point scale:
0= better than usual/no problem; 1= as usual;
2=worse than usual; 3=much worse than
usual, and summed to give total 0 (no stress)
to 36 (worst)
0 (no stress) to
36 (worst)
Activities Barthel ADL76 As in people with Parkinson’s (above)
Frenchay Activities
Index77–79
As in people with Parkinson’s (above)
HRQoL (generic) EQ-5D
Thermometer80,81
As in people with Parkinson’s (above)
EQ-5D Index80,81 As in people with Parkinson’s (above)
SF-36 PCS82 As in people with Parkinson’s (above)
HRQoL (generic) SF-36 MCS82 As in people with Parkinson’s (above)
Psychological
well-being
HADS – anxiety83 As in people with Parkinson’s (above)
HADS – depression83 As in people with Parkinson’s (above)
Yale Depression
Screen84,85
As in people with Parkinson’s (above)
ADL, Activities of Daily Living; EQ-5D, European Quality of Life-5 Dimensions; HADS, Hospital Anxiety and Depression
Scale; HRQoL, health-related quality of life; MCS, mental component summary; PCS, physical component summary;
PDQ-8, Parkinson’s Disease Questionnaire-8 items; PDQ-39, Parkinson’s Disease Questionnaire-39 items; SD, standard
deviation; SF-36, Short Form questionnaire-36 items; VAS, visual analogue scale.
a The nurse assessed the UPDRS, Abridged Emerson and Enderby Screening Assessment Rating Scale voice and articulation
scales, and Timed Up and Go. The rest of the patient measures were completed by self-report, but with nurse assistance
as required. If the nurse read out the questions in an interview situation, respondents had a copy of the questionnaire to
refer to or were provided with laminated sheets showing response options in large print (for Parkinson’s Disability Scale,
PDQ-8, Frenchay Activity Index, Self-Efficacy Scale, SF-36, Speech Self Report Questionnaire). Live-in carers were
asked to self-complete all questionnaires, although a small number found this problematic and were assisted by the
research nurse.
b UPDRS has been the most widely used clinical rating scale for Parkinson’s disease. Parts I–III (mentation, behaviour and
mood; activities of daily living; motor examination) contain 44 questions, each measured on a five-point scale.89,96,97
METHODS
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Outcome assessments
Participants in all groups were assessed in their homes by a research nurse, at baseline, week 6 (at the
end of the 6-week rehabilitation intervention), week 24 [4 months (18 weeks) after the end of
rehabilitation, coinciding with the end of ongoing support for group B], and week 36 (for final follow-up).
For each cohort of 30 people with Parkinson’s (and live-in carers), baseline assessments took place in
the 6-week period prior to the start of the treatment phase. Assessments after the end of the 6-week
treatment phase took place during the subsequent 6 weeks. The assessments at 24 and 36 weeks after
baseline were arranged as close as possible to those stages for individual participants. In the event that
participants were unavailable owing to holidays, illness or other reasons, visits would be arranged up to
6 weeks beyond the stipulated time. Beyond that, the assessment was deemed missed. Those unavailable
at 24 weeks were contacted for their final 36-week follow-up assessment. The time between assessments
was analysed on a per-patient basis.
When follow-up research assessments were due (cohort by cohort), participants were telephoned by the
research office to make an appointment at a time convenient to them. A letter confirming the day and time
of the visit was mailed, together with some of the outcome measures that were suitable for self-completion.
To save time during the research nurse visits, participants (people with Parkinson’s and carers) were asked to
complete these questionnaires in advance (see Appendix 13). At the visit, the research nurse checked or
assisted with the self-completion questionnaires (which included the reporting of service use
for the economic evaluation) and undertook the remaining assessments of the people with Parkinson’s:
single-item depression screen; measures requiring clinical judgement (Timed Up and Go,87,88 posture, gait and
speech items); and falls reporting (also for trial safety monitoring) (see Appendix 14). All questionnaires were
checked for completeness before the research nurse left the participant’s home, and again in the research
office. Any missing or unclear data were checked with participants as soon as possible after each assessment.
Inter-rater reliability
One full-time research nurse conducted assessments throughout the trial. Prior to starting data collection,
visits to the home of members of the PPI group were arranged (a person with Parkinson’s and a live-in
carer) so that the battery of assessments could be practised. The research nurse was accompanied on
these visits by the research manager, so that any problems could be addressed. In particular, this enabled
guidance for the safe conduct of the Timed Up and Go test to be established. It also served to identify the
need for laminated sheets to be prepared with response options (in large print) for different questionnaires
for use when participants could not self-complete and that data needed to be collected from them in
an interview.
During the middle period of the trial, when several cohorts were at different stages of assessment, two
part-time research nurses were employed to assist with the data collection. To ensure consistency of
processes, the assistants were trained by the main research nurse through shared assessment visits.
The first assessments undertaken by the assistant nurses were observed by the senior research nurse and
followed by a debriefing discussion after it was completed.
Blinding
Group allocation was not known at baseline assessment, which took place prior to randomisation.
Databases showing group allocations were not available to the research nurses. Moreover, the research
nurses did not answer the office telephone because participants often called in to alter MDT appointments,
and this would have compromised the nurses’ blinding. Participants were asked not to discuss aspects of
the trial and treatments with the research nurses, and were reminded of this at each assessment visit.
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Despite this, some participants did disclose that they had been treated by mentioning MDT members or the
care assistant during the second and third research assessment visits.
Blinding was broken at the end of the third (24-week) assessment, when research nurses collected
feedback on the acceptability of the interventions (from groups A and B only). It was not possible to collect
data on acceptability separately. Thus, the acceptability questionnaires were placed at the back of the
pack of self-completion instruments that were mailed in advance to participants for the 24-week visit.
Nurses collected and checked completeness of these packs prior to leaving the participant’s home,
and were thus made aware of whether or not the participant had received the MDT intervention by the
presence or absence of acceptability questionnaires. Research nurses might have remembered patients’
groups when they returned for the final 36-week assessment. However, they reported poor recall of group
allocations because there were over 300 participants in the trial, they were undertaking contemporaneous
assessments of several cohorts at any point in time, and there was a gap of 3 or 4 months between
the follow-up assessments.
Acceptability of the intervention
Participants
Semistructured questionnaires were designed to gather feedback on the acceptability of the interventions
from group A and B participants at the end of the 24-week research assessment (separate forms for
people with Parkinson’s and live-in carers) (see Appendix 15). This part of the study sought to capture the
patient and carer voice and experience of the rehabilitation interventions relative to perceived needs and
priorities. The questionnaires contained rating scales and open-text fields regarding how helpful, or how
successful, participants found different aspects of the programme or the programme as a whole, and how
they thought it could be improved. Items on value for money were included.
However, the research nurse found that many participants were having problems recalling the MDT phase,
which had been completed 4 months earlier. As a result, a decision was taken to send the questionnaire
(with questions relating to the PCA component removed) to participants by mail (to protect blinding) at
the 6-week assessment point. Participants were sent a stamped addressed envelope for the return of the
questionnaires. The research office reminded participants by telephone to ensure a good response rate.
This change was implemented from the fourth cohort onwards (i.e. it did not apply to the pilot cohort or
the first two cohorts that are included in the analysis). The acceptability questionnaires continued to be
distributed at the 24-week assessment point to collect feedback on ongoing benefit and the PCA input.
Multidisciplinary team professionals and Parkinson’s care assistants
All members of the MDT and the PCAs were asked to provide reflective feedback (in the form of open
comments) on integrated team working, team functioning and their individual role, and the delivery of
the intervention at the end of cohorts 2, 6, and 8 (see Appendix 16). In addition, a structured feedback
form was circulated at the end of the intervention, asking for Likert scale ratings and comments on
communication and support within the team, delegation of responsibilities, involvement of patients and
carers in care planning, and examples of good practice and challenging situations that they had
encountered (see Appendix 16).
‘Exit’ interviews were also conducted with all team members, and PCAs, to learn about their views and
experiences of MDT working. The interviews were conducted by an experienced qualitative researcher,
who was a member of the project team but who had minimal contact with the day-to-day working
of the MDT. The interview took the form of a conversation, guided by a list of topics (see Appendix 17).
The main points were noted by hand. In addition, during the analysis phase of the study, the lead PNS
wrote a report on the intervention, including observations on team working and illustrative participant
case studies.
METHODS
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Stakeholder interviews
It was originally intended that service providers and a selection of commissioners would be asked for their
views about the intervention, to identify strengths and weaknesses, and barriers and facilitators to its wider
implementation. However, during the project period, significant organisational changes were put in place
within the NHS (replacement of primary care trusts with local commissioning groups) to take effect shortly
after the project ended. This made it difficult to identify the relevant stakeholders. Following discussion
with the external advisory group, it was decided that this part of the project would be integrated into
dissemination activities.
Sample size calculations
Patient sample size calculations were based on detecting clinically meaningful differences in the
primary patient outcome measure. Carer sample sizes reflected the findings of previous work that
suggest that 79% of people with Parkinson’s have a carer.21
It was planned to recruit 270 people with Parkinson’s over a 12-month period across the three areas, with
90 randomly allocated to each of the three groups. This calculation was based on the numbers of people
with Parkinson’s needed to detect differences between groups in changes in the primary outcome:
Self-Assessment Parkinson’s Disease Disability Scale.69,70 Assuming a similar level of variation as in the
day-hospital trial,23 in order to detect a difference in the changes in the disability score of 1.25 [with
standard deviation (SD)= 2.5, size= 5%, power= 80% and a two-sided test], 64 subjects with Parkinson’s
disease were needed in each of the three groups.
Assuming a similar level of variation in the primary outcome – Modified Caregiver Strain Index71 – as in
the day-hospital trial,23 in order to detect a difference between groups in the changes in the Modified
Caregiver Strain Index of 0.535 (with SD= 1.07, size= 5%, power= 80% and a two-sided test), 64 carers
were needed in each of the three groups. In the previous study, 79% of community-dwelling people
with Parkinson’s had a live-in carer.21 Thus, if there were 64 carers per group, this necessitated
246 [(64 × 3)/0.79= 243.04] Parkinson’s subjects, i.e. 82 per group.
In the previous day-hospital trial, the loss to follow-up/non-completion/missing data rate between
recruitment and the 6-month assessments was 26%. However, in that trial, participants attended the day
hospital for treatment (six visits) and research assessments (four visits), and difficulties with transport and
intercurrent illness accounted for missing data and drop-out. We expected less attrition in the SPIRiTT trial
because participants would receive both treatment and the research assessments in their own homes,
at times convenient to them.
Allowing for 10% loss to follow-up/non-completion/missing data rates for people with Parkinson’s,
243.04/0.90= 270.04 patients were required= 90 per group. With 90 patients per group, we expected to
recruit 71 carers per group. These group sizes would also ensure that the samples for patients and carers
would both remain above the critical values of 64 if there was a loss of 5% of carers (and associated
patients) and an independent loss of 5% of people with Parkinson’s.
Withdrawals
Participants could withdraw from the study due to illness or personal reasons. They were made aware
(via the information sheet and consent form) that withdrawal from the study would not affect their future
care, and that data collected to date would still be used in the final analysis. Volunteers who were not
randomised because they failed eligibility criteria at baseline were replaced, but participants who withdrew
from the trial for any other reason were not replaced.
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Data management
Data were entered into IBM SPSS Statistics version 19 (IBM Corporation, Armonk, NY, USA) databases
using the trial unique patient identification number. Separate databases were constructed for:
l information collected at baseline and on outcomes (all four assessments), by cohort, and combined for
the analysis at the end of the trial
l the data from the patient and live-in carer acceptability questionnaires
l items from the CRF that were needed (a) for the calculation of the costs of the treatment programme
(number and duration of therapist visits and telephone calls) for the economic evaluation, and
(b) to illustrate MDT activity (quantifiable variables only, i.e. referrals made, medication changes
recommended, recommendations made by the OT for aids and adaptations).
Contact details and GP details of participants were kept in an administrative database separate from the
research information. All paper data were stored in locked cabinets, and all computer data were stored on
a secure server.
Data were entered by one person and checked by a second, with random checking (using random
numbers and ID numbers) of five persons with Parkinson’s and five carers in each cohort. If errors were
found, the rate of checking was increased. The statistician, who was blinded to group allocation until all
databases were completed, undertook further data cleaning.
Statistical analysis
Data relating to people with Parkinson’s and carers were analysed separately.
The analysis started with an intention-to-treat (ITT) approach, based on group assignment (excluding the
pilot cohort), and including participants who had provided information at baseline assessment but had
subsequently withdrawn, had not been available for assessments or were lost to follow-up. Some
participants completing a baseline assessment had dropped out prior to treatment. A per-protocol analysis
(PPA) was, therefore, also conducted, restricted to participants who fulfilled the protocol in terms of
eligibility, interventions and all outcome assessments.
Baseline data (week 0) were analysed to describe the characteristics of the participants and to check for
significant imbalance between the three groups with respect to background characteristics and outcomes,
using appropriate statistical tests. The characteristics of the participants who were lost in the PPA were
compared with those of the full ITT sample.
All outcomes were analysed at each follow-up assessment point [6 (post MDT treatment), 24 (post PCA)
and 36 weeks (final end point)]. A series of null hypotheses were set out a priori for testing. Groups were
compared with respect to changes in outcome measures between assessment points.
In order to identify short-term effects arising from the MDT intervention, change scores (week 6 minus
week 0) of each participant in the specialist rehabilitation groups (A and B) were compared with those of
participants in the control group (group C). The null hypotheses tested were that there were no differences
between the groups (A+ B vs. C) with respect to change in any outcome.
The impact of the PCA support for group B from week 6 to week 24 was assessed by comparing changes
in outcomes for group A versus group B between week 6 (end of MDT intervention for both groups) and
week 24 (end of PCA intervention for group B). The null hypotheses tested were that there were no
differences between the groups (A vs. B) with respect to change in any outcome (week 24 minus week 6).
METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
20
This analysis was designed to show loss or maintenance of effects arising from the PCA support after the
MDT input ceased.
Medium-term effects were further investigated through a comparison of all groups at 24 weeks (A vs. B,
A vs. C, and B vs. C) using participants’ change scores from baseline (week 24 minus week 0). The null
hypotheses tested were that there were no differences between the groups with respect to change in
any outcome.
In order to identify long-term effects, groups were compared at 36 weeks (A vs. B, A vs. C, and B vs. C)
using participants’ change scores from baseline (week 36 minus week 0). The null hypotheses tested were
that there were no differences between the groups with respect to change in any outcome.
An additional exploratory analysis was performed using each participant’s change score for all outcomes
between week 24 and week 36 (36 minus 24). This analysis provides evidence of trends in each group,
and differences between groups, over the follow-up period after all interventions ceased in week 24.
Although multiple statistical tests were undertaken, adjustments for multiple testing were not made
because a priori hypotheses were specified. Results are presented in full and selective reporting of
significant results has been avoided. Furthermore, most outcomes are independent.
For all of the above analyses of changes, distributions were inspected to identify major aberrations from
normality which could preclude the use of parametric tests. In most cases, raw data failed normality tests,
but change scores were close to normal and parametric tests were used. One-way analysis of variance
(ANOVA) tests were used for comparisons between all three groups, and unpaired t-tests were used for
comparisons between pairs of groups. Within-group changes between assessment points were also
explored using paired t-tests. In each case, a two-sided test was used.
Missing data
Stringent attempts were made to minimise missing data through checking questionnaires as they were
completed, and returning to participants to retrieve missing items. If more than two responses were missing
from an instrument, the whole instrument was disregarded for that individual. As a result, remaining
missing responses within instruments were minimal, averaging 0.40% for people with Parkinson’s and
0.06% for live-in carers (see Appendix 18). These missing items were filled using the established procedures
for that scale (if available), or else setting the value of the missing item to zero (or normal), i.e. the most
favourable value. Some participants found it difficult to complete some outcome measures [e.g. the pain
visual analogue scales (VASs)], and this resulted in non-response for that instrument and a smaller sample
size in the analysis. The research nurses did not carry out the Timed Up and Go test if the participant was in
an ‘off’ state during the assessment or was immobile due to injury or surgery.
Loss to follow-up
Collection of research data from participants in their own homes minimised the loss to follow-up.
If participants could not be reached, or were away from home, or hospitalised at one follow-up point,
they were contacted and asked to complete later assessments.
Analysis of the acceptability questionnaires
Responses from people with Parkinson’s and live-in carers were analysed separately and mainly focused
on those sent by mail at 6 weeks (at the completion of the MDT intervention) from cohort 4 onwards.
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Questionnaires completed at 24 weeks were not fully analysed due to concerns about participant recall.
Research nurses reported that by 24 weeks (4 months after the end of the MDT intervention), some
participants found it difficult to remember the input of different professionals, sometimes confusing trial
therapists with regular health and social care professionals who they had seen in the meantime. Two
issues from the acceptability questionnaire distributed at 24 weeks were analysed: a question asking about
continuing benefit beyond the end of the MDT intervention (at 6 weeks); and two items that specifically
gave participants in group B an opportunity to comment on the PCA input over weeks 7–24.
Quantitative items (rating scales) were analysed descriptively and results were presented as proportions,
means and SDs, depending on the nature of the questions. Text responses were transferred to a
Microsoft Excel database (Microsoft Corporation, Redmond, WA, USA) for analysis. These questions asked,
at the 6-week assessment, how helpful participants found the treatment; the most successful aspects of
the programme; the least successful aspects of the programme; ways in which the programme could be
improved; and for other comments about the treatment and the study overall. For each of these questions,
the written responses were printed out and read several times by a researcher. Irrelevant comments that
did not address the question were removed, including comments that were illegible and those relating
to the research process (e.g. that there were too many forms to fill in). Main themes in the responses
were then identified. The question from the 24-week assessment about continuing benefit from the
MDT intervention was analysed in the same way. The process was independently checked by a
second researcher.
Analysis of feedback from the multidisciplinary team and
Parkinson’s care assistants
Notes taken during the ‘exit’ interviews were combined with reflections provided by team members during
the trial and subjected to thematic analysis98 by the researcher who undertook the interviews. The analysis
was checked by a second researcher.
Economic evaluation
The economic evaluation adopted a NHS perspective. Participants were treated in their own homes and
incurred no costs in accessing treatment.
The resources used in the delivery of the intervention (both MDT and PCA components) were recorded in
the individual participant CRFs. Information relating to patient contact [number and duration (in minutes)
of visits and telephone calls to participants by individual therapists] was transferred to a patient-level SPSS
database, and descriptive statistics were calculated. Time spent with individual professionals was summed
to determine total minutes of contact with the MDT and with the PCA (group B). Data on total contact
time were checked for normality (using histograms) and for variance. Variation was explored between
groups A and B, and within cohorts, with respect to total MDT contact duration and PCA input
(group B only), using appropriate statistical tests.
The costs of the intervention were calculated in Great British pounds (GBP) for 2011, at the level of
individual patients, as the sum of the costs of (1) patient contact time (home visits and telephone calls)
with all members of the MDT and with the PCA (group B), including an allowance for non-patient-facing
follow-up tasks arising from visits or telephone calls, such as writing notes, arranging referrals, and
discussion at MDT meetings; (2) travel expenditures and time spent in travel for home visits; and (3) a fixed
1 hour spent by the PNS in writing a letter to the GP of each participant to report on what care had been
given to their patient.
METHODS
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Costs of staff time were obtained from validated national sources99 (see Appendix 19). The hourly rates
used are inclusive of all on-costs, and management office/administrative support and facilities overheads.
Following discussion with the professionals, an extra 30 minutes per home visit and 15 minutes per
telephone call were added for time spent in non-patient-facing follow-up. The distances from the MDT
base to the home postcodes of all participants in the study were obtained, and the median distance taken
as the basis for calculating the travel costs for all home visits, and the NHS mileage reimbursement rate
was applied. Professional time spent in travel was costed on the basis of an assumed 20 miles per hour
(which was judged appropriate for the suburban/rural nature of the catchment area). Unit costs used in
the calculations are shown in Appendix 19. Costs of the MDT intervention were compared between
groups A and B, and between cohorts, to confirm uniformity of delivery.
The use of health and social care services [hospital in- and outpatient, accident and emergency (A&E),
GP and a range of other community health and social services, respite care in residential settings, personal
social services] were collected by self-report at baseline, 24- and 36-week assessments by recall for the
previous 3 months. Participants were also asked about informal (unpaid care from family and friends).
Service use was analysed descriptively at group level. The costs of health services were calculated at each
assessment point using unit costs obtained from national sources99 (see Appendix 20), multiplied by
the number of units used. Weekly day-care use was multiplied by 12 to give the cost over 3 months.
Contacts with GPs at home and in the surgery were combined as one category, but the appropriate unit
cost was applied to each component. Where participants reported self-paying for services, the costs
were excluded from the calculations. Costs of service utilisation in the intervention groups (A and B) were
compared with each other and with the usual-care group (C) to assess the extent to which the costs of the
interventions may be offset by savings elsewhere in the health and social care system. The costs of tests,
social and informal care reported by participants were not calculated due to insufficient details about
the type and frequency of the service.
Clinical results were inspected to assess the value of conducting a cost-effectiveness analysis. If statistically
significant differences in change scores between groups were found for either the patient or carer primary
outcome measures, or European Quality of Life-5 Dimensions (EQ-5D) Index scores (for quality-adjusted
life-years), at the final end point (6 months), a full cost-effectiveness/cost–utility analysis would be
conducted. Otherwise, the costs of the intervention would be evaluated in relation to the broader range
of patient and carer consequences/outcomes.100
Risks and adverse events
Risks to participants from the trial were considered small, and no higher than those of usual care.
The MDT intervention was delivered by experienced professionals and was based on standard practices
that aim to improve self-awareness and management. It included assessment of home safety and aids and
adaptations, and recommendations made to participants were intended to result in overall improvements
in safety. The care assistants were fully trained, and worked under the instruction of team professionals, in
the support of patients and carers and the implementation of the agreed care plan. However, it is possible
that encouragement to exercise could result in falls that might not otherwise have occurred. Accordingly,
falls were closely monitored and analysed on an ongoing basis. Fall rates reported during the trial were
compared between groups and with baseline falls data. The external advisory group reviewed falls data at
each meeting to ensure that the incidence of falls in intervention groups had not increased significantly
since baseline, or in comparison with the control group. Other potential harms to the experimental groups
included depression if raised expectations were not met, distress when additional input was stopped,
and loss of support from family and friends if the additional care was perceived to reduce the need for
informal support.
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All adverse events (any unfavourable or unintended sign, symptom, syndrome or illness that developed
or worsened during the period of the trial) and serious adverse events (life-threatening or resulting in
hospitalisation, disability or death) were recorded. The information was gathered from various sources,
including report by MDT, research nurses, telephone messages from participants, obituary notices,
and information from doctors. All reported events were reviewed by the project manager, and assessed
for seriousness, expectedness and causality by clinical members of the research team. Any serious adverse
event deemed to be directly related to, or suspected to be related to, the intervention, and unexpected,
was to be reported to the study external advisory group and the ethics committee.
Management and governance
The research team was run on a day-to-day basis by a full-time manager, with help from an administrative
assistant. All aspects of data collection and management were under the supervision of the research
manager, and analysis was undertaken by a statistician. The research team was supported in the delivery
of the trial by an external steering committee, which met twice per year to review progress and ensure
timely completion of milestones. Membership included clinical experts, experienced researchers,
representatives from Parkinson’s UK and the European Parkinson’s Disease Association, local service
providers and commissioners, and people with Parkinson’s and carers.
A PPI group, co-ordinated by an independent PNS, helped the research team at all stages of the project,
from planning to dissemination. It met separately and in conjunction with the research team and advised
on the development of study documents, processes and procedures for recruitment, treatment and
research assessments. The PPI group worked with the research team on the production of newsletters to
participants to keep them updated on the progress of the trial.
Ethical and organisational review
A favourable ethical opinion was obtained from Surrey Research Ethics Committee (application number
10/H1109/1), and the University of Surrey Ethics Committee. NHS research and development approval was
granted by four participant identification centres (Ashford and St. Peter’s Hospitals NHS Foundation Trust,
Frimley Park Hospital NHS Foundation Trust, Royal Surrey County NHS Foundation Trust, and Surrey
Primary Care Trust).
Protocol
The protocol was published.101
METHODS
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Chapter 3 Recruitment and trial processes
Flow of participants through the trial: Consolidated Standards
of Reporting Trials diagram
A total of 464 people with Parkinson’s expressed an interest in participating in the trial and were contacted
by telephone by members of the research team. Of these, 151 did not proceed further: 44 were found not
to meet the inclusion criteria; 88 declined to take part after learning more about the study; 15 were sent
information about the trial but did not respond to subsequent telephone messages left by the research
team; and four expressed interest in participating after recruitment had been closed.
Baseline visits took place to 313 people with Parkinson’s. Among these people, there were 188 live-in
carers who were interested in participating. Following consent and baseline assessment, seven people with
Parkinson’s (with six live-in carers) were found to be ineligible and were excluded because their MMSE
score was< 24, hence 306 people with Parkinson’s and 182 live-in carers were randomised. The group
allocation of people with Parkinson’s (and live-in carers) was as follows: group A, n= 102 (n= 61);
group B, n= 101 (n= 60); group C, n= 103 (n= 61).
Baseline comparisons were conducted on 269 people with Parkinson’s and 155 live-in carers (the ITT
analysis sample). There were 37 people with Parkinson’s and 27 live-in carers who were randomised but
excluded from the analysis. Exclusions arose for various reasons. During the treatment and research phase,
five patients were identified whose diagnosis of Parkinson’s was in doubt, even though they had previously
been clinically diagnosed and were receiving treatment for that condition. These patients were further
investigated by the consultant neurologists and found not to have Parkinson’s disease, and were therefore
removed from the analysis. In addition, there were two protocol violations – a person with Parkinson’s
who was too ill to participate in the trial (live-in carer also excluded from study) and a live-in carer who
scored at the most favourable end of all outcome scales. Data relating to people recruited into the first
(pilot) cohort were also not included in the analysis because the MDT was not at full strength and its
processes were under development (n= 31, of whom one was a wrong Parkinson’s diagnosis).
Randomisation and completion of the trial
The group assignment of 269 people with Parkinson’s (155 live-in carers) included in the analysis was
88 (52) to receive the 6-week MDT intervention only (group A); 88 (50) to receive the MDT intervention
plus PCA support for a further 4 months (group B); and 93 (53) in the usual-care control (group C). Not all
of these participants completed the trial. Attrition occurred at all stages, as indicated on the CONSORT
diagram (Figure 2), including eight people with Parkinson’s who did not receive treatment (two in group A
and six in group B). Some participants who were not available for assessment at 24 weeks were reached
at 36 weeks.
Trial processes
Intervention fidelity
Although the decision to exclude the first cohort from the analysis and to recruit an extra cohort of
participants was taken early in the trial (because MDT staffing increased and processes were consolidated
after the initial cohort had been completed), this course of action is confirmed by an analysis of
intervention delivery. Comparison of the duration of MDT contact time with participants (patient-facing
minutes on home visits plus time on telephone calls) in each cohort showed that people treated in the first
cohort had significantly less MDT input than those in the subsequent nine cohorts. No significant
difference was found in MDT input across the subsequent nine cohorts, or in comparisons of the MDT
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Expression of interest PwP
(n = 464)
Baseline visit for consent and
baseline data collection
PwP, n = 313; LIC, n = 188
Randomised
PwP (n = 306); LIC (n = 182)
Group A PwP, n = 102; LIC, n = 61
Group B PwP, n = 101; LIC, n = 60
Group C PwP, n = 103; LIC, n = 61
Lost at initial screen (n = 151);
•  Not meeting inclusion criteria, n = 44
•  Declined, n = 88
•  Other, n = 19
Excluded (not eligible)
PwP, n = 7; LIC, n = 6
Included in analysis
PwP, n = 269
 LIC, n = 155
Group B
MDT + PCA intervention
PwP, n = 88
LIC, n = 50
Treated by MDT
PwP, n = 82
LIC, n = 47
Lost to follow-up:
PwP, n = 6
 LIC, n = 3
Lost to follow-up:
PwP, n = 2
 LIC, n = 1
Not available:
PwP, n = 6; LIC, n = 3
Lost to follow-up:
PwP, n = 4; LIC, n = 2
Lost to follow-up:
PwP, n = 1; LIC, n = 1
Missed follow-up 2:
PwP, n = 5; LIC, n = 3
Excluded from analysis: PwP, n = 37; LIC, n = 27
•  Pilot /cohort 1: PwP, n = 31; LIC, n = 22
•  Wrong PD diagnosis: PwP, n = 5; LIC, n = 3a
•  Protocol violation: PwP, n = 1; LIC, n = 2
•  Withdrew, no data: PwP, n = 1
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Control group
PwP, n = 93
LIC, n = 53
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LIC, n = 47
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FIGURE 2 Flow of participants throughout the trial: CONSORT diagram. LIC, live-in carers; PD, Parkinson’s disease;
PwP, people with Parkinson’s. a, 1 PwP with wrong diagnosis and also in pilot. Dark green shading indicates an
intervention; light green shading indicates participants in study; and no shading indicates people lost to the study.
RECRUITMENT AND TRIAL PROCESSES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
26
input between group A (received MDT only) and group B (received MDT+ PCA). There was more variability
in the PCA input between cohorts, but differences were still not significant (Table 3). Analysis of the
intervention costs is reported in the economic evaluation section in Chapter 4.
Distribution of follow-up assessments
The main research nurse undertook 757 (76.2%) of the 994 assessments that were conducted. Help was
required in the middle of the trial when several cohorts were being followed up concurrently, and for
holiday cover. The remainder of the assessments were conducted by two assistants. Owing to difficulties
recruiting a suitable assessor on a part-time and temporary basis, a PNS from within the project team and
a PCA (with nursing qualifications) fulfilled the role. The PCA mostly conducted the 24-week assessments,
and the PNS mostly undertook baseline assessments (Table 4). The PCA was masked to the group
allocation of the participants that she assessed, and she was not allocated participants in group B unless
they were in a cohort treated by the other PCA in the trial. The PNS mostly conducted baseline
assessments before group allocation was determined.
Timing of follow-up assessments
Gaps between assessments
For over 90% of participants, there was< 12 weeks (84 days) between the first and second assessment,
indicating that most baseline assessments took place within 4 weeks of the start of the 6-week treatment
period for any cohort, and that most post-MDT treatment assessments took place within 4 weeks of
the end of that 6-week treatment phase. The mean gap between assessments 1 and 2 was 72.0 days
(Table 5). The third assessment [due 24 weeks after baseline/18 weeks (126 days) after the end of
treatment] took place, on average, 136.4 days after the post-treatment assessment. The fourth assessment
[due 36 weeks after baseline and 12 weeks (84 days) after assessment 3], took place, on average, 78 days
after assessment 3.
Assessments in relation to treatment
Assessment 2 took place within a mean of 12 days after completion of the MDT (groups A and B only).
A small number (n= 11) of people had assessment 2 prior to the completion of the MDT input, usually
because sickness or holidays of the participant or professional had delayed the MDT delivery. Assessment 3
took place within a mean of 20 days from the end of the PCA input (group B only).
Adverse events
During the trial, a large number of falls were recorded in the adverse events log, and analysed by
assessment time point and group. Many people reported multiple falls. Data on falls were presented and
discussed with the external advisory group on an ongoing basis. The data revealed no statistically
significant differences in fall rates (number of fallers and number of falls) between groups at each
assessment point (Table 6). Other adverse events that were reported (39 in A, 44 in B and 25 in C)
included infections (chest, gastric, urinary), worsening symptoms and minor surgery (but not requiring
hospital admission overnight).
There were 69 serious adverse events (involving hospital stays or death) recorded for people with
Parkinson’s (24 in A, 26 in B and 19 in C), and two for carers (Table 7). No serious adverse events were
judged to be unexpected by clinical members of the research team. Many adverse events came to the
notice of the research team through the MDT and PCA visits to treatment groups, and this may account
for the lower number of adverse events recorded for the control group (C).
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TABLE 4 Distribution of 994 assessments conducted by research nurses
Assessment
Research
nurse
Group A:
MDT
[n (%)]
Group B:
MDT+ PCA
[n (%)]
Group C:
control
[n (%)]
Total assessments [n (%)] by
Lead
nurse
Assistant 1
(PCA)
Assistant 2
(PNS)
1: baseline Main research
nurse
69 (78) 65 (74) 66 (71) 200 (74)
Assistant 1
(PCA)
5 (6) 5 (6) 3 (3) 13 (5)
Assistant 2
(PNS)
14 (16) 18 (20) 24 (26) 56 (21)
2: post treatment Main research
nurse
78 (91) 79 (96) 71 (82) 228 (89)
Assistant 1
(PCA)
6 (7) 0 (0) 11 (13) 17 (7)
Assistant 2
(PNS)
2 (2) 3 (4) 5 (6) 10 (4)
3: 24 weeks Main research
nurse
9 (12) 64 (88) 25 (30) 98 (42)
Assistant 1
(PCA)
67 (88) 9 (12) 59 (70) 135 (58)
Assistant 2
(PNS)
0 (0) 0 (0) 0 (0) 0 (0)
4: 36 weeks Main research
nurse
80 (100) 72 (100) 79 (93) 231 (97)
Assistant 1
(PCA)
0 (0) 0 (0) 6 (7) 6 (3)
Assistant 2
(PNS)
0 (0) 0 (0) 0 (0) 0 (0)
Total 330 315 349 757 (76) 171 (17) 66 (7)
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TABLE 7 Serious adverse events (hospitalisations and death) reported regarding people with Parkinson’sa
Cohort Group A Group B Group C
1 (pilot) Fall, taken to A&E One fall and fractured neck of
femur
Seizure
Severe stroke
Chest infection
Extreme depression
(suicidal thoughts)
MI
2 Two falls and pneumonia
One fall, contracted MRSA in
hospital
One death (pneumonia)
Vomiting blood
Poor mobility and UTI
Stroke (unconfirmed)
TIA
Endoscopy and stent
3 Condition deteriorated, hospitalised
with UTI
One fall and fractured cheekbone
One fall and TIA
One fall and fractured shoulder GI problems
Colostomy
4 Weight loss, swallowing problems
Pneumonia
Pulmonary fibrosis
Stroke
MI
One fall and UTI
Pneumonia
One fall, discharged with
care package
5 One death (bowel surgery,
heart failure)
One fall and hip replacement
Prolonged hospital stay, transfer to
care home, UTI
Kidney failure/infection
One fall and UTI
UTI, hallucinations
One fall and shoulder damage
Two fractured vertebrae, three
fractured ribs
6 One fall and cracked ribs
One fall; collapsed and PD
medication overdose
Cracked neck of femur
Chest infection
TIA
Loss of consciousness
(hypotension, heart rate)
Pneumonia
One death (cause not known)
Epistaxis
7 One fall
Loss of consciousness/hypotension
Vomiting blood
Viral infection
RTI
Angina
8 Chest pain Chest infection
One fall and fractured kneecap
Dizziness
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Baseline characteristics of participants, and comparison
of groups
Baseline characteristics were analysed for 269 people with Parkinson’s and 155 live-in carers.
People with Parkinson’s
Significantly more of the people with Parkinson’s in group A (MDT only) were men. Although few
participants were current smokers, there was a tendency for more people with Parkinson’s in group C
(control) than in the other groups to have reported smoking in the past. People with Parkinson’s in
group B (MDT+ PCA) had a (just) significantly lower BMI. There were no differences between the groups
with respect to other baseline descriptors including age; with a carer in the study; education; income
group; comorbidities; medication use; time since Parkinson’s diagnosis; disease stage; proportions living
alone; and at risk of social isolation (Table 8).
Regarding previous Parkinson’s care (Table 9), over 80% of people with Parkinson’s reported that they had
a PNS, and over 60% of these had seen the nurse within the last 6 months. A total of 53 (19.7%) either
did not have a PNS or reported that they had not seen a PNS within 2 years. There was no difference
between groups in outpatient hospital appointments for Parkinson’s, with most participants having two
appointments per year. Of the 231 people with Parkinson’s (across all groups) diagnosed more than
2 years previously, 72 (31.2%) had seen a PT within 6 months, but 97 (42.0%) stated that they had not
seen a PT for 2 years or had never/did not know if they had seen one. In comparison with consultations
with PNSs and PTs, the proportions who had seen OTs and SLTs within 6 months were much lower
(11.7% and 9.1%, respectively), and the proportions without contact with these therapists in the previous
2 years/never/did not know were much higher (74.0% and 77.5%, respectively).
Participants reported having a wide range of aids and adaptations, many of which they had purchased
themselves (see Appendix 21). The profile of medications taken for Parkinson’s, and for the management
of non-motor symptoms and medication side effects, is shown in Appendix 22. The only significant
difference found between treatment groups was in the use of glutamate antagonists (which was higher
in group B).
TABLE 7 Serious adverse events (hospitalisations and death) reported regarding people
with Parkinson’sa (continued )
Cohort Group A Group B Group C
9 Chest infection and urinary
retention
Lewy Body dementia and infection
‘Unwell’
Hypertension
One fall and loss of consciousness
10 One fall and fractured arm, pelvis
Pneumonia
One fall and hypertension
Arrhythmia
Collapse (hypotension)
Severe pain and infection
Breathless, weak, fluid in lungs
MI
Total 24 26 19
GI, gastrointestinal; MI, myocardial infarction; MRSA, methicillin-resistant Staphylococcus aureus; PD, Parkinson’s disease;
RTI, respiratory tract infection; TIA, transient ischaemic attack; UTI, urinary tract infection.
a Two serious adverse events were reported for live-in carers: transfer to care home following falls and hip replacement.
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TABLE 8 Baseline characteristics of 269 people with Parkinson’s, cohorts 2–10 (the ITT sample)
Characteristic
Group A:
MDT (N= 88)
Group B:
MDT+ PCA
(N= 88)
Group C: usual
care, control
(N= 93)
Significance Testn (%) n (%) n (%)
Categorical variables
Sex
Male 65 (73.9) 50 (56.8) 49 (52.7) 0.009 Chi-squared
Female 23 (26.1) 38 (43.2) 44 (47.3)
Carer status
No carer 19 (21.6) 18 (20.5) 25 (26.9) 0.546a Chi-squared
Carer (in study) 52 (59.1) 50 (56.8) 53 (57.0)
Of which carer
is spouse/
partner [vs.
family member
or friend]
49 [3] (94.2) 48 [2] (96.0) 49 [4] (92.5)
Carer (not in
study)
17 (19.3) 20 (22.7) 15 (16.1)
Ethnicity
White 88 (100) 88 (100) 93 (100) N/A N/A
Warden-assisted or sheltered accommodation
Yes 6 (7.1) n= 85 8 (9.2) n= 87 5 (5.5) n= 91 0.633 Chi-squared
No 79 (92.9) 79 (90.8) 86 (94.5)
Accommodation type
Owner-occupied
flat/house
82 (94.3) n= 87 84 (96.6) n= 87 89 (96.7) n= 92 N/A N/A
Rented flat or
housing
association
5 (5.7) 2 (2.3) 2 (2.2)
Other 0 (0) 1 (1.1) 1 (1.1)
Education level
Primary to
12 years
1 (1.2) n= 83 2 (2.3) n= 82 1 (1.1) n= 91 0.347 Kruskal–Wallis
Secondary to
16 years
33 (38.4) 36 (41.9) 49 (53.3)
Secondary to
18 years
9 (10.5) 9 (10.5) 6 (6.5)
Vocational/further
education
18 (20.9) 17 (19.8) 14 (15.2)
University 22 (25.6) 18 (20.9) 21 (22.8)
Employment status
Full/part time 8 (9.1) 5 (5.7) n= 87 4 (4.3) n= 92 0.411 Chi-squared
Not employed 80 (90.9) 82 (94.3) 88 (95.7)
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TABLE 8 Baseline characteristics of 269 people with Parkinson’s, cohorts 2–10 (the ITT sample) (continued )
Characteristic
Group A:
MDT (N= 88)
Group B:
MDT+ PCA
(N= 88)
Group C: usual
care, control
(N= 93)
Significance Testn (%) n (%) n (%)
Household income per year
< £12,000 12 (15.8) n= 76 11 (15.5) n= 71 8 (11.0) n= 73 0.984 Kruskal–Wallis
£12,000–20,000 23 (30.3) 22 (31.0) 25 (34.2)
£20,001–30,000 20 (26.3) 18 (25.4) 22 (30.1)
£30,001–45,000 12 (15.8) 9 (12.7) 9 (12.3)
> £45,000 9 (11.8) 11 (15.5) 9 (12.3)
Do you receive benefits?
Yes 54 (62.1) n= 87 49 (57.6) n= 85 49 (53.3) n= 92 0.492 Chi-squared
No 33 (37.9) 36 (42.4) 43 (46.7)
Number reporting
Direct payment of
personal budget
2 (2.3) 1 (1.1) 0 (0) N/A N/A
Attendance
allowance
30 (53.6) 36 (66.7) 29 (59.2) 0.374 Chi-squared
Council
tax benefit
10 (17.9) 11 (20.8) 4 (8.2) 0.192 Chi-squared
Disability
Living Allowance
18 (32.1) 13 (24.5) 20 (40.8) 0.213 Chi-squared
Housing benefit 3 (5.4) 2 (3.8) 1 (2.0) N/A N/A
How long ago were you diagnosed with PD?
< 2 years 13 (14.8) 10 (11.4) 15 (16.1) 0.290 Kruskal–Wallis
2–4.99 years 28 (31.8) 27 (30.7) 29 (31.2)
5–9.99 years 29 (33.0) 23 (26.1) 27 (29.0)
10–14.99 years 14 (15.9) 16 (18.2) 16 (17.2)
≥ 15 years 4 (4.5) 12 (13.6) 6 (6.5)
Modified Hoehn and Yahr disease stage65
0. No sign
of disease
0 (0) 2 (2.3) 4 (4.3) 0.152 Kruskal–Wallis
1. Unilateral
disease
(mild symptoms)
21 (23.9) 21 (23.9) 26 (28.0)
2. Bilateral
disease, minimal
disability
21 (23.9) 19 (21.6) 22 (23.7)
3. Bilateral
disease,
moderate
disability, some
postural
instability
38 (43.2) 34 (38.6) 38 (40.9)
continued
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TABLE 8 Baseline characteristics of 269 people with Parkinson’s, cohorts 2–10 (the ITT sample) (continued )
Characteristic
Group A:
MDT (N= 88)
Group B:
MDT+ PCA
(N= 88)
Group C: usual
care, control
(N= 93)
Significance Testn (%) n (%) n (%)
4. Severe
symptoms
and disability
8 (9.1) 11 (12.5) 3 (3.2)
5. Wheelchair/
bedridden
without help
0 (0) 1 (1.1) 0 (0)
Have you ever smoked?
Yes 38 (43.2) 36 (41.4) n= 87 52 (56.5) n= 92 0.084 Chi-squared
No 50 (56.8) 51 (58.6) 40 (43.5)
If yes: are you a current or ex-smoker?b
Current smoker 3 (7.9) 4 (11.1) 4 (7.7) 0.835 Chi-squared
Ex-smoker 35 (92.1) 32 (88.9) 48 (92.3)
LSNS-664 (range 0–30)
≤ 12, at risk of
social isolation
21 (24.1) n= 87 18 (20.9) n= 86 13 (14.1) n= 92 0.226 Chi-squared
> 12, not at risk
of social isolation
66 (75.9) 68 (79.1) 79 (85.9)
Characteristic
Group A:
MDT (N= 88)
Group B:
MDT+ PCA
(N= 88)
Group C: usual
care, control
(N= 93)
Mean (SD) Mean (SD) Mean (SD)
Continuous variable
Age, years 72.94 (8.63) 74.02 (8.19) n= 87 71.57 (7.88) 0.137 One-way
ANOVA
Comorbidities,
number
3.16 (1.976) 3.00 (1.75) n= 86 3.12 (1.86) n= 92 0.842
Total
medications,
number
per day
6.32 (4.04) n= 87 6.43 (3.77) n= 87 6.84 (4.29) 0.661 One-way
ANOVA
Parkinson’s
medications,
number
per day
2.53 (1.29) n= 87 2.60 (1.48) 2.70 (1.77) 0.757 One-way
ANOVA
MMSE score
(range 0–30)66
28.53 (1.76) 28.52 (1.74) 28.62 (1.73) 0.912 One-way
ANOVA
LSNS-664 (range
0 isolated–30)
16.98 (6.36) n= 87 17.43 (5.92) n= 86 17.55 (5.87) n= 92 0.800 One-way
ANOVA
BMI 25.04 (4.26) n= 84 24.41 (4.12) n= 84 25.97 (4.22) n= 91 0.050 One-way
ANOVA
LSNS-6, Lubben Social Network Scale-6; N/A, not applicable; PD, Parkinson’s disease.
a No carer vs. carer.
b No significant difference between groups in length of time smoked in years, mean (SD): A 16.86 (14.06);
B 25.11 (19.44); C 20.88 (14.55); p= 0.095, one-way ANOVA.
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TABLE 9 Prior Parkinson’s care reported at baseline by 269 people with Parkinson’s, cohorts 2–10 (the ITT sample)
Characteristic
Group A:
MDT (N= 88)
Group B:
MDT+ PCA (N= 88)
Group C:
control (N= 93)
Significance Testn (%) n (%) n (%)
Have PNS
Yes 73 (83.0) 77 (87.5) 79 (84.9) 0.697 Chi-squared
No 15 (17.0) 11 (12.5) 14 (15.1)
If yes: last time saw PNS
< 6 months ago 44 (61.1) n= 72 54 (72.0) n= 75 43 (54.4) n= 79 0.131 Kruskal–Wallis
Between
6 months and
1 year ago
15 (20.8) 12 (16.0) 24 (30.4)
1–2 years ago 7 (9.7) 5 (6.7) 9 (11.4)
> 2 years ago 6 (8.3) 4 (5.3) 3 (3.8)
Last time saw PT (only those diagnosed for ≥ 2 years)
< 6 months ago 20 (26.7) n= 75 28 (35.9) n= 78 24 (30.8) n= 78 0.025 Kruskal–Wallis
Between
6 months and
1 year ago
8 (10.7) 10 (12.8) 4 (5.1)
1–2 years ago 9 (12.0) 15 (19.2) 16 (20.5)
> 2 years ago 12 (16.0) 7 (9.0) 13 (16.7)
Never 19 (25.3) 12 (15.4) 17 (21.8)
Don’t know 7 (9.3) 6 (7.7) 4 (5.1)
Last time saw OT (only those diagnosed for ≥ 2 years)
< 6 months ago 8 (10.7) n= 75 13 (16.7) n= 78 6 (7.7) n= 78 0.142 Kruskal–Wallis
Between
6 months and
1 year ago
3 (4.0) 8 (10.3) 3 (3.8)
1–2 years ago 5 (6.7) 5 (6.4) 9 (11.5)
> 2 years ago 9 (12.0) 10 (12.8) 8 (10.3)
Never 46 (61.3) 39 (50.0) 48 (61.5)
Don’t know 4 (5.3) 3 (3.8) 4 (5.1)
Last time saw SLT (only those diagnosed for ≥ 2 years)
< 6 months ago 9 (12.0) n= 75 8 (10.3) n= 78 4 (5.1) n= 78 0.395 Kruskal–Wallis
Between
6 months and
1 year ago
4 (5.3) 4 (5.1) 4 (5.1)
1–2 years ago 5 (6.7) 7 (9.0) 7 (9.0)
> 2 years ago 7 (9.3) 7 (9.0) 5 (6.4)
Never 46 (61.3) 51 (65.4) 58 (74.4)
Don’t know 4 (5.3) 1 (1.3) 0 (0.0)
continued
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Live-in carers
A higher proportion of carers in group A than in groups B and C were female. Consistent with the people
with Parkinson’s, the live-in carers in the control group were more likely to report previous smoking
behaviours. On average, compared with the live-in carers in groups A and C, those in group B
(MDT+ PCA) reported that they could leave the person with Parkinson’s alone for less time during
the day (p= 0.048) (Table 10).
Baseline outcome measures: comparison of groups
People with Parkinson’s
Participants in group B (MDT+ PCA) scored significantly worse on the Frenchay Activities Index
(p= 0.012),77–79 and tended to display higher dependency on the Barthel Activities of Daily Living (ADL)
measure (p= 0.079)76 than those in groups A and C. People with Parkinson’s in group B also reported
more disability on the primary outcome measure, but this difference was not significant (Table 11).
There was a significant difference between groups in the proportions screening positive on the Yale
single-item Depression Screen (highest in C, lowest in A, p= 0.09).84,85 Groups also differed on some
speech items (C better than A and B, p= 0.026–0.083). There were no significant differences between
groups at baseline in the other outcome measures [including Hospital Anxiety and Depression Scale
(HADS),83 self-efficacy, self-report speech problems, disease-specific and generic health-related quality of
life, pain and mobility] (see Table 11).
Generally, low average levels of disability and functional impairment were observed among the people
with Parkinson’s in the study, with many scoring towards the most favourable end of most of the outcome
scales. Distributions were non-normal, with small numbers of participants reporting significant limitations.
Live-in carers
As with the people with Parkinson’s, the live-in carers in group B scored worse than those in the
other two groups on the Frenchay Activities Index (p= 0.056).77–79 There was no difference between
the groups on any other carer outcome at baseline, including carer strain and stress, ADL, health-related
quality of life, and anxiety and depression. Generally, the carers in the study reported almost no functional
limitations (Table 12).
TABLE 9 Prior Parkinson’s care reported at baseline by 269 people with Parkinson’s, cohorts 2–10
(the ITT sample) (continued )
Characteristic
Group A:
MDT (N= 88)
Group B:
MDT+ PCA (N= 88)
Group C:
control (N= 93)
Significance Testn (%) n (%) n (%)
Number of times per year that usually visit hospital as outpatient to see doctor about Parkinson’s
Never 6 (6.8) n= 81 3 (3.4) n= 81 3 (3.2) n= 81 0.722 Kruskal–Wallis
< once per year 3 (3.4) 4 (4.5) 20 (21.5)
About once
per year
20 (22.7) 25 (28.4) 45 (46.8)
About 2 times
per year
43 (48.9) 38 (43.2) 22 (23.7)
About 3–4 times
per year
11 (12.5) 14 (15.9) 3 (3.2)
More than 4 times
per year
5 (5.7) 4 (4.5) 0 (0)
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TABLE 10 Baseline characteristics of 155 live-in carers, cohorts 2–10 (the ITT sample)
Characteristic
Group A:
MDT (N=88)
Group B:
MDT+PCA
(N=88)
Group C:
control (N=93) Significance Test
Categorical variables n (%) n (%) n (%)
Sex
Male 9 (17.3) 19 (38.0) 15 (28.3) 0.065 Chi-squared
Female 43 (82.7) 31 (62.0) 38 (71.7)
Live with person with Parkinson’s
Yes, all the time 50 (96.2) 50 (100.0) 51 (96.2) Not applicable Not applicable
Yes, some of the time 1 (1.9) 0 (0.0) 0 (0.0)
No 1 (1.9) 0 (0.0) 2 (3.8)
Education level
Primary to 12 years 0 (0.0) n=49 2 (4.3) n=47 1 (1.9) n=51 0.809 Kruskal–Wallis
Secondary to 16 years 19 (38.8) 17 (36.2) 22 (42.3)
Secondary to 18 years 6 (12.2) 6 (12.8) 6 (11.5)
Vocational/further
education
12 (24.5) 13 (27.7) 10 (19.2)
University 12 (24.5) 9 (19.1) 12 (23.1)
Employment status
Full/part time 6 (11.5) 5 (10.0) 10 (18.9) 0.368 Chi-squared
Not employed 46 (88.5) 45 (90.0) 43 (81.1)
Do you receive Carer’s Allowance?
Yes 7 (36.8) n=19 4 (30.8) n=13 3 (20) n=15 0.564 Chi-squared
No 12 (63.2) 9 (69.2) 12 (80)
Have you given up or cut down on work to provide care?
No 41 (78.8) 35 (72.9) n=48 41 (80.4) n=51 0.703 Kruskal–Wallis
Yes, cut down 5 (9.6) 7 (14.6) 4 (7.8)
Yes, given up 6 (11.5) 6 (11.8) 6 (11.8)
On a typical day, how much of the time can you leave the person with Parkinson’s at home alone?
<25% 11 (21.2) 18 (36.7) n=49 11 (21.2) n=52 0.048 Kruskal–Wallis
25% to 49% 9 (17.3) 9 (18.4) 7 (13.5)
50% to 74% 11 (21.2) 7 (14.3) 6 (11.5)
75% to 100% 21 (40.4) 15 (30.6) 28 (53.8)
Have you ever smoked?
Yes 14 (27.5) n=51 19 (38.0) 31 (58.5) 0.005 Chi-squared
No 37 (72.5) 31 (62.0) 22 (41.5)
If yes: are you a current or an ex-smoker?
Current smoker 1 (7.7) n=13 2 (10.5) n=19 6 (20.0) n=30 0.482 Chi-squared
Ex-smoker 12 (92.3) 17 (89.5) 24 (80)
Continuous variables Mean (SD) Mean (SD) Mean (SD)
Age, years 70.01
(7.28)
n=51 72.46
(8.22)
68.73
(7.19)
0.043 One-way
ANOVA
Time spent caring in an
average week, hours
52.07
(60.10)
n=51 59.13
(63.07)
n=48 39.61
(51.49)
n=49 0.252
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Chapter 4 Outcomes and costs
Clinical outcomes
An ITT analysis was conducted for 269 people with Parkinson’s (155 live-in carers), i.e. 306 people with
Parkinson’s randomised, less five people who were later found not to have Parkinson’s, one protocol
violation, one person who withdrew data, and 31 in the pilot group (one with a wrong diagnosis) who
received a reduced version of the intervention. However, eight people (two in group A and six in group B)
did not receive the MDT intervention, and further attrition occurred at every assessment point. Hence the
post-treatment outcomes reported in the text are based on the analysis of participants who fulfilled the
protocol requirements in terms of eligibility, treatment and completion of all four assessments (i.e. a PPA).
This included 227 people with Parkinson’s (and 125 live-in carers) [group A, 75 (45); group B, 69 (37),
group C, 83 (43)], although the sample size was reduced below these numbers for any instrument when
participants failed to complete all four assessments. Comparisons of the results of the PPA and ITT, as
shown in Appendix 23, revealed no differences in the conclusions that could be drawn from the data.
Comparison of people included in intention-to-treat but omitted in
per-protocol analysis
Comparing the 269 people with Parkinson’s included in the ITT analysis with the 226 who completed all
assessments for the primary outcome measure (Self-Assessment Parkinson’s Disease Disability Scale69,70),
those lost to follow-up had been diagnosed earlier and had a higher Hoehn and Yahr (disease stage) score
(Mann–Whitney U test: p= 0.007 and 0.001, respectively), were older, took more medications and
Parkinson’s medications, and had a lower BMI (unpaired t-tests: p= 0.014,< 0.0005,< 0.0005 and 0.002,
respectively). People who lived alone were less likely to complete the trial than those who lived with a
carer (chi-squared p= 0.016). There was no significant difference between those completing and those
dropping out with respect to sex, education, smoking, and social support.
Comparing the 155 live-in carers included in the ITT analysis with the 125 who completed all assessments
for the primary outcome measure (Modified Carer Strain Index71), those lost to follow-up were significantly
older (unpaired t-test p= 0.011). There was no significant difference between those completing and those
dropping out with respect to sex, education, smoking and how long they stated that they spent looking
after the person with Parkinson’s on a typical day.
Graphical representation of findings
To gain an understanding of trends, the mean values from the PPA for each group were plotted for each
outcome across all assessment points (see Appendix 23 for people with Parkinson’s and for live-in carers).
For instruments which measure disability (such that an improvement is a reduction), the scales on the
graphs have been reversed. This is to assist with visual interpretation, i.e. in all cases where the trend lines
are upwards, this represents an improvement in the average condition of participants. However, Parkinson’s
is a degenerative disease, and a reduction in the rate of deterioration (one group compared with another)
may also be a positive outcome.
The graphs of PPA outcomes in Appendix 23 are supported by tables that show baseline (week 0) means
by treatment group, and changes in group means: baseline to week 6 (post treatment) for the effect of
the MDT in groups A and B; week 6–week 24 (end of PCA support for group B) for the effect of the
PCA intervention; baseline to week 24; week 24–36 (final assessment/end point) for trends after both
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© Queen’s Printer and Controller of HMSO 2014. This work was produced by Gage et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
45
interventions had stopped; and baseline to week 36 for the overall intervention effectiveness. The tables
also show the results of tests of significance (p-values) for differences between group means at baseline;
differences between group change scores from baseline (week 0) to week 6, week 6–24, week 0–24,
week 24–36 and week 0–36; and within-group changes for the same periods between assessments.
Tables with the results from the ITT analysis are also shown in Appendix 23, but these results are not
plotted on graphs as the differences from the PPA analysis are small.
The results of the PPA are reported by follow-up period in Tables 13–22 and are summarised in Table 23,
and by outcome measure in Table 24 (people with Parkinson’s) and Table 25 (live-in carers). Outcomes
where there are significant (p< 0.05) and marginally significant (p< 0.10) differences in change scores
between groups are discussed in the text. Information on the within-group changes that account for the
observed differences in the between-group change scores is also provided. Results are not discussed where
change scores between groups are not significantly different, but are shown in the tables.
Short-term effects of the 6-week multidisciplinary team intervention:
groups A and B combined versus group C
Change scores were significantly different, and in favour of intervention groups A+ B, compared with
group C (control), in measures of psychological well-being (Table 13). Participants in the intervention
groups experienced a reduction in anxiety (HADS,83 p= 0.02), while depression (HADS,83 p= 0.05) and the
mental component summary (MCS p= 0.04) score of Short Form Questionnaire-36 items (SF-36)82
worsened significantly in the control group. There was a tendency for those receiving the MDT to show
improvements, compared with those who did not, in the primary outcome (Parkinson’s disability p= 0.09),
the Parkinson’s Non-Motor Symptoms Questionnaire74,75 (p= 0.06) and the EQ-5D health-related
quality-of-life index80,81 (p= 0.07); self-reported speech tended to worsen in the control group relative to
the intervention groups (p= 0.07).
Live-in carers in groups A+ B reported significantly improved psychological well-being (SF-36 MCS
p= 0.02), compared with those in group C. There were no differences in changes between groups from
baseline to end of MDT treatment on any other outcome measure (Table 14).
Medium-term effects of the Parkinson’s care assistant intervention
(weeks 6 to 24): group B (Parkinson’s care assistant support) versus
group A (no Parkinson’s care assistant support)
The impact of the PCA intervention was assessed by comparing changes in outcomes for group A versus
group B between week 6 (end of the MDT intervention for both groups) and week 24 (end of PCA support
for group B) (Table 15). Scores recorded for group A worsened significantly, while those for group B did
not change, resulting in a significant difference in change scores in favour of the intervention group B for
the Parkinson’s Non-Motor Symptoms Questionnaire74,75 (p= 0.05) and the UPDRS posture measure89
(p= 0.01), and marginally for the EQ-5D health-related quality-of-life index80,81 (p= 0.07) and self-efficacy86
(p= 0.09). There was a significant difference in change scores on the Emerson and Enderby voice measure94
that was in favour of group A (p< 0.001).
There was a marginally significant difference in change scores on the live-in carer primary outcome
measure (carer strain71) due to a non-significant increase in strain in group A and a similar non-significant
reduction in strain in group B (p= 0.06) (Table 16).
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Medium-term effects (baseline to week 24): groups A versus B;
A versus C; B versus C
The paired-group comparisons of changes from baseline to week 24 reveal scattered significant effects that
mostly focus on the same outcomes that showed effect at 6 weeks (A+ B vs. C) and over the 18-week
PCA follow-up period (A vs. B). There were no significant effects on the primary outcomes of either people
with Parkinson’s or live-in carers (Tables 17 and 18).
Comparing group A (MDT) and group B (MDT+ PCA), significant differences in change scores from baseline
were observed for people with Parkinson’s in EQ-5D health-related quality-of-life index80,81 (p= 0.04)
and UPDRS posture89 (p< 0.001), due to significant improvements in group B; SF-36 MCS82 (p= 0.04) and
depression (HADS,83 p= 0.02), due to significant worsening in group A; and Emerson and Enderby voice
measure94 (p< 0.01), due to significant improvements in group A. The change in the physical component
summary (PCS) score of SF-3682 was significantly different for live-in carers (p= 0.01), due to a significant
worsening in group B.
The only significant difference in change scores from baseline for people with Parkinson’s between groups
A (MDT) and C (control) was in the Emerson and Enderby voice measure94 (p= 0.02) (A significantly
improved); there was a marginally significant difference in changes in Speech Self Report (p= 0.09)
(C worsened significantly). Differences in change scores between the groups were found for live-in carers
on depression (HADS,83 p= 0.04), due to significant worsening in group C, and marginally in SF-36 PCS,82
p= 0.06 (improvement in group A and worsening in group C, both non-significant).
Significant differences in changes were observed for people with Parkinson’s between group B
(MDT+ PCA) and group C (control) on a larger number of measures: Parkinson’s Non-Motor Symptoms
Questionnaire74,75 (p= 0.05) (B improved, C worsened, both non-significant); EQ-5D Index80,81 (p= 0.04)
and UPDRS posture89 (p= 0.01) due to significant improvements in group B; Emerson and Enderby
articulation scale94 (p= 0.04) (trend for B to improve); and Speech Self Report (p= 0.01) (C worsened
significantly). There were marginally significant differences in the change scores for SF-36 MCS82 (p= 0.06)
and anxiety (p= 0.09) (HADS83), due to worsening in group C [significant for MCS, marginal for anxiety
(HADS)]. There was a significant difference in the SF-36 MCS82 change scores of live-in carers (p= 0.05)
due to a significant worsening in group C.
Changes during follow-up (weeks 24 to 36) when no group received
treatment: groups A versus B; A versus C; B versus C
Significant differences in change scores in favour of group A, compared with group B, were found for
people with Parkinson’s in UPDRS posture89 (p< 0.001) and the Emerson and Enderby articulation
measure94 (p= 0.01) (significant improvements in group A) (Table 19). The difference in change scores for
the Emerson and Enderby voice measure94 was in favour of group B (p< 0.001) (significant worsening
in group A). There was a significant difference in the change scores for live-in carers on depression
(HADS,83 p= 0.03) (group A worsened significantly), and marginally on the EQ-5D health-related
quality-of-life thermometer80,81 (p= 0.06) (group A worsened, group B improved, neither change
significant) (Table 20).
Compared with people with Parkinson’s in group C, those in group A reported significantly improved
mobility (p= 0.01) (Timed Up and Go87,88). However, on all of the other measures where significant
differences in change scores were observed, the results favoured group C: UPDRS gait89 (p= 0.01)
(C improved significantly); Speech Self Report (p= 0.03) (A worsened significantly); Emerson and Enderby
voice measure94 (p= 0.02) (A and C both worsened significantly but by a larger amount in A); SF-36 PCS82
(p= 0.04) (A worsened, C improved, neither change significant). There were significant differences in the
change scores of live-in carers in groups A and C for EQ-5D health-related quality of life thermometer80,81
(p= 0.05), SF-36 MCS,82 p= 0.05 and depression, p= 0.01 (HADS83), due, in each case, to a significant
deterioration in group A.
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Significant differences were found in the change scores of people with Parkinson’s in groups B and C with
respect to UPDRS posture89 (p< 0.001) and the Emerson and Enderby articulation measure94 (p= 0.01)
(C significantly improved in both measures). Marginal differences in change scores in favour of group C
were recorded for UPDRS speech89 (p= 0.07) and SF-36 PCS82 (p= 0.06) (arising from non-significant
improvements in C and deteriorations in B), and, in the primary outcome, Parkinson’s self-reported
disability69,70 (p= 0.09) (due to a significant worsening in B). There were no differences between the
change scores of live-in carers in groups B and C during this follow-up period.
Long-term effect (baseline to week 36): groups A versus B;
A versus C; B versus C
Over the entire study period, there were relatively few differences between groups in outcome trends.
Comparing group A (had MDT) with B (MDT+ PCA), significant differences in change scores were
observed for people with Parkinson’s on SF-36 MCS82 (p= 0.02) and Speech Self Report (p= 0.02)
(group A worsened significantly on both measures), and marginally on UPDRS gait (p= 0.09) (group B
improved significantly) (Table 21). Live-in carers in group A also worsened significantly on SF-36 MCS82
(p= 0.04), compared with group B. There was a difference in change scores between groups A and B for
live-in carers on SF-36 PCS (p= 0.06) (due to improvements in A and deteriorations in B, both changes
non-significant) (Table 22).
Comparing group A (had MDT) with control group C, there was one marginally significant difference in
change scores for people with Parkinson’s between groups A and C, in the Timed Up and Go test87,88
(p= 0.06), reflecting a marginal improvement over the study period in group A. For live-in carers, there
was a significant difference in change scores on SF-36 PCS82 (p= 0.05) due to improvements in group A
and deteriorations in group C, both non-significant.
Comparing group B (had MDT+ PCA) with control group C, there were significant differences in change
scores for people with Parkinson’s on SF-36 MCS82 (p= 0.05) and Speech Self Report (p= 0.03) (due to
significant worsening in group C on both measures). There were no significant differences in change
scores of live-in carers in groups B and C on any measure over the study period.
Multidiscplinary team process outcomes
Data from the CRF showed that, over the course of the 6-week intervention, the MDT made a total of
23 referrals to other professionals (12 to participants in group A, 11 to group B). The PNSs made
40 medication changes and a further 11 recommendations for changes in timing of dose or means of
administration (total changes: 30 to group A and 21 to group B). The OT made multiple recommendations
for new aids and equipment (Table 26).
Acceptability of the programme to participants
Quantitative analysis of feedback questionnaires
At the 6-week assessment, just after the end of the MDT intervention, over 80% of people with Parkinson’s
responding to the acceptability questionnaire (which was sent only to groups A and B in cohorts 4–10)
stated that they found the treatment programme very or extremely helpful, and over 90% stated that
they had learnt a lot of new things about Parkinson’s disease (Table 27a). Almost all of the respondents
stated that they would recommend the MDT treatment programme to others. Three-quarters said that they
would like the programme repeated, mostly on an annual basis. Feedback from group B at 24 weeks about
the PCA intervention was positive, with 84% of people with Parkinson’s reporting that they found it very or
extremely helpful, and that it more than met their expectations [mean score of 75% on a VAS with range
of 0 (greatly fell short of expectations) to 100 (greatly exceeded expectations), and with 50th percentile
representing ‘met my expectations’] (Table 27b). The responses of carers were similar to those of the people
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TABLE 26 Multidisciplinary team process outcomes
Process outcome Group A, n Group B, n
Referrals to:
Neurologist 2 1
Geriatrician 0 0
GP 0 2
Community PNS 4 6
Community PT 0 0
Community OT 1 0
Community SLT 3 0
Counselling 1 1
Community mental health services 0 0
Parkinson’s UK support worker 1 1
PNS medication changes
Change of medication 23 17
Timing change 5 3
Alter means of administration 2 1
Recommendations Recommendations
Number Paticipants, n Number Paticipants, n
OT recommendations for new aids and equipment for:
Dressing 31 26 27 22
Eating/drinking 37 26 43 28
Bath 21 19 30 24
Bed mobility 38 31 51 39
Toilet 34 31 33 32
Walking 7 7 10 9
Stairs 14 13 7 7
Chair/sitting 8 7 5 5
Car 42 33 40 31
Handwriting 25 24 18 18
Garden 2 2 1 1
Shopping 30 24 14 11
Medications 2 2 2 2
Household 51 39 46 34
Hobbies 7 4 3 3
Number of new aids and adaptations reported by participants at 24-week (36-week) assessmentsa
26 (13) 23 (12)
a Control group reported 19 (17).
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with Parkinson’s, except that a higher proportion (90%) stated that they would like the programme
repeated and they rated the PCA input slightly higher.
There were many missing responses to the question on value for money for the rehabilitation programme
(asked at 6 weeks, immediately after the end of the treatment programme). People with Parkinson’s and
carers were asked if they thought that the MDT programme would be good value for money for the NHS
at each of four costs: £235, £435, £635 and £835. These costs were set to provide a range of values
either side of the estimated cost of the intervention of £635. As a group, the live-in carers thought it was
better value for money than did the patients (Table 28).
Qualitative analysis of open-text questions
The main themes emerging from the analysis of the written feedback at the 6-week assessment point
from the people with Parkinson’s and their carers who had received the MDT intervention were that
they valued the individual attention, the opportunity to discuss their problems with knowledgeable
professionals, tailored advice and home visits (Tables 29 and 30). They also commented that they had
learnt a lot about Parkinson’s disease, and how to manage it. These views were echoed by live-in carer
respondents. Suggestions for improvement included more carer involvement, more local health service
involvement, and greater spreading out of the visits. Some also noted the lack of contact with other
people with Parkinson’s (a feature of home-based treatment), and that it would have been useful to have
had the intervention sooner after diagnosis. The full text of all responses from people with Parkinson’s
and live-in carers is given in Appendix 24.
Many of the responses to the question at 24 weeks on continuing benefit from the MDT mentioned
continuing to follow the advice of health professionals and especially doing the exercises that were
suggested (Table 31). Some of the people with Parkinson’s in group B referred to the PCA input that they
had received. They regarded the PCA as a supporter and motivator. However, none of the carers
specifically mentioned the PCA input. This may be a reflection of the wording of the question, which
asked about the benefit from the MDT (not the PCA). The full text of all responses from people with
Parkinson’s and live-in carers is given in Appendix 25.
TABLE 28 Value for money of the MDT
Providing the 6-week multidisciplinary rehabilitation to people with Parkinson’s is an expense to the NHS.
What is the upper sum you think that would be good value? [n (%)]
Respondents £235 £435 £635 £835 Total
People with Parkinson’s 3 (6.8) 12 (27.3) 14 (31.8) 15 (34.1) 44 (100)
Live-in carers 1 (3.7) 3 (11.1) 10 (37.0) 13 (48.1) 27 (100)
Participants in groups A and B only, cohorts 4–10, responding at assessment 2 – immediately post treatment.
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TABLE 29 Qualitative analysis of the feedback on the MDT interventions by people with Parkinson’s, groups A
and B only, cohorts 4–10, at assessment 2 (6 weeks)
Question
Number of
responses
to question
Number of
comments
used per
question Themes emerging from data
Question 1: how helpful did you find
the treatment programme overall?
Please explain
81 75 Increased knowledge and insight into Parkinson’s including
helpful hints and practical advice
Understanding of how to manage their own condition,
boost in confidence and morale
Individual health-care professional contact and tailored input
Having time to talk to well-informed health-care professional
who understood them
Question 5: please explain, in your
view, what were the most successful
aspects of the programme?
87 84 Individual health-care professionals, personal
attention – ‘felt I mattered’
Learning new things/confirming old knowledge,
being able to talk
Visits in the home
Co-ordinated multidisciplinary input
Question 6: please explain, in your
view, what were the least successful
aspects of the programme?
82 73 Individual health-care professionals; some felt that speech
therapy was not needed
Length of programme (too short) – would like follow-ups
A lot of useful information in a short period of
time – too much to take in
Difficult to maintain self-motivation post intervention
33 responses: nothing to improve on/all successful
Question 7: can you think of ways
in which the programme can
be improved?
85 70 More visits from individual health-care professionals/follow-up
post input
Spread out the visits
Have meeting with other PD sufferers
Make it more individualised
Have more carer involvement
37 responses: no way to improve
Question 14: do you have any other
comments about the treatment or
study overall?
76 64 Positive experience, glad to have taken part
Team were professional/approachable/knowledgeable
Would like it to continue/be available to others
Other comments across questions – – Needed just after diagnosis
At early stage no problems so unnecessary, but found tips
for the future useful
Selected quotes:
I have not been able to talk to people about PD beforehand
I now understand a great deal more about Parkinson’s
Although I had a lot of knowledge about Parkinson’s I found that the treatment filled many gaps that I did not
appreciate existed
Helped with motivation but this faded as the visits decreased
All of it was useful and relevant
Very good, would recommend to other Parkinson people
PD, Parkinson’s disease.
Total number of questionnaires sent: 127; total number received: 106.
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TABLE 30 Qualitative analysis of the feedback on the MDT interventions by live-in carers, groups A and B only,
cohorts 4–10, at assessment 2 (6 weeks)
Question
Number of
responses
to question
Number of
comments
used per
question Themes emerging from data
Question 1: how helpful did you find
the treatment programme overall, for the
person that you care for? Please explain
52 49 Learnt new things and gained a better
understanding of Parkinson’s disease
Learnt how to manage specific symptoms
Gave motivation and encouragement
Question 5: please explain, in your view,
what were the most successful aspects of
the programme?
55 52 Individual health-care professions
One-to-one home visits
Reassurance and encouragement from
health-care professionals
Question 6: please explain, in your view,
what were the least successful aspects of
the programme?
51 41 Individual health-care professions
Not covering a specific health topic, e.g. the
psychological impact of the condition
Too short/no follow-on
20 responses: nothing to improve on
Question 7: can you think of ways in
which the programme can be improved?
47 40 More carer input/involvement/carers
meeting/separate session for carer without
person with Parkinson’s present
Local health-care integration
Ongoing programme (some suggested
telephone helpline/one-stop clinic)
19 responses: no way to improve
Question 14: do you have any other
comments about the treatment or
study overall?
50 49 Positive experience
Learnt new things
Health-care professionals very helpful and
co-ordinated
Needed earlier, would be useful soon
after diagnosis
Follow-up would be helpful
Selected quotes:
There is no doubt that the success of this programme can be attributed to the individual interests paid to the person
with PD by the health-care specialists. These are one-to-one discussion, with a shared interest and professional
concern which have been both supportive and stimulating, and have allowed an up to date programme to be
developed on an individual basis. As a carer, I can see how encouraging this has been as my wife grasps on to the
new ideas
The fact of home visits meant that there was no rush and we had their individual attention in our own environment
Knowing that there is help out there if [name] problem gets worse, and knowing what to look for with books and all
the information that was left with us
Very professional. Ticked all the boxes. Well worth the cost to the NHS
Absolutely brilliant cost effective way of incorporating the well-being of Parkinson’s sufferers and their families
therefore making people feel cherished and important within the vast NHS system
PD, Parkinson’s disease.
Total number of questionnaires sent: 70; total number received: 58.
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Economic evaluation
Intervention costs
Analysis of the data contained in the CRFs revealed that most participants received 500 minutes of direct
patient-facing contact time (almost exclusively from home visits, median of six) from members of the MDT
in weeks 1–6. The contact time was the same for both groups A and B. Participants in group B received,
on average, an additional 418 minutes of patient-facing contact time from the PCA (median of seven
home visits and five telephone calls) in weeks 7–24. The PCA asked for input from the MDT for a small
number of patients. The contribution of the MDT during the PCA period (weeks 7–24) was a mean
17 minutes per patient (median 0 minutes) (Table 32).
The mean cost per patient of the MDT (2011 GBP) was £445 (SD £60 group A; £52 group B). This includes
both the patient-facing time spent in home visits and telephone calls, and an allowance for non-patient-
facing follow-up (referral letters, case notes, MDT meetings, etc.) of 30 minutes per visit and 15 minutes per
telephone call. Travel costs, based on mileage, added a further £338 (£275 for professional time in transit,
£63 for the cost of running a car). There was no difference in MDT costs between groups A and B (Table 33).
The mean cost of the PCA for group B was £579 [£310 (SD £109) for patient-related work, and £269
(SD £89) for travel]. There was a small additional MDT cost during the 6–24-week PCA support period of £21
(SD £38) per patient, arising when the PCA identified issues that needed further professional input. The cost
of the PNS providing comprehensive feedback to GPs about all patients at the end of the trial was a further
£50. The grand total cost per patient was £833 for the MDT (both groups A and B), and an additional £600
for the extra PCA input (group B).
Service use
Service use was collected at three assessment points and is reported descriptively (Table 34). Baseline
data refer to the 3-month period prior to recruitment to the study. Service use collected at assessment 3
(24 weeks) relates to the period after the end of the MDT, but does not include the PCA input being
TABLE 31 Qualitative analysis of responses to question on continuing benefit from MDT treatments, groups A
and B only, cohorts 4–10, at assessment 3 (24 weeks)
When the 6-week multidisciplinary rehabilitation intervention ended, did you/person with Parkinson’s continue
to benefit from the treatment? If yes, please explain
Group A (MDT only): themes emerging from data Group B (MDT+ PCA): themes emerging from data
Person with Parkinson’s: 150 questionnaires sent (100% response rate)
63 responses received to question: 58 relevant and legible 65 responses received to question: 62 relevant and legible
Continued with advice from health-care professionals
Aware of what help was available for Parkinson’s sufferers
and sought it out
22 mentioned exercises
Continued with advice from health-care professionals
More confidence
30 mentioned exercises
Nine specifically mentioned PCA input, for motivation
Live-in carers: 86 questionnaires sent (85 received completed)
32 responses received to question: 30 relevant and legible 34 responses received to question: 33 relevant and legible
Continued with advice from health-care professionals
More positive outlook
Continued with advice from health-care professionals
More positive outlook
Greater understanding and knowledge of Parkinson’s
No mention of PCA
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provided to group B at that time. The data collected at assessment 4 (36 weeks) cover the 3-month
follow-up period when no participants were receiving treatment within the study.
Small numbers of participants reported the use of hospital and overnight respite services in care/nursing
homes. Between one-third and half reported outpatient neurology appointments. Overall, the participants
are relatively high users of GP and community therapy services. About one-third of physiotherapy contacts,
and half of alternative therapy contacts, were reportedly organised and paid for privately. Most participants
were over 60 years of age and exempt from paying prescription charges. Of those reporting expenditure
on medications bought over the counter, the average monthly spend, over the three periods, was £9.90,
mostly for pain relief and anti-acid preparations. Of the 75 tests reported, 27 were for brain scans
123{magnetic resonance imaging, DaTSCAN™ [Ioflupane ( I) Injection, a radiopharmaceutical agent used for
dopamine transmitter imaging], computed tomography, unspecified}, and the rest were blood tests.
Almost half of participants reported receiving paid home help (cleaning and gardening), usually for a small
number of hours per week and privately financed. Small numbers (higher in group B) stated that they
received personal care packages through social services. Similar numbers reported unpaid help from family
and friends, including transportation (as driving can be a problem for people with Parkinson’s disease).
The NHS costs of the health service use were calculated on a per-participant basis for each 3-month
period, by study group (Table 35). Self-paid services were excluded from the calculations. Tests, social and
informal care could not be calculated owing to insufficient details on the type and frequency of use.
The per-patient costs are driven by small numbers of high users of relatively expensive services (mostly
overnight hospital stays). The costs vary accordingly within and between groups, the SDs are very high,
and tests reveal only one significant difference, which was in the community care costs at 36 weeks, with
group A higher than group C (p= 0.022). However, no significant differences were observed in total
per-patient costs between any pair of groups at any time point.
TABLE 33 Intervention costs per patient (£, 2011)a
Item
Group A cohort 2–10, n= 83 Group B cohort 2–10, n= 83
Mean
per patient SD Median IQR
Mean
per patient SD Median IQR
Weeks 1–6
MDT total (PNS, PT,
OT, SLT)
445.05 59.91 441.33 65.67 444.61 51.97 436.83 65.83
Travel (staff time
and mileage)
338.19 23.84 333.50 0.00 338.35 26.41 333.50 0.00
Total 783.24 782.96
Weeks 7–24
MDT (support of PCA) – – – – 20.74 38.30 0.00 25.00
PCA – – – – 310.56 109.43 324.48 140.60
Travel (staff time
and mileage)
– – – – 268.67 89.85 275.07 75.90
End
GP letter 50.00 50.00 50.00 50.00
Grand total 833.24 74.00 831.00 82.17 1432.92 227.75 1461.89 274.48
IQR, interquartile range.
a Unit costs used in the calculation are shown in Appendix 19.
–, not applicable to weeks ≥ 24.
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Evaluation
Short-term benefits from the MDT were identified at the end of the intervention period for people with
Parkinson’s in terms of reduced anxiety, and marginally improved non-motor symptom control and
health-related quality of life and reduced disability. Live-in carers in the intervention groups A and B also
recorded significant improvements in psychological well-being (SF-36 MCS) at the end of the MDT input.
Following the continuing PCA support for group B, people with Parkinson’s in group A (no PCA support)
worsened significantly for non-motor symptoms and posture, and marginally for health-related quality of
life and self-efficacy, while scores on these measures for group B did not change. In addition, carer strain at
the end of the 18-week period over which the PCA support was provided tended to be lower in group B
than in group A. However, few sustained effects from the interventions were observed.
Inspection of outcomes at the 6-month trial end point revealed no effect in either the patients’ or
carers’ primary outcome measure, or in EQ-5D scores, and so no formal cost-effectiveness analysis was
undertaken. The MDT intervention was delivered at a cost of £833 per patient, with an extra £600 per
patient for the PCA input (group B). The cost of the MDT was uniform between cohorts, but the PCA costs
were more variable. The treatment protocol focused on providing input tailored to individual needs, and
some participants had more complex issues than others. In addition, some individuals were hospitalised,
or did not complete the PCA component for other reasons, affecting the mean costs of their cohorts.
No significant differences were observed between groups in utilisation or costs of other health and social
services over the trial period.
The qualitative analysis suggests that patients and carers may benefit from the intervention in less tangible
ways, including improved knowledge and understanding of Parkinson’s disease, appreciation of the
individual care and attention they received, and gratitude for signposting to services. Such effects may not
be captured by the trial outcome measures, or in the data on use of other services, but are nonetheless of
importance in a comprehensive analysis of the costs and consequences and consideration of value
for money.
Conclusion
There are some caveats and limitations to the costing study. As this is a domiciliary intervention, the travel
costs are about 40% of the total intervention cost (largely resulting from professional time in transit).
The calculation of the travel costs was based on the median distance from the MDT base to the homes of
participants in the trial, and assumptions about the speed of travel in the local area. However, differences
in the size of catchment areas, and local geography, could affect the travel costs (either way). The service
use costs did not include the costs of tests, social services or informal care, owing to missing and
incomplete information on the nature of the services received. The unit cost of inpatient care was banded,
and the cost of long stays may have been underestimated (although using a pro rata cost would have
increased the variability further).
The trial provides evidence of costs and consequences of one particular programme of specialist
rehabilitation, and PCA follow-up protocol, on the basis of which commissioners can assess the balance
between its resource implications and the improvements in the quality of care that it delivers. Some 40%
of participants who answered the question on the value for money of the intervention on the acceptability
questionnaire stated that they thought the 6-week specialist rehabilitation would be good value for money
for the NHS at £835 (see Table 28). However, the limitations of hypothetical questions of this nature are
well known, and many participants had problems understanding the purpose of the question and chose
not to answer it.
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Chapter 5 Feedback from the
multidisciplinary team
Introduction
Feedback from the MDT about their experience of team working and delivering the intervention was
obtained from various sources. Nine members of the MDT (two PNSs, two PTs, two SLTs, one OT and
two PCAs) were interviewed at the end of the intervention phase (December 2011–January 2012).
In addition, 14 written reflections were available for analysis (four provided at the end of cohort 2, three at
the end of cohort 6 and seven at the end of cohort 8). Eight structured feedback forms were completed
at the end of the project, and the content of the open-comment sections was integrated into the qualitative
analysis of the MDT feedback. In addition, as part of the project analysis phase, the lead PNS provided
written reflection of the development and benefits of interdisciplinary working, illustrated by three patient
case studies.
Findings
Analysis of the responses to structured items on the feedback revealed that all eight professionals rated all
aspects of team working (communication; use of shared documents and joint care planning including
patient/carer involvement; mutual support; delegation of responsibilities; and administrative support from
project office) as good or very good (vs. satisfactory or poor).
Verbal and written feedback from various sources were collated and subjected to a thematic analysis.98
A summary of the findings is given below, organised around the topics used in the exit interview.
Quotes are attributable to participants by number, but no further information is given about the
participants in order to preserve confidentiality.
The multidisciplinary team
Structure and roles
Both of the PNSs perceived themselves as having a leadership role: one qualified this as relating to the
supervision of the PCAs only, and the other (who had the wider remit in the study) recognised herself as
having overall team leadership responsibilities. All respondents were positive about the team and all
ascribed leadership to the one PNS who was centrally involved in the project and had a role in MDT
recruitment. When issues arose with one PCA, the lead PNS arranged for additional training and
supervision, and the reallocation of duties. The role of this nurse was seen as ‘co-ordinator of provision’
and as a ‘troubleshooter’ (Participant 8).
The lead nurse appeared comfortable with her role, although she commented that during very busy phases
of the trial she had insufficient time to keep up with administrative tasks.
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The allied health professionals (i.e. PTs, OTs and SLTs) did not consider themselves to have a leadership role
in the team and stated that they all felt equally part of the team:
. . . all at the same level and all equally responsible.
Participant 8
All of the MDT members felt well supported, with the team described as ‘small, focused, supported’
(participant 7).
Despite joining the project as experts in their field, all commented that they had learned a lot during
the project:
. . . able to collaborate and really understand each other’s roles.
Participant 5
The SLT and PT respondents felt that having a fellow professional to work with in the team was a benefit
to both them and the team as a whole:
. . . perfect with the other physio there.
Participant 8
[X] and I thought the same way.
Participant 3
All of the respondents reported that the team was very well served by the project management and
administrative assistant, who arranged visits and travel expenses, as required. Back-up of this nature played
an important role in the smooth delivery of the intervention, and enabled the health professionals to
concentrate on patient care.
Formation and evolution
Only two of the team members (the OT and one of the PTs) had worked together previously. The
professionals initially appointed to the project were involved in the development of the intervention,
and this helped to secure ‘ownership’. The process of agreeing the implementation of the intervention
protocol and the details of integrating all members was largely seen as smooth, leading to a perception
that the team gelled rapidly:
. . . no major hiccups.
Participant 1
Teams need time to operationalise a protocol and to resolve practical issues. The initial cohort
(subsequently deemed the pilot) was perceived by team members as a development phase (storming
and forming):
. . . sorting out practicalities.
Participant 2
. . . the MDT was finding its feet and getting to grips with the requirements of patients and
the project.
Participant 1
Everything seemed to come together in the second cohort . . . the paperwork . . . team working
well together.
Participant 3
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Initially, team meetings were described as ‘a bit stilted’ (Participant 5), but at all points in the project, there
was an appreciation that the team was multidisciplinary, with all staff being both appreciative and
respectful of the roles of others.
Role of team meetings
Team meetings were valued by all respondents in terms of contributing to the high quality of the service
given to patients, as well as enhancing their own satisfaction with working in the team, and improving
knowledge and understanding of other disciplines.
Patient care was the prime focus of team meetings, enabling clinical judgements to be discussed, plans to
be refined and the need for referrals to be agreed.
The MDT meetings are an important part of the process. Discussing patients with the team helps
highlight issues that may not have come up in my visit and also helps me to know what everyone
wants reinforcing.
Participant 2
Patient care is discussed in depth at team meetings . . . excellent opportunity to share ideas and
expertise and prepare a realistic and relevant care plan.
Participant 2
Meetings were also used to present information on the roles and working practices of team members in
relation to Parkinson’s disease, and these regular teaching sessions increased the understanding of what
each professional could offer, and resulted in an improved holistic approach to care.
I feel I have a much deeper understanding of the role of other members of the team, and am more
able to give advice and reinforce.
Participant 3
As the study progressed, the team became more cohesive and team working became even
stronger: ‘bonded’.
Participant 4
. . . more insight into what each of us is advising.
Participant 7
All respondents were very complimentary about being in the team: ‘best team I have ever worked with’
(Participant 8).
The intervention (treatment)
Value of home visits
The entire MDT reported that working with patients in their homes was one of the most positive aspects
of the study:
. . . make it realistic in situ . . . much better than the day hospital . . . travel time is worthwhile.
Participant 1
Two participants mentioned that some homes could be difficult to work in:
. . . hectic houses with family in and out.
Participant 7
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Balance of professionals
The SLT team members and the PCAs reported some issues about the amount of SLT time available.
This appeared to relate to more patients presenting with communication and swallowing difficulties than
had been anticipated by the project team, who had been working from incidence figures. A second
SLT was subsequently employed. One PT stated that many patients had not previously had access to SLT
before and this might have affected the demand.
The SLTs themselves did report that a small number of patients would ideally have had more SLT input, but
generally they were satisfied that they could meet patient needs within the trial protocol. They particularly
appreciated the emphasis on communication, which contrasts to many NHS settings where attention is
given to swallowing difficulty, with communication needs having a secondary priority:
. . . focus on communication is great.
Participant 4
Culture change
The lead PNS felt that seeing patients at all stages of the disease highlighted the importance of education
and a preventative approach, in order to help people maintain independence for as long as possible. The
PTs felt that the trial intervention offered a major advantage to patients, in that they are seen at an earlier
stage than would generally be the case in the NHS and this allowed preventative work to occur:
. . . getting in early . . . prevention of bad habits.
Participant 3
The contrast with more crisis-driven NHS input was mentioned by four of the team. All participants felt
that the NHS should offer such a service:
. . . people need it.
Participant 5
Project related
Workload
As the project got under way, the amount of paperwork and the scheduling of work emerged as issues,
although the team coped with these and were immensely supportive to each other. Once multiple cohorts
were in progress, the teams had no breaks in their work schedule between cohorts and this relentless
scheduling with no ‘down time’ was seen as ‘very tiring’ by several team members. There were also
comments from five of the team on the structure of the working day being too intensive. Four patient
visits in a day was perceived as very demanding of staff and there were comments about travel time
estimates between visits occasionally being unrealistic, especially in the later cohorts when patients were
more geographically dispersed.
Problems of research environment
All members of the MDT had limited prior experience of a research trial and were initially daunted by the
idea of working to a trial protocol, thinking that it limited their autonomy:
. . . hard to get your head around.
Participant 3
. . . very different to follow a protocol in its entirety.
Participant 4
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However, it was also recognised that the protocol was flexible and allowed the team to identify and focus
on the needs of patients:
. . . were able to tailor input.
Participant 5
. . . information that is tailored to their issues.
Participant 3
Several members of the MDT expressed some frustration with randomisation in that, on occasions,
participants who could clearly benefit from follow-up would not be randomised to that arm of the trial.
The MDT understood and accepted the inevitability of this but nevertheless expressed frustration:
. . . you wish you could swap the randomisation when you can see someone really needs support.
Participant 3
Two of the team members referred to a very small number of patients who were randomised to follow-up
but who were perceived to have fewer needs, or for whom the follow-up was inconvenient. One case
cited was a younger patient who was still in the workplace.
Care assistant role
The PCAs were trained using the materials developed by the team68 and by spending a day with the lead
PNS. They then shadowed the other professionals on their visits. While the PCAs felt that they benefited
from the training, they commented that they wanted more contact with the team in the early stages,
and that they had learnt more from each subsequent cohort of patients.
From the start I felt supported by each of the specialists. This enabled me to expand my knowledge
base as each individual patient query allowed me to learn more about the condition and the effects on
individual patients.
Participant 6
The lead nurse felt that the training could have been enhanced further. She took action to do this by
initially visiting participants with the PCAs but, for reasons of time, this was not possible later in the
project. As was the case with the professional staff, the PCAs found the team meetings very helpful:
. . . team discussion and overview very useful.
Participant 6
The quality of the PCAs was seen as crucial to the success of the intervention. Leaving aside the team
member who left in the early stages of the project, the PCAs were regarded by the other team members
as providing good quality follow-up for patients within their agreed role:
. . . set high standards.
Participant 9
Both fantastic, open and ask questions.
Participant 3
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The PCAs both commented that their remit was clear and that they had no difficulties in staying within it.
They identified their role as mainly reinforcing the advice given by the team and particularly in encouraging
patients to complete their exercises, or in some cases to make an attempt at the exercises:
. . . getting into a routine of exercises is difficult.
Participant 6
Other members of the team also commented on the value of the PCAs reinforcing their advice:
. . . good to be able to tell her to reinforce things.
Participant 1
. . . PCAs used the team well.
Participant 1
The PCAs were able to give specific examples of interventions from the OT, PTs and SLTs as being directly
helpful to participants.
The PCAs were clear that there was a social element to the visits for some participants, but they did not
think that this was the only purpose:
. . . not just social.
Participant 6
The PCAs felt that they had a particularly valuable role for participants who did not have a partner at
home. Again, they related this specifically to the effect of the participant’s ability to manage the exercise
programme supplied. This was noted in relation to speech exercises, and was also mentioned by the SLTs:
. . . no one to prompt them.
Participant 7
One PCA noted that participants tended to expect more of them as the follow-up visits progressed:
Patients have increased expectations and ask more questions as they get to know you.
Participant 6
The PCAs felt that access to the MDT in the follow-up phase was sufficient. Different models of access
were evident, with one PCA relying on the MDT lead to liaise with other team members and the other
being able to contact team members directly. One MDT member was critical of the first model. The PCAs
reported that they felt comfortable going into people’s homes; the trial procedures included mechanisms
to ensure that staff whereabouts were known and monitored when they were working alone. One of the
PCAs felt that telephone calls to follow-up participants were not always satisfactory:
. . . a limit to what you can do: if you were worrying it could be hard to visit quickly.
Participant 7
The PCAs reported that participants were largely positive about their visits:
. . . they have openly said how much they value my time spent with them.
Participant 6
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Potential use of the care package in the NHS
Barriers and facilitators
The integrated team was viewed by members as having worked well. The main barriers perceived were the
workload and resources, and the constraints imposed by the research environment.
Facilitators to successful working of the team were identified as strong leadership; involvement of team
members in the development of the intervention; regular case review meetings; administrative support
from the project office; and the underlying preventative philosophy. In particular, the team meetings not
only improved patient care, but also were a vehicle for delivering mutual support, team cohesion, staff
development (improved knowledge and understanding), and hence enhancing job satisfaction.
Implications for the NHS
All members of the team felt that the NHS could, and should, offer this type of intervention: one
commented that it:
. . . sits comfortably with the NHS role.
Participant 9
In terms of benefits to patients, members of the MDT were unanimous in agreeing that, from their
perspective, the programme was beneficial to patients. Making a difference to patients was seen
as crucial:
. . . clinically making a difference.
Participant 9
. . . saw benefits in someone who looked hopeless.
Participant 7
Improvements in more general well-being were cited also:
. . . well-being . . . didn’t realise there were positives.
Participant 9
The only major barrier to this was considered to be funding:
If the money was there yes.
Participant 1
All members of the team stated that there was a need to improve care for people with Parkinson’s disease,
with greater recognition of the need for preventative care:
. . . getting in early, putting them on the right path.
Participant 3
They stated that the specific contribution to improving care for people with Parkinson’s would be increased
access to SLTs, more time with patients and a structured MDT approach. They also felt that the approach
was better organised and less crisis driven than much of the NHS input:
. . . well organised compared to the NHS.
Participant 5
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One of the staff felt that the project offered a model for ongoing intervention for people with Parkinson’s:
. . . got the blueprint [for the NHS].
Participant 9
Some MDT members identified possible improvements to the intervention: greater inclusion of GPs in the
intervention and support; more selectivity with regard to who would benefit from the programme; increased
access to ear, nose and throat and neurology follow-up; and the inclusion of a counsellor for patients with
long-term conditions.
Reflections of the lead Parkinson’s nurse specialist about team
development and working
Overview
At the start of the project and commencement of the first cohort of participants, the MDT members
were still settling into the project and establishing best working practice methods in order to optimise
interdisciplinary working. The cohesiveness of the team grew stronger as the study progressed and there
was increased awareness of what each team member was able to offer the participants. Seeing clients at
all stages of the disease highlighted the importance of education and preventative work, thus enabling
clients to maintain their level of function for as long as possible. The documentation for the intervention
became well tried and tested and very familiar with use.
Benefits of integrated team working
Professional development and job satisfaction
The team developed a great deal of respect for each other over time and the regular teaching sessions
held at team meetings led to an enhanced interdisciplinary knowledge and understanding, and an
improved holistic approach to care. All members of the MDT became more informed about all aspects of
managing a client with Parkinson’s disease and providing a holistic package of care.
Example: the PNSs gained confidence in giving patients basic advice on physiotherapy techniques, such as
balance and posture exercises, and strategies for improving communication, such as breathing and vocal
exercises. They also gained greater knowledge of equipment and simple tips to help clients with daily activities
(e.g. raising the level of a washing-up bowl in the sink to avoid backache by putting it on top of an upturned
bowl, putting a mug in the sink before pouring boiling water from the kettle to avoid lifting a heavy kettle
and spilling water over themselves, sitting to shave with elbows on the table to steady the razor). The PTs, OTs
and SLTs reported a far greater knowledge and understanding of Parkinson’s medication by the end of the
intervention period. All members of the team experienced high levels of job satisfaction as they felt that they
were able to deliver a very high standard of holistic care supported by a strong back-up team.
Improved standard of care and patient benefit
It proved beneficial for participants that therapists were able to advise them that another member of the
MDT would be able to help them with a particular problem.
As time progressed, the MDT found that integrated team working provided an invaluable opportunity to
share knowledge of individual clients with other health professionals who were also experts in the field.
It enabled clinical judgements to be questioned and discussed.
Example 1: individual therapists felt that a diagnosis of Parkinson’s disease was in question for three
participants. Each therapist was able to discuss her concerns with other team members at the team
meeting. Further visits by therapists to these clients confirmed the findings and these clients were referred
back to their GP or consultant for further investigations. It was confirmed at a later date that, in all three
cases, the diagnosis of Parkinson’s disease was indeed incorrect.
FEEDBACK FROM THE MULTIDISCIPLINARY TEAM
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Example 2: it was also found that participants often imparted different information to each member of the
MDT. The 6-week intervention period and regular team meetings, therefore, provided an opportunity for a
true picture of a participant and their carer to be created. For example, one participant admitted to having
an impulse control disorder which took the form of cross-dressing, but this information was not revealed
to the team until week 3 when confidence and trust in the team had been established. The cross-dressing
itself was not a problem for the participant, but the financial burden it imposed in buying the outfits was
great. The problem was discussed by the team and a management plan was put in place. This symptom
would almost certainly not have been identified at a routine clinic appointment.
Participant case studies
Three case studies (Tables 36–38) were selected to illustrate the methodology of the MDT method of
working, the focus on prioritising patients’ concerns, and the holistic approach to care that this generated.
The case studies provide an indication of the challenging motor and non-motor problems faced by people
living with Parkinson’s on a daily basis, and the complex issues involved in the management of the
condition. The MDT approach enables the full range of symptoms to be addressed by professionals with
expertise in their particular fields, cross-disciplinary issues to be discussed, and patient-centred care
planning and delivery to be undertaken in a co-ordinated way. The 6-week intervention enables the team
to get to know the patient better, and the patient to feel sufficiently comfortable with therapists to be
able to ‘open up’ about their problems and fears. Regular contact between team members provides the
opportunity for each to reinforce the messages of the other, which is to the benefit of patients and carers
and provides job satisfaction for professionals.
TABLE 36 Patient case study 1 (group A: MDT)
Male; aged 67 years; lives alone, no carer; no current services or support
Hoehn and Yahr stage 3; 13 years since diagnosis
Comorbidity: arthritis in wrists
Medication: pramipexole (Mirapexin®, Boehninges Ingelheim Ltd) 0.7mg t.d.s.; Mirapexin® 0.18mg × 2 t.d.s.;
cocareldopa (Sinmet®, Merk Sharp & Dohme) 110mg × 2 t.d.s.; Entacapone 200mg × 1 t.d.s.
Week MDT member Problems identified Actions taken
One PNS (assessment) l Motor fluctuations
l Poor medication
compliance
l Urinary incontinence/UTI
l Drooling
l Apathy and fatigue
l Social isolation
l Still driving but DVLA not
aware of diagnosis
l OPD appointments at
local PD clinic have lapsed
l Reviewed medication and explained importance of
taking medication at correct time(s)
l Advised PwP to take urine sample to GP surgery
for analysis
l Strategies for management of drooling discussed
l Strategies for management of apathy and
fatigue discussed
l Information supplied on local support groups
(PD UK, Age Concern)
l Advised PwP of legal requirement to inform DVLA of
diagnosis (PD UK information brochure ‘Driving and
Parkinson’s disease’ supplied)
l New OPD appointment arranged at local PD clinic
l Care plan commenced and agreed with PwP
Two SLT (assessment) l Mild/moderate dysarthria
l Decreased volume and
articulation
l Increased rate of speech
l Poor syllabification
l Advised on strategies to maximise communicative
effectiveness and encouraged to practise simple
exercises daily in chair including reading aloud for
20 minutes per day
l Care plan updated and agreed with PwP
continued
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Week MDT member Problems identified Actions taken
Three PT (assessment) l Stooped posture
(camptocormia)
l Difficulty turning in bed
l Posture exercises while sitting, stretching and back
exercises when lying down
l Taught and practised strategies for turning in bed
l Care plan updated and agreed with PwP
Three Team meeting:
all MDT members
present
l Poor medication
compliance
l Communication
difficulties
l Posture and
mobility issues
l Driving issues
l Urinary problems
l Importance of medication compliance to be
reinforced by all MDT members
l Encourage continuation of exercises taught by speech
therapist (to improve volume and clarity of speech)
l Encourage continuation of exercises taught by
PT (to improve posture and bed mobility)
l Remind PwP to notify DVLA of diagnosis of PD
l Ensure PwP has taken urine sample to GP as advised
l Review care plan
Four OT (assessment) l Handwriting issues
l Has difficulty reaching up
due to stooped posture
l Handwriting practice
l Wooden clothes hanger with finger stall to manage
light switches; use step at kitchen sink to reach taps
l Care plan updated and agreed with PwP
Five PNS (follow-up visit) l Poor medication
compliance
l Urine sample required for
analysis
l Speech difficulties
l Posture and mobility
issues
l Handwriting difficulties
l Driving issues
l Non-motor symptoms
assessed
l Confirmed with PwP that medications are mostly
now being taken at correct times
l No urine sample provided for analysis as yet;
encouraged to obtain sample as soon as possible
l Encouraged PwP to continue with speech exercises
l Encouraged PwP to continue with physiotherapy
exercises
l Encouraged PwP to continue with handwriting
exercises
l Reminded PwP of legal requirement to inform DVLA
of diagnosis of PD
l Strategies for management of drooling discussed and
general advice given regarding management of the
non-motor symptoms of Parkinson’s disease
l Care plan reviewed
Six PT (follow-up visit) l Poor medication
compliance
l Urine sample required for
analysis
l Speech difficulties
l Posture and mobility
issues
l Handwriting difficulties
l Driving issues
l Reinforced to PwP importance of correct timings
of medication
l Confirmed urine sample has now been taken to GP
surgery for analysis
l Encouraged PwP to continue with speech exercises
l Checked bed exercises, sit to stand technique and
posture in chair; advice given about not doing too
much resistance work on exercise bike but increase
time to help with endurance
l Encouraged PwP to continue with handwriting
exercise(s)
l PwP has now informed DVLA of diagnosis of PD
l Care plan reviewed
Six Team meeting:
all MDT members
present
l Medication compliance
issues
l Urinary problems
l Speech difficulties
l Posture and mobility
issues
l Handwriting problems
l PNS to make referral to community PNS for ongoing
support and reinforcement of established speech,
physiotherapy and occupational therapy
exercise regimes
l Future appointment at outpatient department PD
clinic confirmed for ongoing review of medication
l PNS to make referral to community district
nurse/continence nurse team for follow-up of
urinary issues
l GP informed of MDT input
DVLA, Driver and Vehicle Licensing Agency; OPD, outpatient department; PD, Parkinson’s disease; PwP, person with
Parkinson’s; UTI, urinary tract infection.
TABLE 36 Patient case study 1 (group A: MDT) (continued)
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TABLE 37 Patient case study 2 (group B: MDT+ PCA)
Male; aged 84 years; wife is main carer (aged 82 years and has her own health problems); agency carers attend twice per
week to shower PwP, and provide 4 hours respite per week
Hoehn and Yahr stage 4 (complex stage); 19 years since diagnosis
Comorbidities: myocardial infarctions × 2; prostate problems (has indwelling catheter which district nurses attend to every
3 months); hypotension
Medication: Co-beneldopa (Madopar®, Roche) 250mg q.d.s.; Rotigotine (Neupro®, UCB) 8mg daily
Week MDT member Problems identified Actions taken
One PNS (assessment) l Poor mobility (walks with
two sticks short distances
only, wheelchair for
longer distances)
l Drooling
l Swallowing difficulties
l Postural hypotension
l Hallucinations
(sees objects on floor)
l Carer strain
l Advice given on safe mobility
l Strategies for management of drooling discussed
(letter to GP requesting prescription for atropine
drops or scopolamine patch)
l Advice given regarding pureed diet; full assessment
of swallowing problems to be carried out by
project SLT
l Blood pressure checked; advised to increase fluid
intake and add extra salt to diet
l Advice given on management of hallucinations;
explained the importance of comforting PwP during
hallucinations rather than denying their existence
l Further opportunities for respite to relieve carer
strain considered and discussed
l Care plan commenced and agreed with PwP
and carer
Two SLT (assessment) l Hypokinetic dysarthria
l Decreased range of
movement of articulators
and decreased
facial expression
l Oral-stage dysphagia,
difficulty initiating
swallow reflex; at risk
of aspiration and
undernutrition
l Drooling
l Advice and instructions given to perform simple
exercise programme to maintain range of movement
of articulators (lip, tongue and jaw stretches) and
encouraged to talk more
l Facial exercises given
l Encouragement to swallow; verbal prompts for set
periods in the day
l Letter to GP for prescription of Fortisips (three per
day); wife does not need further help from dietician
as she is already very knowledgeable about how to
fortify PwP’s food
l Continue with thickener in all fluids
l Soft/moist, puree and thickened drinks
leaflets provided
l Educated regarding the nature of swallowing
disorders and their links with chest infections
l Awaiting prescription for treatment to ease drooling,
as organised by PNS
l Care plan updated and agreed with PwP and carer
Three PT (assessment) l Balance problems
and falls
l Posture
l Tends to cross sticks when walking (unsafe);
encouraged to focus on delta frame (already
supplied); strengthening exercises taught and
practised (to maintain strength in all lower
limb muscles)
l Postural exercises taught and practised
l Care plan updated and agreed with PwP and carer
Three Team meeting: all
MDT members
present
l Mobility issues
l Drooling
l Swallowing difficulties
l Dysarthria
l Postural hypotension
l Carer strain
l All team members to encourage PwP to walk with
delta frame rather than two walking sticks (unsafe)
and to remind PwP to perform leg-strengthening
exercises and postural exercises as taught by PT
l All team members to monitor treatment programme
for drooling as prescribed by GP
l All team members to ensure that verbal prompting
for swallowing is still practised
continued
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Week MDT member Problems identified Actions taken
l Check Fortisips have been received and fluids are
still being thickened
l Encourage PwP to continue with facial
exercises to improve articulation
l Encourage to maintain fluid intake and apply extra
salt to meals to maintain blood pressure
l Review level of carer strain and consider possible
respite options (respite at hospice considered; PNS
to discuss with PwP and wife at follow-up visit)
l Review care plan
Four OT (assessment) l Difficulty mobilising
around bungalow
l Difficulty shaving
l Encouraged to use delta frame for mobilisation
l Use electric shaver and sit in chair
l Known to social services
l Requires respite three times per year
l Care plan updated and agreed with PwP and carer
Five PNS (follow-up visit) l Drooling
l Swallowing difficulties
l Speech difficulties
l Posture and
mobility issues
l Carer strain
l Discussion of non-motor
symptoms and general
information for PD
l GP has prescribed scopolamine patches; checked
proper application of patches
l GP has prescribed Fortisips as requested
l PwP encouraged to continue with facial
exercise programme
l Ensured PwP continues to use delta frame rather
than two walking sticks
l PwP continues with leg-strengthening exercises and
postural exercises when he feels able
l Discussed with wife and PwP the prospect of respite
care at local hospice; request sent to GP to refer
to hospice
l Care plan reviewed
Six PT (follow-up visit) l Balance problems
and falls
l Posture
l Drooling
l Swallowing difficulties
l Speech difficulties
l Carer strain
l Checked use of delta frame; wife reported that he
has been practising walking outside with delta
frame and has been doing leg-strengthening
exercises in the kitchen as instructed
l Posture exercises have been regularly practised;
good technique confirmed
l Drooling has improved slightly with
scopolamine patches
l Fortisips now taken three times daily as instructed
by SLT
l Encouraged to continue with facial
exercise programme
l Awaiting confirmation for respite from hospice
l Care plan reviewed
Six Team meeting: all
MDT members
present, including
PCA
l Mobility, balance and
postural issues
l Drooling
l Swallow difficulties
l Speech difficulties
l Carer strain
l Over ensuing 4 months PCA will ensure that PwP
continues to use delta frame for safe mobility
l Over ensuing 4 months PCA will encourage PwP to
continue with leg-strengthening and postural
exercises and report back to PT
l Over ensuing 4 months PCA will monitor the level of
drooling following initiation of scopolamine patch
and will report any untoward side effects to the PNS
l Over ensuing 4 months PCA will continue to
encourage verbal prompting of swallow reflex and
encourage continuation of Fortisip drinks reporting
back to the SLT
l Over ensuing 4 months PCA will encourage PwP to
continue with facial exercise programme reporting
back to the SLT
l PCA will ensure that the hospice contacts PwP and
his wife regarding the possibility of respite care
(confirmed 4 weeks after handover)
PD, Parkinson’s disease; PwP, person with Parkinson’s.
TABLE 37 Patient case study 2 (group B: MDT+ PCA) (continued)
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TABLE 38 Patient case study 3 (group A: MDT)
Male; aged 68 years; wife is carer; no current services or support
Hoehn and Yahr stage 3; 10 years since diagnosis
Comorbidity: hypertension
Medication: Ropinirole 24mg extended release; Madopar® 125mg q.d.s.; Madopar® 62.5mg q.d.s.
Week MDT member Problems identified Actions taken
One PNS (assessment) l Motor fluctuations with
unpredictable ‘off’ periods
l Freezing episodes
l End of dose wearing off
l Recent bereavements have caused
low mood, self-imposed social
isolation and relationship problems
with wife
l Constipation
l Urinary problems (prone to urgency
and frequency)
l Fatigue
l Sleep problems
l Timings of medications reviewed and
discussed; general review of medications
needed by specialist consultant
(outpatient appointment arranged)
l Strategies for management of
freezing discussed
l Timings of medication reviewed to
reduce wearing off
l Discussed support groups available to
help with low mood; contact details
given for PD UK; discussed possibility of
antidepressant therapy at PD
specialist clinic
l Management of constipation discussed
(increase fluid intake in particular)
l Patient education regarding possible
causes of urinary urgency and frequency;
consider possibility of urinary
tract infection
l Strategies for management of fatigue
discussed (PwP needs to ‘pace himself’)
and information booklet supplied
l Discussed ways to improve sleep pattern
and information sheet supplied
l Care plan commenced and agreed with
PwP and carer
Two SLT (assessment) l Decreased volume of speech
and monotone
l Decreased facial expression
l Taught daily breathing and
speech exercises
l Control over breathing explained
l Functional phrases for volumes practiced
l Facial expression exercises practised
l Care plan updated and agreed with PwP
and carer
Three PT (assessment) l Freezing leading to frequent falls
l Small-stepped shuffling gait
l Difficulty turning in bed
l No longer socialising or going on
holiday due to low mood
l Advice regarding freezing strategies and
information sheet supplied
l Gait re-education (increase step length
and slow down)
l Balance exercises taught
l Physiotherapy tips sheet provided
l Discussed mood lifting strategies; need to
have a daily walk explained
l Care plan updated and agreed with PwP
and carer
continued
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Week MDT member Problems identified Actions taken
Three Team meeting: all
MDT members
present
l Motor fluctuations with
unpredictable ‘off’ periods
l Freezing episodes
l Small-stepped shuffling gait
l Decreased volume of speech
l Decreased facial expression
l Bereavement issues leading to
low mood
All MDT members to:
l Check timings of medications as
discussed with PNS
l Remind PwP to attend PD specialist clinic
appointment for review of medications
l Remind PwP of strategies to
overcome freezing
l Reinforce importance of pacing out and
reducing speed
l Encourage PwP to continue with speech
and facial expression exercises
l Discuss bereavement issues with PwP and
his wife and make aware of local support
groups (e.g. Cruise, PD UK)
l Encourage PwP to go for a walk each day
to help lift mood
l Review care plan with PwP and carer
Four OT (assessment) l Dressing issues; difficulty putting
socks on
l Eating issues; difficulty cutting food
l Difficulty extracting bank cards
from wallet
l Try using sock aid; pegs on string to
assist with clothing while toileting
l Use steak knife for cutting food
l Use handybar® (NRS Healthcare, Coalville,
UK) to assist with getting out of car
l Ribbon round credit card to assist with
removing bank cards from wallet
l Care plan updated and agreed with PwP
and carer
Five PNS (follow-up visit) l Motor fluctuations, unpredictable
‘off’ periods
l Freezing episodes and gait issues
l Decreased volume of speech
l Decreased facial expression
l Eating/dressing issues
l Low mood
l Constipation
l Urinary problems (frequency
and urgency)
l Sleep issues and fatigue
l Non-motor symptoms assessed and
general information regarding
PD discussed
l Reminded PwP of forthcoming PD
specialist clinic appointment and further
discussions on timing of medication
l Practised strategies for overcoming
freezing and gait practice
l Encouraged PwP to continue with
speech exercises
l Encouraged PwP to continue with
facial exercises
l Confirmed use of sock aid and steak
knife to assist with dressing and eating
l Discussed issues surrounding
psychological well-being
l Assessed constipation and reminded of
need to increase fluid intake; urinary
issues remain the same; advised to
contact GP if symptoms deteriorate
l Reassessed and discussed concerns over
sleep pattern and fatigue
l Care plan reviewed
Six SLT (follow-up visit) l Low volume of speech
l Decreased facial expression
l PwP reported trying to speak up, and
friends have noticed an improvement
l Practised speech exercises
l Practised facial expression exercises
l Discussed ‘freezing’ in speech; try
yawning to alleviate
l Care plan reviewed
TABLE 38 Patient case study 3 (group A: MDT) (continued)
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Week MDT member Problems identified Actions taken
Six PT (follow-up visit) l Freezing episodes and gait issues
(had a fall in previous week caused
by freezing)
l Decreased volume of speech and
limited facial expression
l Low mood
l Constipation
l Further discussions of freezing strategies
and gait re-education
l Encouraged continuation of speech and
facial exercises
l PwP has been going out for a walk each
day and is finding this has lifted his mood
a little; antidepressant treatment to be
discussed at forthcoming PD clinic
l Ensured PwP continues to maintain a
good fluid intake
l Care plan reviewed
Six Team meeting: all
MDT members
present
l Motor fluctuations
l Speech problems
l Mobility issues
l Constipation and urinary problems
l Psychological issues
l PNS to write referral letter to local PNS
for ongoing support and reinforcement
of exercises initiated by speech therapist
and PT
l Future appointment at local PD
outpatient clinic confirmed
l Letter to GP
PD, Parkinson’s disease; PwP, person with Parkinson’s.
TABLE 38 Patient case study 3 (group A: MDT) (continued)
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Chapter 6 Discussion
Overview of findings
The findings show that people with Parkinson’s receiving a 6-week MDT intervention in their own
homes experienced an immediate reduction in anxiety, and their carers recorded improved psychological
well-being (on the MCS of SF-36). Additionally, people with Parkinson’s in the MDT groups had marginally
reduced disability and improved non-motor symptoms and health-related quality of life (on the EQ-5D
Index). In contrast, depression increased and psychological well-being deteriorated among people with
Parkinson’s in the control group.
The comparisons of groups A and B (both of who received the MDT input) at the end of the subsequent
4-month period of PCA support for group B revealed some benefits for people with Parkinson’s in group B,
compared with group A (no PCA). There were significant differences in change scores between week 6
(end of MDT) and week 24 (end of PCA for group B) in favour of group B in non-motor symptoms and
posture and marginally in health-related quality of life (measured by EQ-5D Index) and self-efficacy. In each
measure, this was due to a significant worsening in group A, suggesting that the PCA input may have
helped to maintain benefits derived from the MDT in group B. There was also a tendency for carer strain to
be lower in group B than in group A at the 24-week assessment point, which was reinforced by qualitative
evidence that showed that carers valued the PCA support.
At the final study end point (36 weeks post recruitment and 3 months after the end of PCA support for
group B), there were few differences between the groups. There were significant differences between
changes in people with Parkinson’s in group B (received MDT+ PCA) and in groups A (MDT only) and
C (control) in the SF-36 MCS and in Speech Self Report due to significant deteriorations in these measures
in groups A and C. The SF-36 MCS of carers in group A also declined, compared with group B. Gait
(UPDRS item) of people with Parkinson’s in group B improved marginally, compared with group A,
while mobility (Timed Up and Go87,88) in group A improved marginally, compared with control group C.
For carers, significant differences in changes between groups were observed in SF-36 PCS due to
non-significant trends for improvement in group A and worsening in groups B and C.
The trial involved a large range of outcome measures at four different assessment points and complex patterns
were observed. There was an overall general trend to worsening in the condition of people with Parkinson’s in
many of the main outcomes over the 6-month period of follow-up, including Parkinson’s-specific disability,
quality of life and non-motor symptoms; ability to perform activities of daily living and participate in social
activities; generic health-related quality of life; depression; self-efficacy; and self-assessed speech and voice.
The trial included live-in carers, both as subjects for the research and as partners in the intervention. Generally,
the carers scored high on functional indicators, but a slight deterioration in general health, and increase in
depression, was observed over the 6-month period.
Overall, the 6-week MDT intervention cost £833 per patient, with an extra £600 per patient for the
continuing 4-month PCA support (GBP 2011). The cost of travel to participants’ homes (staff time and car
running expenses) accounted for about 40% of this. Data on other service use by participants revealed large
variations but no significant differences between groups in total per-participant costs at any time point. In the
absence of evidence of sustained impact on the patient and carer primary outcomes, or on EQ-5D Index
scores, no formal cost-effectiveness analysis was undertaken. However, feedback on the acceptability of the
interventions from patients and carers suggests that they benefit in less tangible ways. In particular, they
report improved understanding of Parkinson’s disease, awareness of available support services and
confidence in self-management. Analysis of the MDT and PCA treatment notes for individual participants
reveals many ways in which the intervention resulted in improved care. Among 176 people with Parkinson’s,
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the PNS made 51 changes to medications, the OT made multiple recommendations for new aids and
equipment and the team made 23 referrals to other professionals. Moreover, five people who had previously
received a diagnosis of Parkinson’s disease were found not to have that condition.
Discussion of findings
There are several possible reasons why the MDT intervention showed little sustained effect. In line with the
commissioning brief, the trial recruited patients at all disease stages, and there is less scope to show
improvement in people with few limitations. Around 25% of people with Parkinson’s had minimal
disability (Hoehn and Yahr65 stages 1 and 2) at baseline. Similarly, high proportions of the live-in carers in
the study had few functional limitations. There is much heterogeneity as to how the disease affects people
with Parkinson’s and trajectories of decline are known to vary.102 For some, disease progression is slow,
reducing the chances of detecting a reduction in deterioration over a 6-month follow-up period.
In addition, many of the patients recruited to the study were already relatively well managed. Over 80%
reported that they had a PNS and 60% of these had seen the nurse within the previous 6 months.
Consistent with other evidence,103 prior access to other professionals was less good; of those who had
been diagnosed for more than 2 years, 20% reported that they had never seen a PT, and 60% stated that
they had never seen an OT or a SLT.
Another consideration is that the PCA ‘dose’ may not have been sufficient to generate a treatment effect
on people with Parkinson’s. Over an 18-week period, participants received a mean of 7 hours, 12 contacts
(five by telephone, seven home visits). Feedback from the PCAs was that they felt that the telephone calls
were not very useful as patients often said that they were ‘fine’ when in fact they had fallen or been unwell.
Therapy outcomes rely on the practice of rehabilitative exercises.104 No measure of compliance was
included in the study, so we do not know if those who engaged fully with the study gained more.
Anecdotally, PCAs reported that they observed very different levels of motivation among participants.
Patients dealing with other health issues alongside Parkinson’s, or with pain, found it more difficult to
practise exercises. Those with cognitive impairments struggled to remember the movements and follow
written instructions. Some were hampered by a general lethargy that made them procrastinate, and left
them unable to perform even essential tasks unless prompted by others. This often led to relationship
difficulties. Loving carers became frustrated in their attempts to help the person with Parkinson’s, and
needed support and reassurance from the PCA. The need for emotional support for carers, as well as for
patients, was a common theme reported by PCAs as cohorts progressed, and may underlie the marginally
significant beneficial effects on carer strain observed to arise from the PCA component of the intervention.
In general, patients were more motivated to practise movement exercises than speech or writing, which
they found boring, or embarrassing as a result of the odd noises involved in speech exercises. Hence other
ways of encouraging practice had to be found, such as writing shopping lists or reading aloud to carers.
While the OTs’ suggestions of simple aids (such as kitchen gadgets) or adaptations (such as grab rails) made
a big difference to the quality of life of some participants, others were resistant to change. Some patients
and carers were unwilling to reduce the risk of falls by reorganising furniture or moving rugs and low tables.
Drug compliance was another problem for some patients, impairing their ability to practise exercises. This
particularly affected people who lived alone, but sometimes even live-in carers (despite timed drug boxes)
did not appreciate the importance of timing and the impact of missed doses. PCAs also recognised that
for some participants, especially those who lived alone, the visits fulfilled a social function, and it was
sometimes difficult to focus on the therapeutic aspects.
Benefits identified from patient feedback (such as improved knowledge and confidence, learning where to
go for help, and feeling that someone is taking an interest) were not directly measured, and were not
DISCUSSION
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picked up in the self-efficacy outcome instrument that was used in the trial. Consideration should be given
as to how to capture such effects in future trials. Evaluative research exploring the impact of community
interventions targeting older and frail people face methodological challenges, and new approaches to
capturing patient and carer outcomes are required.105
Comparison with other studies
There is little prior evidence on the impact of multidisciplinary rehabilitation for Parkinson’s disease.14
In demonstrating some short-term benefits, and very limited effects at 6-month follow-up, the SPIRiTT
findings correspond to those of the other available studies,21,23,27 and with evidence on the effectiveness of
(single-discipline) physiotherapy for Parkinson’s disease.106–109 A study set in a specialist Parkinson’s centre
found that 70% of patients undergoing multidisciplinary treatment improved over 12 months, but the
nature of the intervention (which involved neurology, psychiatry, psychology, functional diagnostic testing,
medication review, home exercise and support) is not directly comparable with a domiciliary
rehabilitation service.19
Conclusive evidence is still needed to confirm the effectiveness of occupational therapy110,111 and speech
and language therapy112–114 for Parkinson’s disease, although their value in clinical practice is recognised
through their inclusion in treatment guidelines.12 Equally, PNSs play a central role in providing local
specialist services, and are highly valued by patients and carers,115 although evaluations have not shown
conclusive improvements in patient outcomes.31,32 The advantages of a cross-disciplinary collaborative
approach to rehabilitation involving all these professions are widely accepted,3,10–13 but clear evidence of
effectiveness is elusive.
Evidence from evaluations of general geriatric assessments and support in the community show
inconsistent effects on outcomes and costs,46,51,52 dependent on the nature and scope of the intervention
and methodology of the study. A systematic review of co-ordinated and integrated interventions to frail
elderly people found only nine RCTs, seven of which reported at least one favourable outcome for
patients. Only two studies included carers, and neither found an effect on carer burden. The reviewers
report a reliance on measures with poor psychometric properties, and a need for more robust evidence.116
Comparison with day-hospital rehabilitation
One objective of SPIRiTT was to compare the results of domiciliary delivery of the specialist rehabilitation
intervention with those obtained from a previous trial conducted by the research team that was set in a
day hospital. People with Parkinson’s (with carers) attended in groups of six on 1 day per week for
6 weeks. They received individual treatments from the PNS, PT, OT and SLT, and group education and
relaxation.26 The day-hospital protocol formed the basis for the design of the SPIRiTT intervention.
SPIRiTT succeeded in delivering a comparable intervention to that provided in the day-hospital trial,
comprising around 9 hours of patient-centred multidisciplinary rehabilitative care for each person with
Parkinson’s.26 In showing some short-term patient benefit, it also confirmed the findings of the day-hospital
study, which was an uncontrolled (pre–post) design.21 A marginal impact on mobility (measured by Timed
Up and Go87,88) was also the only longer-term benefit in both studies.23 SPIRiTT additionally tested if
continuing benefit from a PCA could help to sustain immediate improvements from treatment. Some
evidence was found that the PCA component, while it was being provided, generated some benefits
for people with Parkinson’s [non-motor symptom control, posture and (marginally) quality of life and
self-efficacy] and carers (tendency towards reduced strain).
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Domiciliary rehabilitation was tested in SPIRiTT because the day-hospital trial had incurred facilities overhead
costs, and transport difficulties for those patients without independent means of reaching the treatment
setting.27 In SPIRiTT, expenses associated with professionals travelling to patients’ homes (which accounted
for some 40% of the costs) are substituted for the expense of patient transport, but the use of NHS premises
for treatment is avoided. Much of the cost of professional travel is associated with the time it takes, and,
thus, depends on the catchment area of the team and local geography. In this respect, the travel costs in
SPIRiTT may not be widely generalisable.
The pros and cons of domiciliary rehabilitation were identified in feedback from patients and carers,
and from members of the MDT. Home visits enable professionals to assess safety issues and gain an
understanding of the context of patients’ daily lives, and recommend accordingly. On the other hand,
group activities cannot be provided, and any benefits from group interaction are lost. In particular, some
carers value the opportunity to get out of the home and exchange experiences with other carers, and also
to have individual time with professionals. The feelings of patients about group interventions are more
mixed and some do not want to encounter people with more advanced disease.
A recent trial that directly compared rehabilitation of older people in a day hospital and at home produced
equivocal results and concluded that the costs were the same.117 These findings were based on a limited
clinical sample, and the authors recognised the need for condition-specific evaluations. The evidence now
available from Parkinson’s disease confirms the more general findings, that both types of provision confer
benefits and that relative costs will vary by location.
Strengths and limitations of the study
Although the trial involved a complex design with a difficult patient group, the study ran to time, achieved
the required patient sample size and delivered the intervention without any delays. This was facilitated by
assembling a large pool of interested patients prior to the launch of the intervention, so that several cohorts
could be treated consecutively, during which period the remaining patients were recruited. The trial
experienced a low rate of drop-out through good liaison with participants by the research office, and the
incentive for those in the control group of a full assessment from a member of the MDT if they completed
all of the research assessments. It was a pragmatic study that aimed to reflect realistic service delivery and
provide messages that would be useful in practice. The primary outcome measures (Parkinson’s disability
and carer strain) were chosen to be of importance to people with Parkinson’s and carers in their everyday
lives, and were successful at picking up marginal effects at the end of the MDT intervention and PCA
support, respectively. The intervention was delivered safely, with no observed increases in fall rates,
or unexpected serious adverse events.
The study has several limitations. Recruitment, which took place largely through GPs (via the PCRN) or local
PNS or hospital outpatient clinic lists, did not reach ethnic minorities in the area. This might be because GPs
serving ethnic groups were not involved in the mailing of invitations to their patients, or because people
from these communities are less inclined to volunteer for research. Parkinson’s disease is more common in
men,118 and this was reflected in the study recruitment, which was 60% male. Although the study reached
the planned sample size of 270 people with Parkinson’s, carers were under-recruited. Based on the previous
day-hospital study,21,23 sample size calculations assumed that 79% of patients would have live-in carers and
that they would take part in the research. While this proportion was largely accurate (77% of the SPIRiTT
sample had live-in carers), carers in this study displayed a greater reluctance to be involved in the research
than the carers of the patients in the day-hospital study. There are several possible reasons for this.
Many did not see themselves in a caring role, particularly if their partner was relatively independent and
not requiring assistance. Some carers were out at work, others were frail themselves and not capable
of filling in the forms, and others were just not interested.
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The randomisation process resulted in uneven groups at baseline, with group B (which received the
MDT+ PCA intervention) containing people with higher levels of disability, who had received more
physiotherapy recently and who had lower BMIs than the participants in the other groups. This imbalance
was adjusted for in the analysis through change scores, but the group suffered higher attrition. Although
an ITT analysis was planned, some people had dropped out prior to treatment and others missed later
assessments due to illness, death, withdrawal or loss to follow-up. Such attrition is expected in a trial
involving this patient group, but it led to a decision to prioritise a PPA over the ITT approach.
All research data were collected through research nurse visits to participants’ homes. Although the
instrument battery had been discussed and piloted within the PPI group, in practice it proved quite
onerous for participants to complete. To minimise the length of the research nurse visit, items suitable for
self-completion were mailed in advance. Some participants struggled with the assessments, depending on
cognitive abilities, and required help from the research nurse. In these circumstances, answers were taken
directly from the participant, and never ‘led’.
Questionnaires were checked for completeness before the end of the visit and on return to the research
office, and this resulted in minimal missing data. Instruments were excluded if there were more than
two missing items and remaining items were filled using established procedures for the relevant instrument
(when available). Alternatively, missing values were set to zero (or normal), i.e. the most favourable value.
This occurred in a very small number of instances (0.40% for people with Parkinson’s, 0.06% for live-in carers;
see Appendix 18), and we do not believe that this affected the results in any way. There were a few
circumstances where the research nurses could not conduct the Timed Up and Go,87,88 and participants
experienced difficulties with the pain VAS, meaning that the sample sizes for those instruments were reduced.
As the trial progressed, the load of research assessments was too great for one nurse, and two assistants
were employed. Owing to problems recruiting on a temporary and part-time basis, the two assistant
research nurses were employed from within the project team (a PNS and a PCA). Most instruments were
self-reported by participants, but to ensure inter-rater reliability in items requiring judgement (gait, posture
and some speech scales), the nurses were trained and observed in early visits. However, we cannot rule
out the possibility that differences in judgement affected results. In particular, several significant differences
were found in nurse-rated scales involving the 24-week assessment, which was largely (58%) conducted
by one of the supplementary assessors (see Table 4).
All reasonable precautions were taken to keep all of the research nurses blinded to the group allocation of
the people they were assessing. The PNS was assigned to baseline assessments (before group assignment is
determined) and the PCA did not assess people she was treating. To avoid unblinding, research nurses had
no access to study databases and did not answer the telephone in the research office, as patients often
called in to alter MDT appointments. Participants were constantly reminded not to give away their group
allocation, but they frequently did mention, during the second assessment (immediately after the MDT
intervention), that they had seen a member of the team. Many were confused by the study processes and
did not understand the importance of the distinction between the treatment team and the research
assessors. Unblinding occurred anyway at the end of the third assessment when the research nurses
collected the feedback questionnaires from participants who had received treatment, enabling them to
distinguish control participants but not the allocation of others between groups A and B. The main research
nurse carried out over 750 assessments and was visiting people in several cohorts at any point in time, and
reported that, generally, she was not able to recall group allocations, if they had been disclosed to her.
It had been planned to collect feedback from the patients and carers about the acceptability of the
intervention at the third (24-week) assessment point, after both the MDT and the PCA components were
completed. However, it became apparent that participants suffered recall problems about the MDT
intervention, which had ended 4 months earlier. Hence, from the fourth cohort onwards, acceptability
questionnaires were additionally mailed to participants after the second assessment (at 6 weeks).
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Feedback was still collected at 24 weeks to elicit views about continuing benefit from the MDT,
and specifically about the PCA component (group B only).
Study instruments
The trial contained a large number of outcome measures, and experience with using these may be of
relevance to the NHS outcomes framework.119 Trends across the assessments were not consistent, making
interpretation difficult. Most instruments selected for the study are widely used and validated for older
people, and for people with Parkinson’s in particular (including Parkinson’s Disability,69,70 Barthel ADL76 and
Frenchay Activities Index77–79). The disease-specific (Parkinson’s Disease Questionnaire-8,72,73 Non-Motor
Symptom Questionnaire74,75) and generic (EQ-5D,80,81 SF-3682) health-related quality-of-life instruments that
were included are recommended for use in Parkinson’s disease.120
Problems were encountered in the administration of some instruments, which may render the results they
provided less reliable and reduce their utility. Many participants were unable to grasp the concept of rating
using VASs, and did not have the fine motor skills required to complete them accurately. This resulted in
non-response for the pain VAS measure, the validity of which has, in any case, been questioned for use
in Parkinson’s disease.90 In line with other studies,93 the measures collected confirmed that patients rate
pain worse during ‘off’ periods, because dopamine drugs alleviate discomfort. However, Parkinson’s
patients’ experiences of pain are complex,93 and the large fluctuations reported by patients from one
assessment to the next rendered this measure difficult to analyse. Similar problems were experienced with
the data generated by the EQ-5D Thermometer,80,81 which varied markedly for some patients over time.
Difficulties with using this measure with older people has also been recorded by other researchers.121
Some participants who were frequent fallers had trouble remembering the number of falls they had, and
the data available for analysis were severely skewed (a small number of participants reported over 100 falls),
so this outcome was explored in binary form only (i.e. whether or not a participant said they had fallen in
the assessment period). In addition, further data on falls were accumulated from a variety of different
sources for the adverse events log, and this information correlated poorly with participants self-report
during assessments. The adverse events log, which was analysed for safety reasons and reported to the
external advisory group on an ongoing basis, showed no significant differences between treatment groups
in number of falls at any point in the trial.
The single-item nurse-rated gait, posture and speech scales are well validated,89,96,97 but have only four or
five points on the scales and are thus relatively blunt instruments, most often used in clinical situations
rather than for research purposes. Speech assessments were conducted at the visit and relied on
judgement. Although nurses followed closely the official guidance for raters, recording voice or
conversation for later independent assessment would have been more reliable and avoided any concerns
about inter-rater reliability. Though unvalidated, the speech self-report measure used in the study proved
sensitive. In contrast to many instruments which focus on breathing and articulation, this measure asks
respondents to report the frequency of speech and conversational problems and is thus relevant to
everyday functional communication. It is routinely used in clinical practice by therapists involved in the
study, and deserves to be tested further for its psychometric properties.
Research nurses reported difficulties arising from ‘on/off’ fluctuations experienced by people with
Parkinson’s affecting performance on some outcome measures, such as the Timed Up and Go,87,88 and
nurse-assessed posture, gait and speech items. In a small number of cases when the participant was
experiencing a serious ‘off’ phase, these measures were not conducted. No record was taken of whether a
participant was ‘on’ or ‘off’ at the time of assessments, and this could have varied between data collection
visits and may account for large individual fluctuations in some measures observed during the analysis.
Although notes were made about the chair used for the Timed Up and Go assessment (with or without
arms, and height of seat), it was not always possible to ensure consistency in the home setting, and this is
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another reason why the marginally significant findings on this measure at the final 36-week follow-up
point should be interpreted with caution. At around 18 seconds, the mean (and SD) values for Timed Up
and Go recorded in SPIRiTT were higher than those recorded in more controlled environments
(13.7 for ‘on’, 17.2 for ‘off’87), but lower than those in the day-hospital study.23
The Yale Depression Screen84,85 was administered in the study to assess its effectiveness for use with
people with Parkinson’s. Although the proportions screening positive fluctuated a lot, the instrument
correlated closely at baseline, for both people with Parkinson’s and carers, with both the HADS depression
subscale83 and the SF-36 MCS82 (p< 0.0005 in all comparisons).
Although psychometrically sound, and probing (among other things) levels of confidence in self-management,
the six-item Self-Efficacy Scale used in the study86 did not pick up the improved confidence that, in feedback,
patients and carers reported feeling that they had gained from the interventions. This may be because the
instrument used was designed for chronic conditions in general and was not sufficiently tailored to the
particular problems of people with Parkinson’s. Other research has suggested that self-efficacy in Parkinson’s
disease is mediated by family support.122 Of importance is the need to focus on outcomes that matter to
patients rather than clinicians,123 and most instruments in the study were selected with that in mind. However,
the diversity of symptoms, and variability in the way that these affect people with Parkinson’s, makes
measurement of outcomes challenging.124
Multidisciplinary team intervention
Increasing numbers of people are living longer, often with multiple long-term conditions. It is recognised
that no single discipline or professional can provide complete care for this group,29,30 and emphasis is
being placed on interprofessional working.125 In the context of long-term neurological conditions, the role
of nurse specialists is seen as pivotal to provide support and continuity of care across disciplinary
boundaries and longitudinally.126 Debate exists around the definition of the term ‘interprofessional
working’, which is closely linked to the concept of ‘co-ordinated care’.127 Different models of
interprofessional working have been identified: integrated teams, case management and collaborative
networks.128 The interprofessional working within SPIRiTT fits the definition of an integrated team. A range
of external factors facilitate or inhibit team formation, and influence team structure, working processes
and evolution. Important among these are management and financial arrangements, the historical
organisation of service delivery, local geography and power relations.125,129,130 Team effectiveness is
enhanced by diversity of expertise, alignment of professional goals, good communication, strong
leadership and access to a broad network of other organisations.129,131
The SPIRiTT team was formed for the purposes of the research, and worked parallel to existing community
services. Through its emphasis on prevention, and providing more time for professionals to get to know
individual patients, the SPIRiTT intervention differed from usual care within the NHS, which has increasingly
become crisis driven.53 This holistic approach to care, and the strength of the interprofessional working
relationships, contributed to reported high levels of job satisfaction.
The MDT professionals identified that a key factor in the success of the intervention was that they were
closely involved in its design and development, both prior to starting treatment and through the process
of reappraisal after the first cohort, in which unanticipated practical issues were addressed and more
effective processes were put in place. Consolidated by strong leadership, the team bonded over time.
Good communication, regular team meetings and mutual respect between all team members, including
the PCAs, ensured that patients received a co-ordinated package of care. Individual professionals taught
and learnt from the other disciplines, and, by gaining a better understanding about what others do, they
were each able to advise and reinforce the messages to patients. The team could concentrate on patient
care and function efficiently because of strong managerial and administrative back-up in the project office.
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The use of trained assistants to provide therapy and monitor patients is consistent with NHS workforce
policy that seeks to develop roles for non-registered support workers.60,61 This approach offers a potentially
flexible and low-cost means of providing ongoing care for patients. Support workers are widely used
within different models of care throughout the NHS,132 and have been shown effective in team-working in
community settings.133,134 The quality of care assistants is crucial for safety and efficacy reasons,57 and so
training and supervision are of paramount importance.58 The PCAs in SPIRiTT were trained using materials
developed for the purpose by the research team,68 and through shadowing professionals from each
discipline within the MDT. They were monitored by the lead PNS, but liaised, as needed, with other
professionals regarding patient care. They were fully embedded in the MDT, attending meetings and
contributing to discussions around care planning. Despite concerns about demarcations when skills are
mixed, no such issues were encountered. The PCAs reported working within their competencies, feeling
fully supported by professional members of the MDT, and gaining knowledge and confidence as the
intervention progressed.
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Chapter 7 Conclusions
In 2006, the NICE guidelines for Parkinson’s disease recommended early referral and regular access to abroad range of medical and allied health professionals, but gave no recommendations as to how to
organise the multidisciplinary care.12 The All Party Parliamentary Group inquiry on Parkinson’s Disease
(APPGPD) was carried out in 2009 amid growing concerns about variations in access to the comprehensive
services and expert multidisciplinary care needed by people with this complex condition.33 The inquiry found
evidence of significant inequalities in service access across the whole of England, Wales and Northern
Ireland to all aspects of care. It concluded that the value of therapy and social care services in the
management of Parkinson’s disease is not being recognised by many health and social care professionals,
resulting in early decline in an individual’s condition and adverse impact on the carer’s health.
A clear picture of the key components of high-quality services for people with Parkinson’s disease and their
carers was provided to the APPGPD inquiry through evidence from professionals working in health and
social services and those directly affected by the condition. The report highlighted the importance of
integrated MDTs delivering care to people with Parkinson’s and carers; provision of information about all
aspects of living with the condition and the range of services and sources of support available; and
guidance on how to access these services.33
The SPIRiTT intervention incorporates key aspects of interdisciplinary team working (shared goal setting
and care planning, effective communication channels and appropriate referrals to other specialities) and a
client-centred approach that invited participants to prioritise their concerns. It also addressed the needs of
carers who have a crucial role to play in assisting clients in their daily activities. Feedback from participants
suggested that it was effective at increasing their understanding of the condition and providing
signposting to other services. Results from the RCT show that people with Parkinson’s experienced reduced
anxiety, a tendency for improved symptom control and health-related quality of life, and reduced disability
after the MDT intervention. There is also evidence that ongoing PCA input helped to maintain some of the
benefits, while it continued. Similarly, carers recorded improved psychological well-being and a trend
towards reduced strain from the MDT and PCA contributions, respectively. Support for carers is a high
policy priority135 because it improves their ability to cope with complex situations and protects their health,
and hence has the potential to avert a breakdown in care and the need to introduce expensive external
assistance. The overall SPIRiTT intervention represented an improvement in quality of care at a cost (2011
GBP) of around £1433 per participant (£833 for the 6-week MDT specialist rehabilitation; £600 for
4 months of PCA support).
The National Service Framework for long-term conditions was introduced in 2005 to improve services for
people with neurological conditions,30 and, since then, spending in this area has increased. However, a
recent report by the National Audit Office (which focused on Parkinson’s disease, multiple sclerosis and
motor neurone disease) has reported poor implementation and worsening in key indicators of quality of
care.136 Particular problems identified were variable quality of the diagnosis process, fragmented and
poorly co-ordinated ongoing care and poor information and advice to patients. With changes in the
structure of decision-making in the NHS, local clinical commissioning groups will be responsible for
purchasing services.137 This provides both opportunities for innovation and quality improvement, and risks
of perpetuating existing variability in access. Information on alternative specialist community rehabilitation
models (structures, processes, impacts and costs), such as that provided by the SPIRiTT trial, is important to
enable evidence-based decisions to be made by service planners and commissioners.
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Further research
The findings from this study point to the need for further research on the relative benefits and costs of
alternative models of specialist multidisciplinary rehabilitation for people with Parkinson’s in the community
to provide evidence for local service commissioners and providers. While this and other studies20,21 have
confirmed that patients can benefit from multidisciplinary rehabilitation in the short term, the means by
which the improvements gained can be sustained need further investigation. One possibility, suggested in
feedback from participants, is to spread the professional input over a longer period of time, and this
deserves to be explored.
The use of PCAs for extended support beyond the end of a 6-week MDT intervention produced some
benefits for patients, compared with those without ongoing PCA support. Carers also reported some reduced
strain during the PCA intervention. More research is required on the potential of PCA support by exploring
how the nature and ‘dose’ might affect outcomes, both for people with Parkinson’s and carers, and whether
or not support provided over an extended period could be effective at avoiding costly hospitalisations.
Future research should select outcome measures carefully and focus on those that are patient and carer
centred, and are relevant to their daily functioning and quality of life. Methods need to be found to
incorporate intangible benefits from interventions into evaluations of their effectiveness, such as improved
understanding of the condition and confidence in self-management. In addition, studies should be
powered to enable subgroup analysis according to disease stage because issues important to patients and
carers change with disease progression, and incorporating those with few limitations in the analysis may
conceal effects occurring in other groups.
CONCLUSIONS
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Appendix 2 Poster
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Appendix 3 Telephone-screening pro forma
DOI: 10.3310/hsdr02510 HEALTH SERVICES AND DELIVERY RESEARCH 2014 VOL. 2 NO. 51
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Gage et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
139
APPENDIX 3
NIHR Journals Library www.journalslibrary.nihr.ac.uk
140
Appendix 4 Information leaflets, consent forms
and letters to participants
Information leaflet: person with Parkinson’s
DOI: 10.3310/hsdr02510 HEALTH SERVICES AND DELIVERY RESEARCH 2014 VOL. 2 NO. 51
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Gage et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
141
APPENDIX 4
NIHR Journals Library www.journalslibrary.nihr.ac.uk
142
Information leaflet: live-in carer
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Consent form: person with Parkinson’s
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Consent form: live-in carer
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Baseline visit confirmation letter
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Appendix 5 Background information collected
at baseline
Nurse-collected from the person with Parkinson’s
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Self-reported background information from person
with Parkinson’s
DOI: 10.3310/hsdr02510 HEALTH SERVICES AND DELIVERY RESEARCH 2014 VOL. 2 NO. 51
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Gage et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
153
APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
154
DOI: 10.3310/hsdr02510 HEALTH SERVICES AND DELIVERY RESEARCH 2014 VOL. 2 NO. 51
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Gage et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
155
Self-reported background information from live-in carer
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Appendix 6 Baseline exclusion letter
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Appendix 7 Eligibility confirmation and
randomisation letters
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Appendix 8 General practitioner notification letter
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Appendix 9 Fact sheets for multidisciplinary
team participants (educational component of
the intervention)
Parkinson’s UK information sheets on:
l Parkinson’s and diet
l drug treatments for Parkinson’s
l constipation and Parkinson’s
l looking after your bladder and bowels in Parkinsonism
l foot care and Parkinson’s
l fatigue and Parkinson’s
l sleep and night-time problems in Parkinson’s
l speech and language therapy
l general information about benefits.
Fact sheets developed by the SPIRiTT team:
l physiotherapy general tips
l relaxation.
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Appendix 10 Generic information for control
group participants
(Also provided to intervention groups.)
Parkinson’s UK. Parkinson’s and You. London: Parkinson’s UK; 2010.
Parkinson’s Disease Society. The Carer’s Guide. London: Parkinson’s Disease Society; 2008.
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Appendix 11 Multidisciplinary team roles and
intervention protocols
Parkinson’s nurse specialist
Role
l To provide expert Parkinson’s management to maintain maximum independence for patients.
l To act as a reliable source of information about clinical and social issues that were of concern to people
with Parkinson’s and their carers.
l To ensure appropriate timely referral to essential services such as therapy or social care.
l To empower and educate people with Parkinson’s and their carers.
l To identify the tolerance and efficacy of medication.
l To complete adverse event forms as per the project protocol.
l To reinforce all MDT treatment programmes.
Protocol
Initial assessment (1.5 hours):
l collection and collation of baseline information including data of diagnosis, medical history, current
support services and falls history
l completion of MDS-UPDRS
l review of Parkinson’s medication
l review of current problems as identified by the person with Parkinson’s
l provision of leaflets and advice as appropriate
l blood pressure checking and recording.
Follow-up visit (1.5 hours):
l discussion of non-motor symptoms including drooling, swallowing, constipation, urinary problems,
sexual and relationship pain, apathy, fatigue, depression, hallucinations, anxiety, dizziness, sleep
problems, dyskinesias, motor fluctuations, end of dose ‘wearing off’ and nausea
l reinforcement of all MDT treatment programmes
l provision of an agreed care plan reflecting the needs and wishes of the participant and their carer.
Physiotherapist
Role
l To improve the quality of life for people with Parkinson’s by improving/maintaining levels of function
and independence.
l To increase awareness of Parkinson’s and its effect on functional ability including posture, mobility
and transfers.
l To give advice and education on preventative strategies/measures.
l To provide an agreed care plan reflecting the needs and wishes of the participant and their carer.
l To complete adverse event forms as per the project protocol.
l To reinforce all MDT treatment programmes.
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Protocol
Initial assessment:
If during the initial assessment there were problems with poor posture, transfers including bed mobility,
balance and falls, mobility including freezing and turning, then a further in-depth assessment followed
which could include, as appropriate, the Lindop Parkinson’s Assessment Scale or the Berg Balance 7-item
short-form version.
All participants received a physiotherapy tips information leaflet covering transfers, freezing, posture and
mobility information and strategies.
A patient-specific programme tailored to the participant’s individual needs was provided.
This programme included:
l Yale balance exercises (levels 1–5)
l Roche exercises for people with Parkinson’s disease
l posture handout including specific exercises and posture advice
l Keep Moving booklet (PD UK)
l handwritten individual tailored exercises as appropriate.
Physiotherapy interventions included treatment for improving:
l functional activities including bed transfers and bed mobility
l posture
l balance and prevention/reduction of falls
l mobility problems including freezing and turning.
Speech and language therapist
Role
l To give advice on the speech and swallowing disorders that could arise with Parkinson’s disease.
To explain how these disorders come about and educate as to the importance of targeted exercise
programmes. Use of diagrams, etc., where needed, to explain swallow function.
l To provide advice regarding how to access local speech and language therapy services and to refer on
to these services if appropriate.
l To ensure that individuals knew how to recognise dysphagia that may be associated with Parkinson’s
disease and to seek appropriate support.
l To improve the patient’s quality of life through structured exercise programmes designed to maintain
and improve function.
l To advise on modified food/fluid consistencies where these might improve swallow function and
reduce the risk of aspiration and to refer to videofluoroscopy where appropriate. To engage carers/
family members as to the role they could play in support.
Protocol
All participants received an initial assessment (1.5 hours):
l understanding the individual’s perception of their own speech/swallowing problem through discussion
with them and their family and with the use of rating scales
l understanding if they have previously undergone speech and language therapy and what form this
has taken
l evaluation of posture, breath capacity and control, i.e. their ability to support speech
APPENDIX 11
NIHR Journals Library www.journalslibrary.nihr.ac.uk
172
l evaluation of their habitual and possible optimum volume for speech
l evaluation of diadochokinetic movements for speech and possible impact on articulation
l evaluation of any swallowing disorder
l if swallowing difficulties were present, assessment of cranial nerve function and Sydney
Swallow questionnaire
l completion of adverse event forms as per the project protocol
l reinforcement of all MDT treatment programmes.
Following their assessment, individuals were advised as appropriate on suitable exercises/strategies to help
with their specific difficulties. These exercises were provided in written form and could have included:
l a facial exercise programme to maintain muscle flexibility
l breathing and phonation exercises to maximise volume
l functional phrases to incorporate volume work into meaningful task
l poetry/pacing exercises to work on rate and intonation
l tongue twisters/reading aloud to work on articulatory imprecision.
Further written leaflets were available to provide advice on a number of modified food and
fluid consistencies.
Where appropriate, individuals were offered a second appointment to follow-up on the exercise
programme. Onward referral to the local speech and language therapy service or for videofluoroscopy
assessment was made if required.
Occupational therapist
Role
A single assessment (1.5 hours) was carried out for each individual:
l to assess an individual’s ability to perform day-to-day activities
l to advise on appropriate aids, equipment or adaptations to help the individual maintain independence
l to provide information and explanations about the various resources, services and benefits which are
available to help maintain family life, work and leisure interests
l to advise on coping strategies to help with Parkinson’s symptoms such as fatigue, handwriting and
communication difficulties
l to refer to other services and organisations that offer support or help
l to ensure completion of adverse event forms as per the project protocol
l to reinforce all MDT intervention programmes.
Care assistant
Role
l Provide ongoing support to patients and their carers using agreed care plans as formulated by
therapists and nurse specialists for a period of up to 18 weeks.
l Attend MDT meetings at start of intervention phase for detailed handover of designated individuals
from team therapists/nurses.
l Clarify the role of the project care assistant with the participant and their carer and their importance for
the project outcomes.
l Emphasise the importance of doing prescribed exercises and the long-term benefits which could
be gained.
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l Demonstrate the exercises to the participant and their carer and encourage regular practice.
l Keep detailed and legible records of progress made by the participant at each visit and document any
identified problems or changes required during the participant/carer review process.
l Report any identified problems to the appropriate member of the MDT and provide regular feedback to
the therapist/nurse until the problem is resolved.
l Meet regularly with the PNS to discuss individual participant progress and issues which have arisen.
l Ensure completion of adverse event forms as per the project protocol.
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Appendix 12 Client record form
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Appendix 13 Outcome measures: self-report
questionnaires
Person with Parkinson’s self-report questionnaire
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Appendix 14 Outcome measures: nurse
assessments
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Appendix 15 Intervention acceptability
questionnaire
Person with Parkinson’s intervention
acceptibility questionnaire
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Live-in carer acceptibility intervention questionnaire
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Appendix 16 Reflective feedback forms from the
multidisciplinary team
Cohort 2
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Cohort 8
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Appendix 17 Exit interview topics for the
multidisciplinary team
l Personal role and team leadership.
l Experience of the team: forming, evolving, working, ending.
l Team size and composition – missing professionals.
l Role and integration of the PCAs.
l Barriers and facilitators to effective team/interprofessional working.
l Differences from NHS working and implications for the NHS.
l View of programme and delivery, and lessons for the future.
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Appendix 18 Analysis of missing items in
multi-item outcome measures
Sample sizes of single-item outcome measures (people with Parkinson’s only) in the PPA were as followsand are reduced (compared with the full sample of 227) for Timed Up and Go, posture and gait
(because observations could not be done if the person with Parkinson’s was experiencing an ‘off’ period),
and for pain (due to participants finding difficulty understanding the concept of the VAS): EQ-5D
Thermometer, n= 226; Timed Up and Go, n= 210; UPDRS posture, n= 212; UPDRS gait, n= 212;
UPDRS speech, n= 226; pain VAS, n= 164; Emerson and Enderby voice, n= 226; Emerson and Enderby
articulation, n= 226; Yale Depression Screen, n= 225; and falls, n= 226.
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Appendix 19 Unit costs used in the calculation
of intervention costs
TABLE 40 Unit costs used in the calculation of intervention costs
Professional
Overall unit costsa (£/hour)
Patient-related work In-home patient-facing care
Nurse specialist 50 50
PT 34 34
OT 34 34
SLT 34 34
PCA 24 29
Fixed cost items
Professional time spent to write notes, discuss patient at team meetings, etc. 30 minutes per home visit
15 minutes per telephone call
Median mileage per visit 23
Travel costs, £/milea 0.45
Professional time in travelling Based on 20 miles per hour
One hour of PNS time per patient to write letter (report) to GP £50
a Costs are taken from Curtis.99
The hourly rates used are inclusive of all oncosts, and management office/administrative support and facilities overheads.
DOI: 10.3310/hsdr02510 HEALTH SERVICES AND DELIVERY RESEARCH 2014 VOL. 2 NO. 51
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Gage et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
255

Appendix 20 Unit costs for analysis of
service use
TABLE 41 Unit costs for analysis of service use
Service used Unit cost (£) Note; page (section number)a
A&E attendance, including
emergency transport
223 91 (7.1): A&E services not admitted, weighted (national) average of all
services (£106), plus mark-up for paramedic transfer of £117, calculated as
50% of average cost of all paramedic services (£234) (because 25% of
people reporting use of A&E stated that they did not use hospital transport,
and the rest stated they used it either all or some of the time)
Hospital day case 686 91 (7.1): weighted average of all stays
Hospital overnight ≤ 4 nights 549/night 91 (7.1): non-elective inpatient short-stay daily rate
Hospital overnight > 4 nights 2334 91 (7.1): non-elective inpatient long-stay rate (for whole stay)
Day care (per session) 36 28 (1.4): local authority day care for older people
Care home (per day) 71 26 (1.2): assumed private sector establishment cost per permanent resident
week for older people £497
Nursing home (per day) 130 25 (1.1): private sector nursing homes establishment cost per permanent
resident week for older people £719
Hospital neurologist 40 203 (15.5): consultant medical, £162 per hour, assume 15-minute consultation
Hospital geriatrician 40 203 (15.5): consultant medical, £162 per hour, assume 15-minute consultation
Psychiatrist 40 205 (15.7): consultant psychiatrist, £162 per hour, assume 15-minute
consultation
GP surgery visit 36 149 (10.8): £3.10 per surgery/clinic minute, for consultation lasting
11.7 minutes
GP home visit 121 149 (10.8): 23.4 minutes including travel time
GP telephone call 22 149 (10.8): telephone consultation lasting 7.1 minutes
GP out of hours 121 149 (10.8): 23.4 minutes including travel time
PNS (per contact) 25 144 (10.4): nurse specialist hourly rate £50, assume 30-minute contact
(same clinic and home visit)
District or practice nurse
(per contact)
14 Practice nurse, 144 (10.6): £51 per hour face-to-face contact,
allow 15 minutes= £13. District nurse, 141 (10.1): £73 per hour,
£18.25 per home visit
PT (per contact) 17 133 (9.1): £34 per hour community PT, assume 30 minutes
OT (per contact) 17 134 (9.2): £34 per hour community OT, assume 30 minutes
SLT (per contact) 17 135 (9.3): £34 per hour community SLT, assume 30 minutes
Psychologist (per contact) 30 137 (9.5): £60 per hour clinical psychologist, assume 30 minutes
Social worker (per contact) 30 156 (11.2): approved social worker adult services, £59 per hour, assume
30 minutes
Alternative therapist
(per contact)
30 Assumed as social worker
Health-care assistant
(per contact)
10 145 (10.5): clinical support worker (community), £29 per hour, assumed
20 minutes
a All unit costs taken from Curtis (page and section numbers as shown).99 Costs are fully loaded and include oncosts;
non-patient-facing patient-related work; management, administrative and facilities overheads and qualifications.
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Appendix 21 Baseline aids and adaptations
TABLE 42 Baseline aids and adaptations reported by 269 people with Parkinson’s
Type of aid/equipment Group A, n (%) Group B, n (%) Group C, n (%) % self-paid
Electric wheelchair 1 (1.4) 3 (3.9) 2 (2.6) 100
Manual wheelchair 4 (20.8) 18 (23.7) 14 (18.2) 70
Walking trolley 9 (12.5) 10 (13.2) 7 (9.1) 54
Walking frame 16 (22.2) 32 (42.1) 21 (27.3) 43
Crutches 2 (2.8) 1 (1.3) 2 (2.2) 20
Electrically operated easy chair 15 (20.8) 15 (19.7) 9 (11.7) 98
Raised-height easy chair 3 (42.0) 2 (2.6) 4 (5.2) 67
Chair raise 6 (8.3) 4 (5.3) 7 (9.1) 12
Seat raiser 1 (1.4) 0 (0.0) 1 (1.3) 50
Table tray on wheels 3 (4.2) 1 (1.3) 1 (1.3) 100
Special cushions 4 (5.6) 5 (6.6) 8 (10.4) 94
Hospital bed 8 (11.1) 8 (10.5) 8 (10.4) 83
Leg raiser 0 (0.0) 0 (0.0) 0 (0.0) 0
Back rest 1 (1.4) 3 (3.9) 0 (0.0) 25
Bed table 1 (1.4) 1 (1.3) 1 (1.3) 100
Grab rails (bedroom) 16 (22.2) 25 (32.9) 19 (24.7) 15
Monkey pole 0 (0.0) 2 (2.6) 0 (0.0) 100
Commode 6 (8.3) 8 (10.5) 5 (6.5) 42
Raised toilet seat 7 (9.7) 17 (32.4) 15 (19.5) 15
Bed pan 7 (9.7) 17 (32.4) 15 (19.5) 84
Adapted shower unit 12 (16.7) 14 (18.4) 4 (5.2) 67
Bath seat 12 (16.7) 14 (18.4) 11 (14.3) 43
Grab rails (bathroom) 37 (51.4) 50 (65.8) 46 (59.7) 65
Incontinence aids 5 (6.9) 13 (17.1) 4 (5.2) 62
Kitchen gadgets 14 (19.4) 9 (11.8) 13 (16.9) 100
Special cutlery 2 (2.8) 3 (3.9) 7 (9.1) 100
Ramps inside and outside 2 (2.8) 7 (9.2) 2 (2.6) 82
Electric stair lifts 3 (4.2) 7 (9.2) 7 (9.1) 82
Adaptation conversion to car 1 (1.4) 1 (1.3) 2 (2.6) 100
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Appendix 22 Analysis of prescribed medications
TABLE 43 Analysis of prescribed medications (N= 269 at baseline)
Group
Item
Total
n (%) p-value Test
0
n (%)
1
n (%)
2
n (%)
3
n (%)
Parkinson’s medications
Levodopa preparations
A 11 (12.5) 48 (54.5) 29 (33.0) 0 (0.0) 88 (100) 0.278 Chi-squared
B 6 (6.9) 51 (58.6) 29 (33.3) 1 (1.1) 87 (100)
C 7 (7.5) 56 (60.2) 26 (28.0) 4 (4.3) 93 (100)
Total 6 (5.7) 15 (14.3) 58 (55.2) 26 (24.8) 105 (100)
Dopamine agonists
A 34 (38.6) 50 (56.8) 4 (4.5) N/A 88 (100) 0.978 Chi-squared
B 30 (34.5) 53 (60.9) 4 (4.6) N/A 87 (100)
C 36 (38.7) 53 (57.0) 4 (4.3) N/A 93 (100)
Total 100 (37.3) 156 (58.2) 12 (4.5) N/A 268 (100)
MAO-B inhibitors
A 63 (71.6) 25 (28.4) NA N/A 88 (100) 0.387 Chi-squared
B 70 (80.5) 17 (19.5) NA N/A 87 (100)
C 71 (76.3) 22 (23.7) NA N/A 93 (100)
Total 204 (76.1) 64 (23.9) NA N/A 268 (100)
COMT inhibitors
A 79 (89.8) 9 (10.2) N/A N/A 0 (0.0) 0.263 Chi-squared
B 83 (95.4) 3 (3.4) N/A N/A 1 (1.1)
C 87 (93.5) 6 (6.5) N/A N/A 0 (0.0)
Total 249 (92.9) 18 (6.7) N/A N/A 1 (0.4)
Glutamate antagonist
A 83 (94.3) 5 (5.7) N/A N/A 88 (100) 0.021 Chi-squared
B 74 (85.1) 13 (14.9) N/A N/A 87 (100)
C 89 (95.7) 4 (4.3) N/A N/A 93 (100)
Total 246 (91.8) 22 (8.2) N/A N/A 268 (100)
Anticholinergics
A 87 (98.9) 1 (1.1) N/A N/A 88 (100) 0.585 Chi-squared
B 84 (96.6) 3 (3.4) N/A N/A 87 (100)
C 91 (97.8) 2 (2.2) N/A N/A 93 (100)
Total 262 (97.8) 6 (2.2) N/A N/A 268 (100)
continued
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TABLE 43 Analysis of prescribed medications (N= 269 at baseline) (continued )
Group
Item
Total
n (%) p-value Test
0
n (%)
1
n (%)
2
n (%)
3
n (%)
Medications to manage non-motor symptoms and side effects
Antidepressants
A 81 (92.0) 7 (8.0) N/A N/A 88 (100) 0.608 Chi-squared
B 79 (90.8) 8 (9.2) N/A N/A 87 (100)
C 88 (94.6) 5 (5.4) N/A N/A 93 (100)
Total 248 (92.5) 20 (7.5) N/A N/A 268 (100)
Dementia medications
A 83 (94.3) 5 (5.7) N/A N/A 88 (100) 0.744 Chi-squared
B 81 (93.1) 6 (6.9) N/A N/A 87 (100)
C 85 (91.4) 8 (8.6) N/A N/A 93 (100)
Total 249 (92.9) 19 (7.1) N/A N/A 268 (100)
Antipsychotics
A 85 (96.6) 3 (3.4) N/A N/A 88 (100) 0.163 Chi-squared
B 87 (100) 0 (0.0) N/A N/A 87 (100)
C 92 (98.9) 1 (1.1) N/A N/A 93 (100)
Total 264 (98.5) 4 (1.5) N/A N/A 268 (100)
Anxiolytics/muscle relaxants
A 87 (98.9) 1 (1.1) N/A N/A 88 (100) 0.153 Chi-squared
B 84 (96.6) 3 (3.4) N/A N/A 87 (100)
C 93 (100) 0 (0.0) N/A N/A 93 (100)
Total 264 (98.5) 4 (1.5) N/A N/A 268 (100)
Antiemetics
A 87 (98.9) 1 (1.1) N/A N/A 88 (100) 0.999 Chi-squared
B 86 (98.9) 1 (1.1) N/A N/A 87 (100)
C 92 (98.9) 1 (1.1) N/A N/A 93 (100)
Total 265 (98.9) 3 (1.1) N/A N/A 268 (100)
Osmotic laxatives
A 87 (98.9) 1 (1.1) N/A N/A 88 (100) 0.358 Chi-squared
B 87 (100) 0 (0.0) N/A N/A 87 (100)
C 93 (100) 0 (0.0) N/A N/A 93 (100)
Total 267 (99.6) 1 (0.4) N/A N/A 268 (100)
Antisecretory medications
A 88 (100) 0 (0.0) N/A N/A 88 (100) 0.389 Chi-squared
B 87 (100) 0 (0.0) N/A N/A 87 (100)
C 92 (98.9) 1 (1.1) N/A N/A 93 (100)
Total 267 (99.6) 1 (0.4) N/A N/A 268 (100)
N/A, not applicable.
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TABLE 44 Total number of medications for Parkinson’s, non-motor symptoms and side effects
Group
Item
Total
N (%) p-value Test
0
n (%)
1
n (%)
2
n (%)
3
n (%)
4
n (%)
5
n (%)
6
n (%)
A 3 (3.4) 19 (21.6) 37 (42.0) 22 (25.0) 6 (6.8) 0 (0.0) 1 (1.1) 88 (100) 0.871 Chi-squared
B 1 (1.1) 18 (20.7) 42 (48.3) 16 (18.4) 8 (9.2) 1 (1.1) 1 (1.1) 87 (100)
C 1 (1.1) 21 (22.6) 45 (48.4) 21 (22.6) 4 (4.3) 1 (1.1) 0 (0.0) 93 (100)
Total 5 (1.9) 58 (21.6) 124 (46.3) 59 (22.0) 18 (6.7) 2 (0.7) 2 (0.7) 268 (100)
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Appendix 23 Per-protocol and intention-to-treat
analysis of outcomes
Tables show the baseline means (SD) and changes in means between assessment points for the PPA(top table) and ITT (bottom table) analyses. Data from the PPA are graphically represented. For instruments
where the outcome measures disability (such that an improvement is a reduction), the scales have been
reversed to assist with visual interpretation, i.e. in all cases where the trend lines are upwards, this represents
an improvement in the average condition of participants in the group. However, Parkinson’s is a degenerative
condition, and a reduction in the rate of deterioration (one group compared with another) may also be a
positive outcome.
Sample sizes are shown in Table 45.
TABLE 45 Sample sizes
Analysis N Group A, n Group B, n Group C, n
ITT
People with Parkinson’s 269 88 88 90
Live-in carers 155 52 50 53
PPA
People with Parkinson’s 227 75 69 83
Live-in carers 125 45 37 43
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Appendix 24 Comments from people with
Parkinson’s and live-in carers at 6 weeks regarding
the multidisciplinary team intervention
People with Parkinson’s
People with Parkinson’s: text responses to acceptability questionnaire at assessment 2 (6 weeks),
immediately post MDT treatment, groups A and B only, cohorts 4–10.
Question 1: how helpful did you find the treatment programme overall? Please explain.
Each of the interviewers brought up some helpful hints on dealing with the problems I face now and with
some that are still in the future. Good, practical advice was given.
Extremely lovely people and explained everything in detail.
The advice I was given would show results much later e.g. arranging my bedside, exercises,
writing practise.
More detail than previously received.
Some parts were more relevant than others.
I have found the treatment programme very helpful in answering my queries and in the suggestions given
to help me in dealing with Parkinson’s disease.
I was made very aware of a number of preventative strategies for all features of my condition: that is,
what to look out for and how to prolong usage of voice and gestural flexibility. I found the insights and
tips very helpful.
It was helpful to find out what were the Parkinson symptom’s and what were caused by the drugs.
Very beneficial modification suggested re-medication by specialist nurse. Constipation successfully
managed by suggested medication. Slippery bed sheet.
The programme was very informative and I have gained further knowledge about Parkinson’s disease and
how to cope better with various problem areas.
Meeting with various experts it was good to be able to ask questions as they arose. I found the visits
interesting and things were noticed that were not ‘visible’ to me before this trial.
I was made aware of the various therapies and services available to Parkinson’s sufferers in a useful 6 x 2hr
session of presentations organised by the local PDS [Parkinson’s disease specialist] nurse. However, it was
invaluable to have dedicated individual sessions with each of the therapists and nurse specialists. The 2
sessions with the physiotherapist were particularly helpful and I regret not having had them soon after my
diagnosis in Nov 06.
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Each specialist gave another view of what was being done to improve day to day living – thinking of
alternatives or reinforcing other ideas. Referred to speech therapist for swallowing problems and help with
balance, walking and exercise.
It was great to learn ways of overcoming some of my difficulties which were easy to follow and with
persistence would actually help to give results.
I have not been able to talk to people about PD [Parkinson’s disease] beforehand.
I learnt quite a lot about how to take my tablets etc., also useful exercises.
Overall I found that the experience increased my natural pessimism since I am now aware of more things
that might go wrong e.g. swallowing. However, I was encouraged by the professional team to see that
being positive is part of the rehabilitation.
Being shown how to do things, i.e. using the bath. Being told about things on the market, i.e.
carrying trays.
It helped me to focus on the issues that concern me most and offered me solutions to some of
the problems.
I was able to discuss with them various points, also demonstrate where required.
Those that visited me were interested and they also knew their subject.
As I am in the early stages of Parkinson’s I am still very independent but what I found helpful was being
shown what was available to help in the future as my Parkinson’s takes its course.
The treatment was individually tailored to my needs. Thoughtful questioning elicited several difficulties
which I experience and can be helped to manage. Poor posture and its attendant problems of clavicular
breathing, poor voice production and incorrect body alignment were all explained to me. I found the
treatment programme incredibly helpful.
Very informative and made me feel more at ease.
After having Parkinson’s for so long (4 years) I was grateful for any input which will help me manage
myself. I would feel I had failed if I did not try my very best to cope. All suggestions were helpful and I
have incorporated everything I could in my everyday life.
Many useful of information, discussed and noted.
Advice on treatment and other general aspects of the disease, given on a one-to-one basis was
comprehensive. In addition, a dialogue was established quickly, allowing for an efficient use of time
available. The competence and understanding of the team members was outstanding.
I now understand a great deal more about Parkinson’s.
We had aspects of Parkinson’s disease explained and how it affects the functions of the body. Also we
were shown how it is possible to deal with some of the effects.
Any queries I had were answered for me by a very professional team of people.
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It gave me a good insight into Parkinson’s, I know a lot more now about the condition etc.
Gave a better understanding of Parkinson’s.
I was most impressed with the quality of the experts that came to see me.
The care and understanding of my illness was exemplary in all cases. I really felt that at last, something is
being done to help myself and others suffering from the awful aspects of Parkinson’s. The information
sheets that I received were all helpful.
I found the programme particularly helpful as it was carried out in the home in a relaxed manner,
on a one to one basis. Experience of hospital visits to consultants (10 mins if you are lucky) and PDNS
[Parkinson’s disease nurse specialist] (20 mins) do not compare with the high quality of most of the
assessments carried out on this programme. The professionals appeared to listen and were enthusiastic.
However, it did seem rather intensive as it was effectively delivered over a 4 week period.
General explanations to problems.
The programme provided general information over a broad range of possible problems; provided advice
tailored to my own problems; gave the opportunity to ask questions.
Parkinson’s problems explained. Conditions that might arise in the future. Drug treatment mobility
problems. Effects on myself. Modifications to home e.g. additional bannister rail.
Would have been much happier if this treatment and information had been given in the beginning when I
was diagnosed.
I have learnt a lot about Parkinson’s and what to expect in the future.
The fact that out of the blue I was being helped was in itself a great boost to my morale. I attend [local
hospital] for physio and exercises but I found it difficult to be disciplined to carry through the exercise at
home on a regular basis. Now I find that so many of the exercises can be done as I go about my
daily chores.
Some of the researchers had more knowledge of PD [Parkinson’s disease] than others.
The programme helped to reassure me that I could cope with my Parkinson’s symptoms and thus
improved my self-confidence. It also provided a lot of useful information and exercises to help maintain my
physical abilities.
Although I had a lot of knowledge about Parkinson’s I found that the treatment filled many gaps that I did
not appreciate existed.
I learnt more about Parkinson’s.
Treatment in the last 6 weeks has been very helpful where the SPIRiTT team has been great.
A very professional approach which has given me confidence in dealing with Parkinson’s.
All members of the teams were prepared to listen and to explain queries and provide solutions to queries I
might have enquired.
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The team helped me to appreciate my problems with Parkinson’s and all the team were very supportive
and patient in explaining ways to help keep me mobile. The team have helped my wife and I to come to
‘terms’ with the problems posed by Parkinson’s.
My writing is now so poor that I was quite unable to record all of the advice given to me by the various
therapists, which I deeply regret, because it was given by each in a most friendly and professional manner.
My memory is now not what it was and that was another disappointment for me that after each visit I just
could not remember the amount of advice given. But to be given the basis of a one-to-one consultation
was a special treat. They make a wonderful team. They were ALL extremely helpful.
Staff well trained and helpful. Paperwork very good. Well organized. Beneficial having the full team
coming to the house to give advice and to talk things through. Good physio exercises.
I have been very lucky with my treatment mainly because I have a very good GP and [name] who works at
[a local hospital]. The information passed on by your team mirrored everything I have learned over the past
couple of years, which shows the right information is being passed on!
I am probably very lucky that the Parkinson’s problem is low level and has not developed too quickly.
The physiotherapist advice is probably the most important (person too!). Her exercise programme
reaches the specific body areas that are relevant to my level of Parkinson’s.
Very nice and knowledgeable people.
The survey will be very helpful in establish how the services available for the PD [Parkinson’s disease]
sufferer can be best used and what is best value for money. It will show I am sure, that the infinite variety
of symptoms, are best treated one-on-one (or at least in small groups). I retain my starting unease that the
answer to the question which your research project points can be made in one word, which is ‘yes’ – thus
making money available for a much more important subject which is ‘cause’.
When I first agreed to participate in the programme I was fairly fit apart from the Parkinson’s, then my
osteoporosis caused a fracture of the spine. I explained this when I was contacted for the second time.
Therefore during the programme I couldn’t always judge any improvement in my condition.
Helpful hints and tips for practical management of daily task. Helpful physio exercises encouraged.
Detailed and relevant questionnaires and a team of well-informed specialists enabled one to locate one’s
“position” on the “Parkinson’s scale” and appreciate the importance of the therapy.
Helped with motivation but this faded as the visits decreased.
Although the services that came were indeed very helpful, the reason for the moderately tick was that in
my opinion more could be done by having help with the emotional side of the illness. Also massage and
relaxation – the massage to ease out tight muscles and retraction of sinews. The relaxation to help combat
feeling tense.
I was made aware of aspects of Parkinson’s disease e.g. symptoms, helpful problem solving. The
opportunity to talk to professionals was particularly valuable as this is not always satisfactory with GP
consultant as their time is short.
Filled a lot of gaps in my knowledge in the understanding of the disease and to have a dedicated hour
with a top professional is almost unheard of in the public sector!
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The entire programme gave me a better insight into the many varied problems that are manifested
by Parkinson’s.
The best part of the programme was the lady who helped with the various simple exercises. Although
there are no results as yet I feel as if there will be – given time.
1. I learnt a lot about the condition and all questions were answered honestly. 2. I was reassured about
the long term prospects, and types of medication. 3. I learnt the importance of exercises to keep supple.
4. I was given lots of hints and tips to help this.
It was helpful to have the help and views of the various experts each approaching the same problem
(Parkinson’s) but from a different angle.
It’s given both an insight of how we can help with Parkinson, so that it does not take over.
All of the healthcare specialists gave me information, some of which I have acted on now and will
remember for the future.
There was quite a lot of information that I did not know this applies to the rest of the questionnaire.
As yet am able to manage very well so did not need much advice.
By refreshing the knowledge that was given to me when first diagnosed I helped me to cope with the
future – if only with communication skills with relatives/friends!
Everybody was very positive and I was sort of depressed at the time, and they were all so nice and kind
and positive and that lifted me.
Overall I think it was a good programme with lots of advice documentation exercises etc. also time to
discuss Parkinson’s disease, all in the comfort of your own home. My thanks to all for their help
and advice.
Six responses were removed as research related/not answering the question/illegible.
25 gave no response to the question.
Question 5: please explain, in your view, what were the most successful aspects of the programme.
All of it was useful and relevant.
Having more knowledge about Parkinson’s and dealing with the medication.
Motivation to do certain tasks, morale boosting, consult my GP about medication (high blood pressure).
The nurse.
Suggestions for exercises and implements to help in day to day situations. Provision of literature to help
deal with problems as they arise.
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A chance to advice that is invaluable before it all gets worse. A chance to ask questions and get guidance
from specialists in the field.
Discussion on on-going exercises.
Physiotherapy exercises.
Management advice most useful and agreed by consultant Neurologists support to carer.
I can’t pick out anything as the whole programme was successful for me.
My symptoms are solely in my right arm and I learnt that when walking I didn’t move the arm but did
move the unaffected area. In need to physically move the right arm to ‘swing’ naturally.
First and foremost, the coordinated programme of sessions by the collective support team. I have been
lucky with my own experiences but I know that for most of my local fellow sufferers, their exposure to and
awareness of the support therapists and services has been very hit and miss.
Home visit which was relaxed and easier to discuss problem on ideas with, not as much time pressure.
Learning how to smile again (which I nearly missed, as I didn’t ask the sp. [SLT] therapist because I didn’t
know she dealt with that) I was lucky that the nurse or physio (sorry I can’t remember which) picked up on
it and got me the facial exercise sheets. Having facial expressions has brought great relief and elation to
my wife and daughters.
Finding out more on how to cope with PD [Parkinson’s disease] Just being able to talk.
Parkinson’s Nurse’s for information on medication etc., also exercising and finding alternative ways to do
movements that are not quite so easy now.
Provision of practical advice e.g. improve your handwriting by writing with a big, fat pen.
It made me feel I mattered to the NHS. It’s very easy to feel insignificant especially with a confidence
sapping illness like Parkinson’s. I now feel there are people I can turn to for help.
To be able demonstrate and discuss various points with the people that came to see me.
The fact that these are people who care enough to help in the case of Parkinson’s, especially I’m in the
late stages.
Exercises and personal attention.
Being shown what is available in the future.
I very much appreciated that the treatment was ‘home’ based. I was also delighted to be questioned as an
individual and given a programme to suit my individual needs. It is such a help to be given assistance in
order to prevent problems with such things as poor posture before they become a real issue.
1. The physiotherapist exercises to improve my balance. 2. The occupational therapists suggestions to
improving my writing.
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Provided a better awareness of the progress of the disease. Very useful in pin-pointing weaknesses in my
understanding of the topics that I can work on with the help of my wife. It is probable that I attempt to
play down problems that I foresee in the future. When the progress is explained by the team members I
see that I do accept the prognosis less pessimistically.
I knew more about Parkinson’s after this programme than I have known in the last 8 years.
All the elements were good but the voice improvement and way ‘freezing’ when walking could be
managed were the best.
Nothing could be improved from my perspective.
It made me realise that there are people to listen to me if needed.
Difficult to say. Speech and physio helpful.
I made me understand and feel a bit better.
I was impressed with how thorough they all were. The initial folder given by the occupational therapist
was full of very useful information. One person gave me the information to get a new timer pill box.
The most successful aspect was the change of medication to mirtazapine which so lifted my mood of
despair and anxiety. Two different neurologists had failed to help, but the PDNS [Parkinson’s disease nurse
specialist] who wrote to my GP concerning this did so much more.
Nurse/physio input and feedback to bring info up to date. The analysis of current state of deterioration
was helpful.
Home visits, time allowed, individual input, explanations given to support advice.
The team were all specialists in their field so I was confident in their opinions. I didn’t have to travel to
the interviews.
Coming to terms with Parkinson’s. All is not lost. Physiotherapy.
The exercises.
Physio made me realise the importance of keeping it up.
Speech and breathing exercises.
The physiotherapy – I would have liked to have further visits from [physiotherapist]. I feel that would have
been more beneficial.
Mainly in giving me a broader perspective and understanding of Parkinson’s and the action I can take to
reduce the symptoms.
Mobility and balance although the programme was hindered because of my back problem.
Physiotherapy – advice on bing trolley to balance better – advice on turning over the bed useful.
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Learning how to deal with Parkinson’s.
The physiotherapist giving me exercises to maintain my posture and physical fitness.
Physio and speech.
Difficult to single out a specific area of work as the multidisciplinary approach deliver and used exercises.
The most successful aspects for me were the physio visits. The PDNS because she knew exactly the
experiences of people with Parkinson’s. The most successful aspects for me was being at ease in my own
home environment.
Reassurance that my effort in getting on with life regardless of any problems is the right attitude.
It has helped my wife to understand my problems and the teams effort to keep me mobile including
encouragement to persist with the exercises.
(a) The one to one basis of each consultation was very impressive and superbly conducted by each
therapist (b) the easy manner of each – professional but friendly and unpretentious, (c) the enquiring mind
applied by each to my particular requirements and needs which they all readily took on board, and
(d) their anxiety to do what they could to make life easier for me.
Different therapist visiting. Different views.
The team’s visits.
There are plenty of things for me to do to help myself and the team gave me the encouragement
I needed.
Hard to say with preventive therapy.
All of it, do not change a thing. For people who are not coping too well it would be more relative for
them and very helpful.
Exercise regime. Speech and language exercise.
There does not seen to be an even spread of problems from one Parkinson’s affect person to another.
My problems are minor when I view others with Parkinson’s. It is all important but for me some of the
practises may assume greater priority as the problem increases.
All aspects were enjoyable.
The practical exercises: e.g. how not to choke on ones food, how to keep constipation at bay, how to
avoid the blues – in that how best to meet the inevitable challenges of this disease in old age.
Finding out aspects of the disease which helps you to understand the reasons for various aches and pains
and posture.
Extra information on the disease.
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Physio – exercises. Occ. Health – encouragement to purchase and use rollator and helpful hints for
practical management of daily tasks.
The team generate confidence that aspects of the disease can be improved or circumvented provided the
patient makes a continuing effort to exercise correctly.
Much of the information and advice given was already known as I have ha PD [Parkinson’s disease] for
many years, but revision of these appeared to help.
1. Being able to talk at length about how Parkinson’s affects me, get it off my chest as it were. 2. Made
me feel that I wasn’t going to “be a victim” that I was the one responsible for myself – not to rely on
others for help. Personally do what I can for myself – seek out what I need. In fact I had a big break
through because of SPIRiTT in enabling me to find on old resource of mine for help (self-help books).
Which got me out of my rut, and I am actually doing a small art exhibition at a local craft fair.
One to one for an hour. The OT procedures and practical guides.
The exercises are probably the most valuable aspect.
The fact that it is multidisciplinary.
Physiotherapy. [Parkinson’s nurse] two interviews.
All those who visited me more helpful, but I have no one at home helping me.
One and one work and team.
I have learnt that different people have different symptoms and have been able to tell family and
friends – all of whom help us and are supportive in many different ways.
Most of all I appreciated the explanations and suggestions – little beacons of hope lighting areas
of despair.
His speech is greatly affected the speech therapist has helped a lot.
The fact that I don’t drive and can’t get out anymore, so the best thing was that the therapists came
to me.
To enable them to understand about Parkinson’s more.
Interesting to chat in a relaxed atmosphere.
That the professionals come to the patient’s home and coordinated their input – it is very difficult for my
GP to spare any time to do this.
I had lost confidence and got into a depressive state and seeing anybody in a short period of time lifted
me and I picked up on their positivity. It was good that I did not have to wait long to see the next person.
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The speech and physio therapy sessions.
1. I think I have become more stable. 2. Voice projection techniques were very helpful but I am finding it
difficult to remember at times.
The detailed discussion with the PNS including work of the Parkinson’s Disease Society also the speech
therapist and physiotherapist exercise programmes.
Three responses were removed as research related/not answering the question/illegible.
19 gave no response to the question.
Question 6: please explain, in your view, what were the least successful aspects of the programme.
It seemed unnecessary to have the follow-up sessions with [care assistant].
I cannot identify a ‘least successful aspect’ other than that it should then be supported by an organised
programme of coordinated follow-up sessions at least annually.
Seem to be answering the same questions several times. Basic background – list of medicines, length of
suffering Parkinson’s etc. could perhaps be compiled to supply each professional so that this was
not necessary.
The Parkinson’s nurse, as I already have one!
Learning that it finishes so soon!
Seeing too many different people over a short period of time. It was hard to digest and practise so much
good advice. This is partly because we had so many other things happening at the same time and not
necessarily a fault of the programme.
I’m not good at the exercises. I find them very tiring. I’ve tried but cannot do them every day as some days
I cannot walk at all.
The Language Therapist has the least relevant to me.
The least successful aspect of the programme were their brief duration. I feel awe that many people would
really benefit from some input by professional care assistants on an intermittent but regular basis after
professionals have decided on a suitable programme for them.
The trial is carried out without involvement of my GP.
Hard to keep up the exercises after the programme has come to an end.
All aspects were successful but I learned less from the language and speech therapy as it is probably the
least troublesome problem.
Follow up beyond the 6 week point.
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Not really a rehabilitation programme as needed on going contact to assess effectiveness of advice given
and adapt accordingly. Plus needed contact telephone numbers for advice. Mostly focussed on excellent
assessments. Needs greater emphasis on keeping carer healthy, my husband felt quite neglected and some
questionnaires inappropriate for carer.
I got least from the OT because I don’t have any problems that needed her help.
No problems with speech.
The OT.
I had been well served by the occupational nurse previously therefore I didn’t need another visit so
soon after.
One-off visits seemed insufficient. I would have liked more return visits to assess my progress (if any)
or otherwise.
Thankfully at present I do not need any aids so that the OT input was the least successful.
Now knowing the cause.
Handwriting not successful.
The least successful was the speech therapy.
It was generally very positive with good aspects it would be helpful if the programme continued for at
least 6 months.
This is a difficult one to answer. Upon reflection though, whilst “posture” was covered, I was a bit
disappointed I was not offered practical advice as to how to start correcting my developing Parkinsonian
‘gait’ by suggesting braces or suchlike undergarments. Also, with hindsight the seeming rapidity of
consultations made it difficult to absorb the advice of one before the next turned up – the timetable
seemed to me to be too concentrated (for me), but I have no alternative to suggest, I’m sorry the
treatment programme would have to be extended.
Hard to say with preventive therapy but I was a bit disappointed in that it seem there is not a lot I can do
to remedy my poor typing apart from using voice recognition techniques.
Too much filling in of forms. Better to spend the time on teaching the various exercises. Timetable of visits
too sporadic.
Speech.
Speech therapists not needed.
The fact that the care and understanding does not carry on.
Need some feedback.
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Parkinson’s Nurse – as it seemed as if from the 2 visits that I had their role was mainly to take down facts
and figures for the office side of things. But I understand that the SPIRiTT programme needs the facts
and figures.
[Parkinson’s nurse] was so busy that she changed the appointment – stayed long enough to complete her
paperwork but did not stay to provide information/guidance on how to liaise with Parkinson’s nurse [named].
The fact that it does rely on self to give the necessary help and I was greatly lucky in this!
I would like to have had more tact with [PD nurse named] since she is attached to the [local hospital] as a
resident-member.
I found myself being part of a team which without basis. Take up at start of programme not clear.
I don’t have a speech and language problem at the moment but I wouldn’t hesitate to contact a therapist
if I needed one.
Sessions were too long. I found it difficult and tiring to concentrate towards the end. One hour sessions
would be better.
The OT advice and information was very good but in my present condition mainly not applicable. However
there will most likely be a time when it will be.
Responses that did not identify a least successful aspect
Nine people said ‘none’ or ‘nothing’ was least successful.
I have only positive comments.
I would not criticize any of the advice and help that I was given. It would have been better though to have
been given this advice earlier in my condition.
As previously mentioned I can’t fault the attention and information given
Each aspect was covered satisfactorily.
All were equally successful.
I am unable to make any comments as I gained something from everyone.
Each section was valuable, and all sessions were helpful.
None, I was very interested in all aspects of the program.
In my view there were not any least successful aspects of the programme.
It is hard to say as all aspects helped.
I cannot think of any. It was extremely well thought out.
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Sorry, I can’t think of any drawbacks.
I thought it was all successful.
Found it all very helpful.
None, all aspects were successful.
I regard all aspects as successful.
They were all successful, but as I have said, it depends on ones stage of Parkinson’s which aspect is
most helpful.
None, all sessions were very useful.
I enjoyed them all.
None of it. It will be relative in different ways to different people so it is all theirs.
I can’t really point to any one aspect as being unsuccessful.
No unsuccessful aspects – all were positive.
None. It met all expectations.
Nothing. I was pleased to see people do things and welcomed their input and they all had
something offer.
For me I think speech/breathing exercises were the most helpful. However, also think that the whole
management was very essential.
Nine responses were removed as research related/not answering the question/illegible.
24 gave no response.
Question 7: can you think of ways in which the programme can be improved?
I would find it helpful to have more visits from the Parkinson’s nurse to discuss such subjects as diet and
bladder and bowl problems.
Put more/most profile in Group A.
Would be nice if a nurse could make home visits on a regular basis rather than having to go to the
hospital. It would also be nice to have someone to advise what benefits/help is available.
As I said above, to make the most of these sessions, they need to be supported by a coordinated
programme of reinforcement visits.
Maybe meeting others.
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If visits could be spread over a longer period it would be easier to focus on each suggestion and to make it
part of our routine. Towards the end of the programme it would be useful to have a forum at which any
participants of the programme who visited could share helpful advice and ask questions.
The programme could be extended since it is so valuable to patients.
Extend the programme to cover more deprived areas of the country.
Limited contact details of team members should be provided to the person with Parkinson’s and the Carer,
making it relatively easy to discuss problems that arise for specific conditions. Currently, it is difficult to
identify the problem and the associated specialist.
Would appreciate a close relationship with a PNS. Her ‘hands on’ experience is invaluable.
The review of symptoms and (dis)abilities would provide monitory of progression of disease.
More one to one sessions.
I found it stressful and tiring to have 2 visits in a week, new exercises to do and still continue with daily
necessities. Perhaps the programme could be extended to allow just one visit in a week.
Ways to improve ones well-being. Worry about the future.
More physio would be useful.
Maybe reviewed at certain time tables?
Apart from suggesting an adjustment to the programme to make it less intensive I’m sorry I can’t be more
helpful. At the end of the treatment I was left with the impression that my future is in my hands, and will
depend on the amount of time I am prepared to devote to the copious exercise programme which was left
with me.
Perhaps a few tips advice for the carer e.g. to intervene when the patient is having difficulty in doing up
buttons, or not.
Make sure the people who are not coping get the support they need. Maybe introducing the people who
are not coping to people who are relative to their age. I feel the boost some people could get and stop
the ‘wood through the trees’ symptoms could refocus people again and move on!
Timetabling of visits could be improved – more evenly spaced if possible.
From initial visit determine the therapist needed.
Employing more staff to give more help and advice.
The literature hand out is very good. Improved by including a schematic diagram of how levodopa is
converted to dopamine in the brain and the role of carbidopa and COMT. Could stimulate thoughts about
the medication and its timing.
More one to one sessions with therapists.
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1. Monthly assessment by a Parkinson’s Nurse in collaboration with person who has Parkinson as to
what the course for following month would be i.e.: exercise – speech etc. 2. Massage for easing out
tightened muscles and sinews. 3. Complimentary therapies such as homeopathy – relaxation and holistic
therapies – Bowens reflexology etc.
Who cares about the carers? There needs to be more emphasis on the support given to the carers and
their interface with the patient.
More “leaders” coming in to see if you were doing the necessary things, like exercise.
To have it more individualised – did not feel occupational therapy/SALT [speech and language therapy]
very relevant as not needed.
Do not think it necessary to have 2 visits from a physio and a PNS.
Not really. It is about right – the time in between was good. the only thing would be useful would be a
card with health care professionals photographs to remember who each person was because of the short
space of time in between visits.
Increase the physio and speech therapy sessions.
More time on physio thereby.
Needs to be done early on soon after diagnosis, as well as later, and focus on prevention. Advice line
contact would be useful. Needs to reflect length of programme that professionals would need to assess,
plan, implement, evaluate and amend.
Responses that did not identify an area for improvement
23 people said ‘none’ or ‘no’ area for improvement.
Three people said ‘not at the moment’.
Two people said ‘not really’.
It was well thought out just as it was.
All my questions were answered.
Not really all aspects seem to be covered.
No I cannot see how the programme can be improved but then I am not an expert!
Could not be improved as not much to work on.
You are doing a wonderful job and I hope the current programme will prove that further and deeper
investigations are needed. Thank you all.
Not really. All aspects were covered.
I was satisfied with the programme; it went far beyond my expectations.
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15 responses were removed as research related/not answering the question/illegible.
21 gave no response.
Question 14: other comments
I cannot fault the programme at all. Also found no one was in a hurry and that alone gives a
person confidence.
Having had a telephone number makes me feel better. I enjoy the interaction and compassion.
I have been appreciative of the help given through the study and hope that my contribution has been of
some help.
A very positive experience – pleased to have taken part in it!
I was in hospital for 4 weeks with pulmonary fibrosis right in the middle of my 6 weeks. As a result I was
not able to follow up on the planned exercises and activities.
Perhaps the emergence of spring weather has helped! Overall the timing has been brilliant.
If this was an annual event it would be good to review progress from one year to the next.
I welcome the study and am delighted that in such difficult times it has been possible to put such a
well-mannered, talented team together with such a strong support base. I look forward to the results of
the study and hope that it provides the basis for a co-ordinated programme of support for ALL
Parkinson’s sufferers.
The entire team were friendly, helpful and non-intimidating (with their advice and suggestions). They put
me at my ease, yet were truly professional.
Thank you to everyone for being so nice to me.
The specialists who called on me were very caring and friendly, which made the questions and answers
very easy to answer, in all a very worthwhile program.
I have enjoyed meeting the helpers and have found it a great help.
It’s been a very positive experience.
In my opinion all aspects of this programme was extremely helpful, including the pamphlets.
My wife has filled in this form. I have written answers on a piece of paper for her to copy but my writing
would not be understood. Many thanks. I think we have both gained from the study and will miss
the visitors!
A very good idea and very well organised.
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Thank you for allowing me to participate in this. I am very grateful.
The value of the treatment was limited since Parkinson’s affects me to a very limited extent. However, I
hope that my inclusion were worthwhile as an outlier.
It’s unusual to find a study that will certainty have an effect on the well-being of the interviewee. This is
one such study and could form a bench mark to others.
I found the whole study very interesting. I learnt a lot and I found everyone in the team very friendly and
helpful. It was so personal and not just a number.
We were glad to have been involved in this study, and hope it will continue to offer help.
Got what I wanted out of it. Seeing the Parkinson’s nurse specialist, physiotherapist etc. The team is doing
a brilliant job.
I was very apprehensive about the programme at first and then found it very useful and informative.
The difficulty with two types of analysis is the wide range of ability depending on whether one is
“switched off” or “switched on”.
I would like to see it further developed with on-going support which could be delivered at centres for the
mobile. Definitely keep the initial home assessments. Needs to have greater support and contact with
consultant neurologists as the consultant I see was disappointingly dismissive of the suggestion made by
the PDSN regarding medication. Also dietary input would be very relevant.
I wish that the programme had been available as an assessment when I was diagnosed so that I could
have begun remedial exercises straight away. Doing the voice exercises occasionally would have given me
warning that my breathing was deteriorating and that my voice was losing its flexibility.
Appears to be a carefully thought out programme. An initial assessment might be helpful to tailor make a
list of treatment for an individual. It could for example be split into four parts representing different stages
of the disease.
Thank you to all the professionals in this time.
I would like the assessments to continue on a regular basis. It is reassuring to have someone I know that I
could contact if I wanted help.
I thought it was very good and helpful. In question 9 and 10 I indicated that I would not want to have the
rehabilitation programme repeated with the frequency suggested but would be interested in a repeat
at 2 or 3 year intervals. Overall very worthwhile.
I would just like to say that overall performance of the entire programme was very professional and kindly
carried out.
Very positive with all the team members welcome in our home.
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Only to express my thanks to all the team for the great support given and also the enthusiasm they
generated for the SPIRiTT project.
I was given no prior warning to the detailed nature of this questionnaire and I would like to think it could
have been sent to me at the beginning of the treatment so that greater care with each therapist could
have been taken in some way to record my responses before memory-rot set in. The latter and wretched
writing skills have made completion of the questionnaire all the more time consuming I feel my responses
to be inadequate, but I have done my best. I’m so sorry – you do deserve better.
Very good would recommend to other Parkinson people.
We find it very interesting. Would like to know any outcomes.
Before any of this treatment begins, it is so important to get their minds focused first. If they cannot be
bother to get out of bed none of it will work. They must except and move on and that help should
come first.
Not sure of distinction between physiotherapy and occupational therapy.
All of you are doing a fantastic and very important task – I hope the results will eventually be able to share
your views.
All ‘visitors’ were very helpful put me at ones ease and were sympathetic. They appeared to be reasonably
clear as to what they were trying to get out of the study, but I hope that this study in itself will sharpen
the individual effort made by the NHS as a whole. e.g. I don’t need (much) help on exercises; I do need
help on more aspects of mind over matter. The recognition of the individuality of symptoms is most
important if more research into the causes of this foul disease [writing ineligible].
I hope this isn’t the end of interest in letting people know about Parkinson’s.
(a) Nurse helped with drugs – information. (b) OT advised me on items to purchase which will help me.
(c) Physio took great time finding exercises that would help me.
Very helpful and informative.
The ‘Just Met My Expectations’ was/is not a really fair way of marking what I thought as an excellent
programme put together by the SPIRiTT Team. It is because in my opinion the National Health Service is
not able to treat people in a holistic way as well as what its good at already.
Many thanks to be included in this particular scheme. It produced more confidence in myself and my wife.
Since being diagnosed in 2000 I have always felt I was affected to a relatively low level of Parkinson’s.
This study has reinforced that view and has given me some appropriate actions to take.
Overall useful to have taken part.
Everyone I’ve met has been so friendly, helpful and knowledgeable – thank you all so much.
I was very pleased that i was given the chance to take part in the survey.
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Was impressed by the extreme pleasantness and approachability of the team, who obviously enjoyed
their work.
Excellent programme put together and idea. Very much appreciated and it helped me very much. Overall,
very very good and should be available to people as soon as someone is diagnosed. I was left out in the
cold and had no idea what to expect and what would happen. It was only a few years later, that I was
sort of brought into it and told about things, so I think initially someone should visit and say “This is
Parkinson’s and what it is about” and then followed up with the 6 week multidisciplinary
team programme.
When my health centre sent me the letter rejoining this programme I didn’t know what to expect.
However I have been very grateful for everyone’s care and attention.
12 people said ‘no’ or ‘no other comment’.
12 responses were removed as research related/not answering the question/illegible.
30 gave no response.
Live-in carers
Live-in carer’s text responses to acceptability questionnaire at assessment 2 (6 weeks), immediately post
MDT treatment, groups A and B only, cohorts 4–10.
Question 1: how helpful did you find the treatment programme overall? Please explain.
Information was good and explanations clear and thorough, and all was done with kindness and great
respect to my husband.
Physio exercises for balance and strength very useful. Also info from Parkinson’s specialists. Others not so
directly relevant.
My husband was given exercises to help prolong flexibility etc. and we learned a lot about non-motor
symptoms and were given suggestions to help deal with problems. It was very informative and we learned
a lot.
The breadth of the programme and the multi discipline input gave me a full picture of Parkinson’s disease
in all its aspects. Especially, it made both my husband and me think more clearly about the best way to
look after him and his individual needs.
Cheerful and helpful.
A better understanding of Parkinson’s that I already had gained over the past 10/12 years with [name].
The physio was the most helpful in emphasizing the need to keep mobility by various forms of
exercise – good for motivation.
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The visits and interest of taking part and being involved made [NAME] more alert and made more effort in
exercising and getting around on his own.
We gained a comprehensive range of extra knowledge and lots of strategies and physical exercises to
counteract problems encountered in daily life, and exercise routines to help with mobility, balance,
flexibility and forward thinking (i.e. anticipation and management of everyday difficult situations). Above
all, it was highly motivational and changed my husband’s attitude to one of willingness to co-operate
because he understood reasons behind strategies and exercises.
Lots of information – advice – practical help meeting people from different disciplines.
Made both of us more focused.
As a result of consolidation of advice and strategies, he has gained confidence, some independence and a
more positive attitude.
Physiotherapy.
He is in the early stages of Parkinson’s so is still very independent. It was very useful to know that these
treatments are available and some were also helpful now in showing how he could maintain
his independence.
This is the first time (in 9 years) that we have both been involved in such a programme, as carer and as
PD [Parkinson’s disease] sufferer. The discussions we have had, both during the visits of the healthcare
professionals – and afterwards – have been extremely beneficial and have created an improved
understanding for me in the reasons for treatments, for exercises, for facilities (to improve manoeuvrability)
which I have subsequently been able to discuss and develop with my spouse.
Gave us the opportunity to talk about Parkinson’s disease and the effect on both our lives. The
explanations, all very clear, on how the effects of the illness can be modified or delayed, with drugs,
exercises and keeping fit.
Gave us information and helpful suggestion of dealing with some of the problems.
Very nice people, who explained everything so well and professional.
Programme of exercises covering posture, walking and balance very helpful in preventing fall. Voice and
breathing exercise assist voice/speech.
I know what to expect in the future and what to do to help the condition e.g. Exercises 1. Movement 2.
Speech.
Some helpful exercises and information.
Gave a better understanding.
The change of medication has made my life so much happier.
Really good to have different perspectives and overall update. Definitely positive and motivating for my
husband while in progress.
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Insufficient time – Assessment (only in the main). For a programme to succeed the needs to be feedback
and incrementing advancement accordingly. Too short. Felt like a research project not a programme.
I found the fact the patient (PwP) was seen for so much longer, and in check our home, so I felt a true
understanding of how his life was affected (as people are so different) could be been
[incomplete sentence].
We now understand more aspect of Parkinson’s. We are encouraged that our own exercise routine
included most of the suggested exercises. The programme uncovered some new problems that we are
now tackling with new exercises. We are both very encouraged to continue resisting Parkinson’s and have
been able to adjust our daily routines to include more exercise.
The information given enabling a greater understanding was extremely helpful. The exercises were
also helpful.
[Name] has gained more insight into his condition and it is encouraging to see him more determined to
overcome his condition as best he can.
It helped us understand Parkinson’s a little more.
It helped understanding of the condition.
Everyone who has visited my husband has been really positive with practical encouragement.
Made [name] more aware that exercise can help him and also the importance of taking
medication regularly.
It was helpful as my wife found it pleasant to converse with people who are aware of how a person with
Parkinson’s feels.
Positive encouragement that fits our philosophy for just getting on with life.
I found the support given by the team extremely helpful. It has helped us to cope with the Parkinson’s.
This helped both of us in helping and coping with the disease and its effects. Also felt somebody was
listening to how we felt about it.
I felt that my wife had been given encouragement and the means to help herself in her daily struggle
with PD [Parkinson’s disease] talking to knowledgeable and supportive people about the disease was
extremely valuable in my view.
The specialists’ input/suggestions have been very helpful with respect to coping with tasks/actions which
are proving difficult.
Helpful hints and tips for practical management of daily tasks. Helpful physio exercises set
and encouraged.
Motivated my husband to do more exercise.
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Helpful at point of combat but seemingly very little lasting effect. Pack of booklets/leaflets very useful.
My wife is now calmer about her problem and her day to day coping.
This reinforces most of what I know because I am a nurse. Great to have my husband to have one to one
with a professional therapist.
Has given [name] lots of tips and also increased his positive outlook on his condition.
My understanding of Parkinson’s is greatly improved thanks to all of our visitors.
For me as his carer it has helped a lot with his speech.
The programme inspired my husband to exercise and follow the speech therapy programme.
Impressed by all members of staff who visited. Advice given very helpful but would like assurance that in
the future a programme would be available or contact base that a carer would ask for advice re
progression of Parkinson’s.
Three responses removed as research related/not answering the question/illegible.
Six gave no response to question.
Question 5: please explain, in your view, what were the most successful aspects of the programme.
Personal care and attention – friendliness of therapists and their methods of teaching. Leaflets and reading
material the help.
Having a chance to talk to specialists and learn about the disease in your own home. Having specialists see
patient moving and using things in own home.
The information provided about way Parkinson’s affects the body was helpful and reassuring. It reduced
stress and resulted in an earlier visit to the GP to deal with frequency of urination.
1. Although I’ve read much about PD the clarity of each participant gave me answers to the disease.
2. We could not have asked for more helpful, interested and likeable team – such a pleasure to meet each
one of you. 3. The programme helped to confirm that as things are at the moment, I’m helping
understand in the right way to see him and his need for independence.
By being present with [name] so we both know what has to be done – i.e. exercises etc.
Important with someone who has Parkinson’s to feel he is not forgotten. One often loses friends when
speech is difficult and involvement in interests has disappeared. These visits gave him something to have in
the future to feel he has to ‘improve’ so it doesn’t seem so hopeless but is manageable and that there is
help there.
For me, learning how the brain affects not only physical movements, reflexes and repercussions of lack of
balance and perception of space but also learning how it releases chemicals, hormones etc. differently,
thus affecting mood, memory, senses etc. My husband’s behaviour suddenly began to make sense!
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Knowing what was going on and why, made a big difference to my own emotional acceptance of the
condition, and to my attitude as carer (i.e. informed instead of bewildered). Secondly, learning that there
were lots of things that we could actually do (to make life easier and to commit to an exercise
programme) helped enormously with morale and motivation.
Information gained.
Re-assuring my wife, helping her see how well she is coping.
Being able to discuss Parkinson’s with qualified persons and have some of our questions answered.
The most important aspect of the programme was the high lighting and consolidating of strategies both
new and previously learned but forgotten. The final fortnightly visits of the carer re-enforced these and
were very useful in keeping up the momentum, making exercises part of a daily routine.
Good ideas from all on how to manage Parkinson’s. Exercise regime suited to the person’s individual
needs. The care and concern shown. Someone to talk to and able to express a carer’s concern for not only
the person with Parkinson’s but also for the carer.
Exercises
Allowed him to continue with advice.
Just knowing that this help is available. Also for the reinforcement to the importance of keeping active.
There is no doubt that the success of this programme can be attributed to the individual interests paid to
the person with PD [Parkinson’s disease] by the health-care specialists. These are one-to-one discussion,
with a shared interest and professional concern have been both supportive and stimulating, and have
allowed an up to date programme to be developed on an individual basis. As a carer, I can see how
encouraging this has been as my wife grasps on to the new ideas.
My husband does not yet require active help, with most tasks of daily living he remains independent if
slower than pre-diagnosis. It gave him hope that there were things he could do rather than increasing
drug dosage. Time to talk re illness.
They were all successful but speech and physio had the most impact for us.
My wife was anti this programme at first, she handles things in her own way, as nobody seemed to care.
Have changed her mind we find the programme really really helpful.
Speech, posture, swallowing were excellent.
It was good to know that exercise in all forms can only be helpful. It was good to learn how to deal with
various problems and particularly what to do to slow the progress of Parkinson’s.
It gave my husband a programme to follow.
One to one treatment.
DOI: 10.3310/hsdr02510 HEALTH SERVICES AND DELIVERY RESEARCH 2014 VOL. 2 NO. 51
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Gage et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
357
The approach and kindness of all concerned.
Helping understand what processes were operating and how to make a difference all professionals
working together made of joined up and you felt things progressed overall no matter who the
professional was.
The fact of home visits meant that there was no rush and we had their individual attention in our
own environment.
The professionals had time to explain and to listen to our problems, time is always at premium when
dealing with the medical profession.
The questionnaires and interviews provided the first full assessment of [name] problems. The interviews
were tailored to tackle problems [name] has and provide enough information to access help with future
problems. Meetings in our home meant that [name] was more relaxed than after travelling to another
venue. [Name] is v. hard of hearing. We were impressed with the way the therapists spoke clearly and not
too quickly and consistently faced him so he could lip read.
The information imparted.
The programme gave [name] more insight into his illness and the physio made him realise he needs to
keep up the exercises. I still need to ‘encourage’ him though!
During the sixteen years since my husband’s diagnosis of PD [Parkinson’s disease]. I had never had the
opportunity to discuss his illness with anyone. The G.P. did not seem very interested, or to know a great
deal about the disease. This programme has given me contact with the experts with whom I was able to
discuss PD and ask questions.
The help the physio gave my husband with his balance and walking.
Helping me to understand and therefore act.
My husband is keen to get on with exercises each morning – that needs motivation!
The physiotherapy and the speech/language therapy.
The physio visits seemed to be the most beneficial to my wife for the future.
Promoting of physical exercise.
Helping my husband with his mobility and general encouragement.
Although it still tries my patient’s. As i find him very demanding and not much time for myself.
Already answered previously the nurse and the physio were of particular benefit. We had already had a OT
from our surgery (at my request) visited before the research OT otherwise the OT would have been much
more useful. If we had this help on a regular basis it would have saved me a lot of time and stress, trying
to find out what help I could get for my husband.
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Probably mobility and speech considerations. Problems associated with both on going a great deal on our
everyday life.
My appreciation of what Parkinson’s effects are has been heightened and hence I tend to watch more
carefully when problem activities are undertaken by my wife. The ‘one-to-one’ aspects of the programme
are without doubt successful.
Physio – exercises. Occ. Health – encouragement of purchase and use Rollator and helpful hints for
practical management of daily tasks.
Suggested we got in touch with our local occupational therapist and social services which have proved
very helpful. The in depth questionnaires obviously understand some of the problems involved.
I was a pleasure to see and chat with all the visitors who did their best to inform and help but then was
very little we weren’t aware of already about the condition. It was encouraging for the patient and
instigated motivation for a while.
Not worrying about sharing. Not so self-conscious. She enjoys physio exercising.
Having contact with up to date practitioners, lengthy periods of time, who were able to demonstrate very
clearly and succinctly their view and helpful ideas.
Although I was not present at the sessions, [name] has reported back useful tips and info. I also feel it has
helped him with a more positive attitude.
Knowing that there is help out there if [name] problem gets worse, and knowing what to look for with
books and all the information that was left with us.
Showing me how to get my husband with his speech and walking.
Helping my wife to understand and live with her symptoms and helping me to do the same.
The programme has helped with my wife’s stability and voice projection. It has also increased
her confidence.
Three responses removed as research related/not answering the question/illegible.
Three gave no response to question.
Question 6: please explain, in your view, what were the least successful aspects of the programme.
Speech – patient not always compliant to practise.
OT is not relevant yet.
Naturally too short. Not dealing with any psychological problems that could have been labelled talked
through with disabled and carer but perhaps this is not part of the program but is a part of the whole.
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The short period spent with the Parkinson’s person was not able to assess the whole day care. I quite
understand this is not probable.
Speech and language because didn’t take part.
The OT but only because it isn’t needed at the moment. But it was useful to know about for the future.
Obviously the programme appeared to be too brief, and the allocation of time and resources needs to be
discussed, but information here would have more value from the experience of the healthcare specialists
(particularly in a world where we are resource-limited!).
Could be frustrating to listen whilst my husband, was too positive re his abilities and how he felt. We did
resolve this. It is difficult to give a different point of view that doesn’t destroy their confidence.
The only downside was that the visits could not continue.
Really would be better to have some follow-ups to keep on track, so will be interested on feedback from
the group that has this.
This was not in all reality a ‘rehabilitation’ programme.
The frequency of the visits made it a rather stressful experience at times because we already have rather
busy days. [Name] tires easily so his ‘day’ can be quite short. These follow-up questionnaires ask us to
remember who told us what in order to comment on the value of the topic. It is almost impossible
because of the overlap between one discipline and another and because of the speed with which one visit
followed on from another.
Given [name] condition i.e. not having much of a problem with speech, speech therapy was not too
helpful, but others may need this. The patient’s condition at any given time should dictate the
support given.
We had an OT visit early on in [name] diagnosis who helped with a few aids and changes so there was not
much required at this visit.
The Parkinson’s Nurse visited two weeks in succession and asked the same questions. I would have
thought that an interval of several weeks or even months may have been more beneficial. I did not see the
point of the second visit.
I felt my husband’s needs did not require the OT or SLT.
I believe the least successful aspects from the speech therapist.
Thought I would find more about medication.
None, really. All aspects covered proved useful. But OT was perhaps least successful but not sure how
much else could be done.
APPENDIX 24
NIHR Journals Library www.journalslibrary.nihr.ac.uk
360
Rather a lot of information in a short time.
The caring role seemed to be more secondary as a retired RGN I do not know a good deal about the care.
I was however not asked about how I felt or what problems I had or my expectations for myself or
my husband.
Responses that did not identify a least successful aspect
Eight people said ‘nothing’ or ‘none’ was least successful.
All team members had a wide knowledge of Parkinson’s Disease. Their advice on managing the everyday
problems, were very much valued.
Found it all very helpful.
I have no complaints at all.
I cannot think of any. It was very informative and helpful.
To be honest, nothing obvious comes to mind.
None, it was all well planned.
None really.
It was generally positive and with good results.
Programme was successful.
All were successful.
10 responses were removed as research related/not answering the question/illegible.
Seven gave no response to question.
Question 7: can you think of ways in which the programme can be improved?
Additional visits from any particular specialist as required by individual.
A one stop clinic where you would be able to see all members of the team and specialist Parkinson’s
disease consultant with an appointment system, but also an ability to telephone and speak to an
appropriate member of the team if a problem arose.
By being on-going.
Very difficult. Managing the person/disease as it advances is very difficult on the carer. On more than one
occasion ‘breaking point’ was reached. I think ‘caring’ could be looked at, i.e. on the best way to
relaxation, physically and mentally.
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Maybe more visits from an experienced Parkinson’s Nurse. A close association with the patient’s GP would
be an advantage.
More integration with local Parkinson’s services (and inspiring them to work together more!).
More input for carers and how carers can help – No support offered for carers – Focus totally on PD
[Parkinson’s disease] patients.
The programme would have been better for us with more time between visits. The time spent at each visit
was about right. We believe the most benefit to us would have come from this at the time [NAME} was
diagnosed because we would have been more knowledgeable about how far Parkinson’s was already
affecting [NAME] and about the help available.
The patient should be assessed then the treatment schedule set up.
More physiotherapy input.
I would have liked to have had an interview on my own on one occasion. There were things I would like
to have said, out of my husband’s presence – not wanting him to think that he was in any way a burden
to me.
Maybe reviewed at certain timetables.
It would be helpful if the programme could continue for 6 months.
Not really. Everyone’s different carers meeting perhaps.
Recommendation to local groups for speech therapy and physiotherapy.
Increasing speech therapy and physiotherapy input. Easier more frequent access to a Parkinson’s nurse.
Massage could well be therapeutic and helps to relieve stiffness and pain.
More physio.
Some therapeutic input for the carer. I was interested in being present in the meeting but could have
easily not taken part at all. I feel that the carer needs to be more involved in the therapists’ mind.
Including more physio and speech therapy treatments e.g. 4 of each.
The sessions were too long. I really think they should be about a hour. Concentration is difficult
after them.
Programme can only be improved if the services can be continued. Having learned that every Parkinson’s
patients care needs progress at different times it would be helpful if their needs could be monitored at
regular intervals. Elderly carers need assurance when symptoms change and advice.
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Responses that did not identify an area for improvement
Eight people said ‘no’ or ‘not really’ area for improvement.
Only more of the same.
Nothing springs to mind.
Not really – carrying out a survey/team trial couldn’t really be carried out without forms! Possibly the form
filling could be ‘fine tuned’ but I fully understand the need for forms!
No! It was very comprehensive and covered just about everything.
Not yet.
No – everything worked well.
Sorry, nothing obvious comes to minds.
No, brilliant!
No, very good as it is!
Seven responses were removed as research related/not answering the question/illegible.
11 gave no response to question.
Question 14: other comments
To want to commend and thank all the therapists for their approach both of carer and patient. Without
exception they treated us with kindness and respect and imparted their expertise in very understandable
ways. We were very impressed with them all. Thank you.
Thank you for the opportunity of taking part.
It was a very positive experience and I am pleased to have taken part in it. It was very informative
and helpful.
I’d like to re-iterate how much we appreciated the kindness and patience shown to us by each of the
professionals involved in SPIRiTT. We were privileged to be part of the cohort and we very much enjoyed
meeting each of the sessions.
Patient has now enrolled for group speech therapy. This is an achievement.
Nice to know there are others out there working at Parkinson’s problems and its effect on patient and
carer – (usually unpaid spouse). During the early stages of confirmation of ‘Parkinson’s’ we were left to our
own devises somewhat with the expectation of GP trying to settle out the main course of medication
for [name].
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I am not really involved at this stage as a carer but will be interested to read the final report to see if this
has kick-started any exercise programme for those further down the line.
It is very difficult to assess improvement or input over this short time, if I have not found it exceeded my
expectations it is because I don’t know what my expectations should be and each member of the group
were very good. A direction or understanding of the study would have helped. It has been very difficult to
assess the particular import of the study as we have not long ago been helped by the local specialists
above, who helped enormously and left little for these dedicated people to add. If we had not been
involved with local specialists, the difference would have been easier to assess.
It was very intensive, but the information was all put over in a very friendly, motivational and “patient-aware”
manner. All the health care professionals were pleasant, friendly and easy to talk to, non-intimidating, and we
felt each visit was time well spent. I strongly hope the study achieves all its objectives, as it has been so
worthwhile for myself as a carer, and my husband as a patient, to take part in!!!
It was very helpful and I gained further knowledge of Parkinson’s.
Very professional. Ticked all the boxes. Well worth the cost to the NHS.
Would be nice to have a “2 monthly” follow up, the support given was appreciated.
We feel we definitely benefited from the programme. Rather than repeat the whole programme, it would
be very helpful to have regular visits, say twice a year, from the physiotherapist and speech and
language therapist.
Just to say thank you. I don’t feel so isolated now knowing there are people outside our home with
helpful and caring ideas most of which I shall endeavour to take on board.
I think it has been beneficial.
The follow-up – twice a year – would be most helpful.
This is an amazing programme for both PD [Parkinson’s disease] patients and their carers. Not only does it
generate interest in the difficulties encountered and brings tailor-made advice on the manner in which
these may be overcome, but it also demonstrates how latest ideas on treatments may be used to
advantage, thus enhancing a patient’s quality of life for the future. The more widespread adoption of such
a programme is to be thoroughly recommended.
Absolutely brilliant cost effective way of incorporating the well-being of Parkinson’s sufferers and their
families therefore making people feel cherished and important within the vast NHS system.
No – but we were very happy to take part and there were many benefits.
All members of the team were very helpful. In managing Parkinson’s. A cure is the ultimate wish, however,
every assistance is valuable.
The study should be continued with the present understanding of the carers needs.
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In the past we have had quite good input from other Parkinson’s nurses and OTs. What was particularly
effective here is that they worked as part of a team and it all felt co-ordinated. Also, the whole team were
so positive and inspiring and left you feeling that there is always some small thing that can make things
more positive.
Focus was more towards “treatment” or rather “assessment”. It cannot be called rehabilitation. Six weeks
was not long enough to establish a treatment regime. Only 2 visits from each of the physio and PNS and
one from OT.
I thought all the professionals were very punctual, easy to talk to, and listened to us and very helpful – and
also had time.
We would have benefited from this type of assessment soon after [name] diagnosis for 2 reasons: 1) It
would have given a base for measuring future effects and tailored exercises could have begun earlier.
2) The questionnaire promoted discussion between us of topics we had not previously considered together
and this discussion has been illuminating and re-enforced us as a team fighting problems. All exercises
were intended to mitigate what were seen as Parkinson’s problems. Our experience is that [NAME] was
gradually losing fitness prior to diagnosis. The medication allowed him to begin a home exercise
programme which has improved his general fitness and confidence. This type of exercise should probably
be advised for all Parkinson’s sufferers. It is difficult for anyone to keep up exercises alone particularly if
Parkinson’s is causing memory problems. We think the spouse/carer should be helped to exercise with the
P[arkinson’s] sufferer to improve the likelihood of the exercises continuing, to check that the exercises are
being carried out properly and to keep their own fitness. I think the term carer should be discarded in
favour of ‘enabler’ because it emphasises the team aspect of living with PD [Parkinson’s disease] and
because becoming a spouse’s carer is the most important aspect of the relationship rather than wife/
husband as previously.
This type of support should be provided to each patient when first diagnosed by the NHS.
Well organised and beneficial.
[Physiotherapist] seemed the most well informed with regard to PD [Parkinson’s disease]. She was a great
inspiration to us. I am not convinced that the single visits were of any great value. I would like to see
assessments repeated two or three times a year from all the specialists. I look forward to seeing the final
report on this survey.
The above is only on the reports I have back from my husband. Thank you for visiting him it would be very
good to have the team back in the future.
The overall performance of the entire programme was very professional and kindly carried out.
It should be obvious but congratulations should be given to personnel for choosing first rate people.
I wish to express my thanks for the support given by everyone concerned with the project.
All visitors very helpful especially the man answering phone very helpful. Good work.
I do hope that the NHS will fund this on a regular basis for Parkinson’s sufferers and their carers. Please do
let us know the results of the survey.
I found the various leaflets very useful, information in a straightforward manner.
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Very pleased that we participated.
Very helpful and informative.
It is good to involve the carer as the disease affects both our lives.
I felt the title was a little misleading. To me multi-rehabilitational programme suggested a more intensive
course of therapies – not a couple of visits over the six weeks from a speech and a physiotherapist. I don’t
think my husband benefitted much from these, maybe this is because he has had PD [Parkinson’s disease]
for over 12 years and is in the more advanced stages of the illness.
A very useful insight into the latest thinking and technique. Very good for the patient to have the time of
so many disciplines, especially so if they are not so confident in their own PD [Parkinson’s disease] nurse
which my husband is not. All of the practitioners were very professional and pleasant and thank you very
much for being included in this survey.
Many thanks to all involved for your care and support towards [NAME] – he has found it an uplifting
experience in a difficult year.
The study was well worth giving the time spent on it. Your team of ladies were wonderful.
As explained above, most of the visits involved my wife not myself, although she did tell me all about
them. Her symptoms are still relatively mild, and my involvement in day to day routines has not needed to
change much so far. I did not really know about, or have expectations with regard to the visits, and I do
not feel able to comment meaningfully on them, apart from feedback information from my wife. The
overall effect was obviously beneficial and confidence building, and should symptoms worsen, the need
for and effect of advice/help would increase proportionally for both of us.
The treatment visits encourage the client its keep up the regular exercise routine.
There is need for follow up in say a years time.
OT not really applicable at the moment – gave advice for future use of equipment at a later date.
One response was removed as research related/not answering the question/illegible.
Eight gave no response to the question.
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Appendix 25 Responses from people with
Parkinson’s and live-in carers at 24 weeks regarding
the multidisciplinary team intervention
People with Parkinson’s
People with Parkinson’s: text responses to acceptability questionnaire at assessment 3 (24 weeks),
immediately post PCA treatment, groups A and B only.
People with Parkinson’s: group A
Question 11: when the 6-week multidisciplinary rehabilitation treatment ended,
did you continue to benefit? If yes, please explain how you benefited.
Since the programme started my condition has deteriorated. Some of the benefits then, will not be the
same in the future so who knows?
By the various suggestions into practice – especially physio.
Unable to remember.
Made me try harder with all my activities.
Learnt things about Parkinson’s disease.
Do exercises every evening.
Incorporated facial exercises and walking exercises into gym routine.
Voice improved, techniques learned for eating, getting out of chair and bed.
By being aware of what is available to Parkinson’s sufferers.
I am more aware of how I can help myself and I know what is available as and when needed.
I tried harder to slow down on my speech. I also do exercises every morning to keep things
working correctly.
Continue to practice speech therapist suggestions and physio.
Made me find exercise and hydrotherapy.
I continued to do the exercises.
Continued with the exercises but unfortunately Parkinson’s has now become worse.
I am sure I will benefit but I have had a urine infection.
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Have been shown how to cope with various aspects of Parkinson’s and given a better understanding of
what can be done.
Some benefit from speech therapy and exercises but not ready sure that if was totally beneficial.
As [name] goes to a gym three times a week he continued with this and not the exercise, as this would
have recount exercising all the time. However it would be a benefit for most people.
It gave me the opportunity to put into practice the suggestions, ideas and routines that they had and to
see the results and benefits.
Useful exercises – information.
I tried to continue with exercises. The speech therapist explained about the weakness in my voice and how
it was caused by PD [Parkinson’s disease].
Only a little because I was hospitalised with IPF [idiopathic pulmonary fibrosis] shortly afterwards.
Access to physio was of great benefit. Also felt our own experiences had been put to good use which
would improve funding and treatment of newly diagnosed sufferers.
With my speech.
Doing exercises.
Remembering to speak loudly and clearly.
Comprehensive exercise.
Not sure.
1. My handwriting has improved. 2. General reassurance.
I continue to do the exercises.
The treatment and specialists optimism was infectious.
There was so much literature to read and answer problems as the exercises were very helpful.
Retained the knowledge – but self-motivation reduced after it ended. Would like it to be on-going.
By learning more about actual disease.
Snippets of information were useful for later.
Greater understanding of condition and ideas for managing it.
Personal Trainer has now been engaged to keep carry on with programme.
I feel I benefited from the advice given by the professionals and feel more motivated to exercise. Balance
has improved.
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From the various exercises shown to keep mobile, and other advice given.
Exercises.
Exercise seems to be the most important.
Speech therapy and exercises have been good.
By continuing with the advice and exercises.
I retain the improved confidence that resulted from the rehabilitation treatment and continue to benefit
from the exercises and information.
Following advice from physio.
General improvement in mobility.
There was no continuing treatment to benefit from!!
Kept up with exercising tried to remember what they said.
Can still use the knowledge gained.
Much better informed about aspects of the disease.
By applying the lessons learned from home visits.
Nothing other than explained before. Also, understanding of why the speech and swallowing is affected,
means able to understand what is happening.
I benefited from observing the changes in performance of the various exercises.
SALT [speech and language therapy] input.
The positive recalculation of my waning remaining gifts and talent, providing a full life. Positive attitude.
Focused my mind more on controlling my movements affected by the Parkinson’s.
Some of the knowledge e.g. times of taking pills have been altered which has proved to be beneficial.
The equipment recommended has really helped, especially the back roll.
Helped with balance.
Gained one or two ideas for coping with minor problems.
Got me rethinking about my health.
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Assessment 3: people with Parkinson’s, group B
Question 11: when the 6-week multidisciplinary rehabilitation treatment ended,
did you continue to benefit? If yes, please explain how you benefited.
It helped with my confidence and ability.
From exercises.
Exercise.
I have become more aware of problems with balance and also of my quiet speech and the need to talk
much more loudly and distinctively.
Teaching us the way to keep on moving, not to sit around doing nothing.
Learnt new things about PD [Parkinson’s disease].
The information and knowledge from the healthcare professionals was utilised after the 6 weeks in daily
life, with benefit.
[Care assistant] input kept it going.
Greater all round awareness.
Encouraged to think about how to improve on wellbeing.
Continued with suggestions made by team.
Following instruction sheets on both exercises and face movements.
From the regular programme of exercises.
By keeping up with the exercises.
Continue with posture exercises. Consult paperwork for useful reference.
Having someone come in and suggest and follow-up at next visit was a motivator. Knowing there are
things to do to alleviate symptoms.
We have confidence to have learned more about Parkinson’s disease.
A reminder to maintain the regime.
Yes because I continued with the recommendation – I contacted social services which resulted in hand rails
being installed bed rails and pillow lifter. Without the information I would have still been struggling out
of bed.
In the short term the CA [care assistant] carried on with the work set out by the physiotherapist. The main
on-going benefit to me, is the recognition that in order to keep my symptoms under control and
potentially reduce the speed of deterioration I must help myself. In my case dedicate time to practice
movement and flexibility but also to take regular aerobic exercise.
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Tried to do more exercise.
Learnt new things about PD [Parkinson’s disease] that can be applied to day to day life.
Able to use mobility suggestions on a regular basis.
Continued exercises both physical and speech therapy with carers encouragement.
More aware of movements.
I am more aware of the support available.
This answer is predicted, because we only finish the programme this week. However we are sure the
benefit will continue.
I continue to exercise as instructed and try to maintain a positive attitude.
I am still keeping up with the exercises to keep me mobile for longer, also received information from
Parkinson’s nurse.
With [care assistant] coming in, enabled support needed to continue benefiting.
I am more confident in knowing what exercises will improve/maintain what mobility I have and my speech.
I carried on using the information I was given and found it very helpful (i.e.) exercises and speech therapy
More knowledge on how to manage Parkinson’s.
I have become reconciled with Parkinson’s and am clearer about what I should do.
I have learnt more about PD [Parkinson’s disease] which is very helpful to me in dealing with my general
slowness, my tendency to tire quickly and with speech difficulties and balance.
Exercising, etc.
My speech, balance, swallowing improved enabling me to enjoy life more. Unfortunately curtailed by
my stroke.
Were given some good tips for doing things.
A better understanding of the need for exercise and the need to keep trying and not to indulge in
self-pity.
Exercises – continued doing exercises, and has prompted me to join a local exercise group.
Kept me focused.
I have been stimulated to keep going particularly with daily exercises.
I know now how to keep up my mobility.
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Period of time insufficient to assess the benefits.
Provided necessary discipline for the exercises.
Regular exercises. I mean to do well with working on exercises and breathing to improve my speech.
I learnt the exercises to help my posture etc. and I was motivated to keep doing them. It also helped get
over the early part of my PD when I was slightly down.
Speech better. Walking a little better.
Increased confidence in handling Parkinson’s.
Continued with exercises.
It has confirmed my thoughts about physical fitness. Both patient and carer need to be able to work
together to make sure that any exercises are done, and to encourage each other.
Felt the exercises were valuable and effective, even though physical condition deteriorated.
Continuation of exercises has been helpful.
I met experts in the problems of creeping problems. The team of this survey gives confidence that
Parkinson’s is not a killer but can be controlled and most of the control comes from a team of experts and
it is up to the individual to motivate and apply the advice given. The rehab is up to you.
Continued our exercises. Encouraged me to attend local exercise class.
The six weeks on its own would not have had much of a result but the extra input received certainly
bettered the outcome.
I felt that my stress levels were a lot lower. And that when I did the exercises and the breathing and voice
exercises that my capabilities improved breathing more easily. Also I would like to have the opportunity to
meet/contact other people who have Parkinson’s – maybe we could set up a web group? This would be
very useful.
I was able to continue the advice given as to mobility etc. and motivate myself to keep pushing the
boundaries of what I can presently do in all aspects of my day to day living.
I felt more confident having survived it.
Doing the exercises from the physio with [care assistant] was beneficial.
By using the ‘hints and tips’ given to me and continuing the exercises.
Continued with the exercises with [care assistant].
By having the follow-up appointments with CA [care assistant].
Follow-up visits from [care assistant]. Also the positive attitude of the healthcare professionals encouraged
me to be positive and act on the information they gave me.
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Live-in carers
Live-in carers’ text responses to acceptability questionnaire at assessment 3 (24 weeks), immediately post
PCA treatment, groups A and B only.
Live-in carers: group A
Question 11: when the 6-week multidisciplinary rehabilitation treatment ended,
did you and the person you care for continue to benefit from the treatment?
If yes, please explain how you benefited:
We recognised the need to buy wheelchairs, etc.
More aware of resources available.
It was good to think back to what the person has told you.
It was good to see that John included the suggestions into this exercise regime.
Forgotten some of the things we learned so not as effective as it would be.
Understanding the illness was of great value.
Better attitude in general.
Continuation of exercises maintains mobility and flexibility.
Unfortunately the person I care for got a urine infection after the rehabilitation treatment ended – which
has been a setback. Therefore, at the moment, I cannot answer this question but feel that we certainly
will benefit.
Made carer and patient feel more positive about the future and ability to cope.
Continued with the exercises and speech therapy for a period of time.
It got him enthused to attend a weekly exercise class. Understanding the importance of letting him be as
independent as possible for a long as possible.
He confirmed to try and do the things he was shown to keep the illness steady.
Awareness of moving and speaking in the patient reinforced what I was saying.
Kept more focused on exercises etc.
Probably greater awareness of the whole problem
Yes with physiotherapy – but not so much occupational – or speech and language – and [PDNS] is
invaluable – but she is our PDNS [Parkinson’s disease nurse spcialist] and easily contactable.
Using some of the tips provided, but difficult to maintain the programme.
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More positive on being able to slow down the progression and the disease with self-help, e.g. exercises,
voice control.
We benefited by the information and greater understanding of what is possible with a bit more effort.
To have someone to talk to, to explain things to you.
Gave a real boost to sheet with re-mobility but this has diminished. Someone comes in to the home was
much more helpful than just seeing professionals in a clinic environment.
It gave the patient a focus with specific exercises which gave benefits as well as ‘feel good’ and ‘can
do’ mentality.
Still doing the exercises. [Name] has increased motivation to do them.
We both understand the condition better.
It keeps us going on.
If only one aspect was beneficial it was the advice of getting in and out of bed and moving about in
the bed.
New attitude point of view exercise and talking without about things generally.
It gave my husband things to work at and gave him a purpose to exercise.
We reminded ourselves about what we had been told and applied the knowledge to the current situations
as they happened.
Live-in carers: group B
Question 11: when the 6-week multidisciplinary rehabilitation treatment ended,
did you and the person you care for continue to benefit from the treatment?
If yes, please explain how you benefited.
Learning more about Parkinson’s and ways of helping my husband.
The discipline of exercise has kept the muscles toned so when he is able to walk, he can do so very well.
The treatment offered a sufferer and bench mark for the patient and carer and reinforced by visits with
practical application.
Advice given and exercise programme helped in continuing care. Provided helpful ways of managing
things like ‘freezing’, getting in and out of bed etc.
Learnt knew things about PD [Parkinson’s disease].
Continued with exercises.
We were encouraged to carry on with the suggestions received.
The exercises were very helpful.
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With the help of the Parkinson’s Nurse from [local hospital] we continued with private physiotherapy at
[local day centre]. This is aiming to improve posture and mobility beyond our expectations.
It was good to learn more about Parkinson’s Disease.
A fuller knowledge of what was involved.
My husband continues with recommended exercises, from physio and speech and language which should
help slow the diseases progress. Our knowledge base is much greater.
It drew our attention to all the disciplinary we were shown are most important and we hope to be able to
keep it up for the benefit of my husband.
My wife has learnt she has to be more disciplined in carrying out ‘in house’ treatment/exercises etc.
It is too soon to answer this accurately, as the programme only finishes this week. Predicted
response – benefits in balance and mobility should continue, as we will certainly keep up all the things
we have learned.
I was able to answer questions from my wife. Refer to literature.
When speech or mobility problems are at their worst we have strategies to try to overcome them.
He tries whatever possible to exercise but speech now is very difficult.
Improved knowledge of the problems and how they are relevant and relate to the patient. New ways of
caring for/attending to PD [Parkinson’s disease], e.g. exercise regimes for balance improvement,
importance of stature maintenance. Improved knowledge of therapies, e.g. impact of drugs used etc.
Made you feel more confident.
Exercise advice continuing.
By remembering what we were advised to do to keep Parkinson’s at bay, my husband’s Parkinson’s is slow
in changing, thankfully.
It gave my wife confidence and determination.
Time will tell – as it has only just finished!
My husband concentrated on the physio exercises.
I was assured by my husband that he had learnt many exercises and had a greater knowledge of
the condition.
When [NAME] remembers to do the exercises he moves much better and speaks more clearly.
Physio exercise and positive attitude to the future.
By being in the way of doing some of the exercises on a regular basis.
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Continuation of speech and physical exercises has helped my wife over the last weeks. We feel less
isolated than before.
Explanations of what to expect of the Parkinson’s sufferer and hence a deeper understanding of
their situation.
The programme helped to encourage the patient in exercising with both voice and body.
My wife is now more relaxed and happier.
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